<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>BCSC1920_S01_C18IDX_p335_368_8P</title>
		<link href="BCSC1920_S01_C18IDX_p335_368_8P-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC1920_S01_C18IDX_p335_368_8P" lang="en-US">
		<div id="_idContainer000" class="Basic-Text-Frame">
			<p class="em-only_endmatter-title ParaOverride-1">Index</p>
			<p class="em-only_endmatter-idx1">(<span class="endmatter-idx1_italic">f</span> <span class="endmatter-idx1_symbol">=</span> figure; <span class="endmatter-idx1_italic">t</span> <span class="endmatter-idx1_symbol">=</span> &#173;table)</p>
			<p class="em-only_endmatter-idx1">Abatacept, 180</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">ABCDE</span> mnemonic, for melanoma, 221</p>
			<p class="em-only_endmatter-idx1">Absence seizures, 207</p>
			<p class="em-only_endmatter-idx1">Absolute risk reduction, 22</p>
			<p class="em-only_endmatter-idx1">Abuse, elder, 185–187</p>
			<p class="em-only_endmatter-idx1">Abusive head trauma, 299</p>
			<p class="em-only_endmatter-idx1">ACE inhibitors. <span class="endmatter-idx1_italic">See</span> Angiotensin-converting enzyme (ACE) inhibitors</p>
			<p class="em-only_endmatter-idx1">Acquired immunodeficiency syndrome (AIDS). <span class="endmatter-idx1_italic">See</span> HIV</p>
			<p class="em-only_endmatter-idx1">Acromegaly, 48</p>
			<p class="em-only_endmatter-idx1">Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, 78</p>
			<p class="em-only_endmatter-idx1">Activated partial thromboplastin time (aPTT), 139, <br />144</p>
			<p class="em-only_endmatter-idx1">Activated protein C (APC), 139</p>
			<p class="em-only_endmatter-idx1">Activated protein C re&#173;sis&#173;tance, 146–147</p>
			<p class="em-only_endmatter-idx1">Active immunization, 223</p>
			<p class="em-only_endmatter-idx1">Acute coronary syndromes (ACS)</p>
			<p class="em-only_endmatter-idx2">anticoagulants for, 93–94</p>
			<p class="em-only_endmatter-idx2">definition of, 83</p>
			<p class="em-only_endmatter-idx2">myo&#173;car&#173;dial infarction. <span class="endmatter-idx2_italic">See</span> Myo&#173;car&#173;dial infarction</p>
			<p class="em-only_endmatter-idx2">treatment of, 93–95</p>
			<p class="em-only_endmatter-idx2">troponins associated with, 87</p>
			<p class="em-only_endmatter-idx1">Acute disseminated intravascular coagulation, 146</p>
			<p class="em-only_endmatter-idx1">Acute myo&#173;car&#173;dial infarction</p>
			<p class="em-only_endmatter-idx2">description of, 83</p>
			<p class="em-only_endmatter-idx2">non–&#173;ST-&#173;segment elevation, 83</p>
			<p class="em-only_endmatter-idx1">Acute thyroiditis, 45</p>
			<p class="em-only_endmatter-idx1">Acyclovir</p>
			<p class="em-only_endmatter-idx2">description of, 277–278</p>
			<p class="em-only_endmatter-idx2">Epstein-&#173;Barr virus treated with, 261</p>
			<p class="em-only_endmatter-idx2">herpes simplex virus treated with, 260, 278</p>
			<p class="em-only_endmatter-idx2">varicella-&#173;zoster treated with, 261</p>
			<p class="em-only_endmatter-idx1">Acyl ureidopenicillins, 272</p>
			<p class="em-only_endmatter-idx1">Adalimumab, 180</p>
			<p class="em-only_endmatter-idx1">ADAMTS13, 142</p>
			<p class="em-only_endmatter-idx1">Adaptive immunity, 246</p>
			<p class="em-only_endmatter-idx1">Adefovir, 279</p>
			<p class="em-only_endmatter-idx1">Adenocarcinoma, esophageal, 219</p>
			<p class="em-only_endmatter-idx1">Adenomas</p>
			<p class="em-only_endmatter-idx2">gonadotroph, 48</p>
			<p class="em-only_endmatter-idx2">lactotroph, 48</p>
			<p class="em-only_endmatter-idx2">null-&#173;cell, 48</p>
			<p class="em-only_endmatter-idx2">pituitary, 47–49</p>
			<p class="em-only_endmatter-idx2">plurihormonal, 48</p>
			<p class="em-only_endmatter-idx2">somatotroph, 47–48</p>
			<p class="em-only_endmatter-idx2">thyroid, 46</p>
			<p class="em-only_endmatter-idx1">Adjuvant chemotherapy, 239</p>
			<p class="em-only_endmatter-idx1">Adolescents</p>
			<p class="em-only_endmatter-idx2">hypertension in, 68</p>
			<p class="em-only_endmatter-idx2">perioperative management for ocular surgery in, <br />283</p>
			<p class="em-only_endmatter-idx1">Adult Treatment Panel (ATP), 71, 74</p>
			<p class="em-only_endmatter-idx1">Advanced cardiac life support (ACLS), 299</p>
			<p class="em-only_endmatter-idx1">Advanced glycation cross-&#173;link breakers, 65</p>
			<p class="em-only_endmatter-idx1">Advanced glycation end products (AGEs), 65</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Aedes aegypti,</span> 265</p>
			<p class="em-only_endmatter-idx1">Affective disorders, 195–196</p>
			<p class="em-only_endmatter-idx1">Aflibercept, 27, 240<span class="endmatter-idx1_italic">t</span>, 241</p>
			<p class="em-only_endmatter-idx1">Age/aging</p>
			<p class="em-only_endmatter-idx2">depression associated with, 188–190</p>
			<p class="em-only_endmatter-idx2">eye changes secondary to, 183–184</p>
			<p class="em-only_endmatter-idx2">physiology, 183–184</p>
			<p class="em-only_endmatter-idx2">psy&#173;chol&#173;ogy of, 188–190</p>
			<p class="em-only_endmatter-idx1">Age-&#173;Related Eye Disease Study 2 (AREDS2), 79</p>
			<p class="em-only_endmatter-idx1">Age-&#173;related macular degeneration (AMD)</p>
			<p class="em-only_endmatter-idx2">depression associated with, 188</p>
			<p class="em-only_endmatter-idx2">exudative, obstructive sleep apnea and, 127</p>
			<p class="em-only_endmatter-idx2">statins and, 78–79</p>
			<p class="em-only_endmatter-idx2">vision loss caused by, 184</p>
			<p class="em-only_endmatter-idx1">Airway</p>
			<p class="em-only_endmatter-idx2">in asthma, 123</p>
			<p class="em-only_endmatter-idx2">in cardiopulmonary resuscitation, 297</p>
			<p class="em-only_endmatter-idx2">hyperreactivity of, 124</p>
			<p class="em-only_endmatter-idx2">obstruction of, 126</p>
			<p class="em-only_endmatter-idx1">Airway devices, 298</p>
			<p class="em-only_endmatter-idx1">Airway inflammation, eosinophilic, 124</p>
			<p class="em-only_endmatter-idx1">Alcohol withdrawal syndromes, 68</p>
			<p class="em-only_endmatter-idx1">Aldose reductase inhibitors, 40</p>
			<p class="em-only_endmatter-idx1">Alemtuzumab, 180</p>
			<p class="em-only_endmatter-idx1">Alfentanil, 290</p>
			<p class="em-only_endmatter-idx1">Aliskiren, 63</p>
			<p class="em-only_endmatter-idx1">Alkylating agents, 240<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx2">Beh<span class="endmatter-idx2_accent">ç</span>et disease treated with, 173</p>
			<p class="em-only_endmatter-idx2">description of, 179</p>
			<p class="em-only_endmatter-idx1">Allogeneic hematopoietic stem cell transplantation, <br />for thalassemias, 134</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_greek">α</span><span class="subscript _idGenCharOverride-1">1</span>-Antitrypsin deficiency, 124</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_greek">α</span><span class="subscript _idGenCharOverride-1">1a</span>-Antagonists, 309<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_greek">α</span><span class="subscript _idGenCharOverride-1">1</span>-&#173;Blockers</p>
			<p class="em-only_endmatter-idx2">“first-&#173;dose effect,” 63</p>
			<p class="em-only_endmatter-idx2">hypertension treated with, 62–63</p>
			<p class="em-only_endmatter-idx1">Alprazolam, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Alternative hypothesis, 5</p>
			<p class="em-only_endmatter-idx1">Alternative payment models (APMs), 32</p>
			<p class="em-only_endmatter-idx1">Alzheimer disease, 209–210</p>
			<p class="em-only_endmatter-idx1">Amantadine, 205, 279</p>
			<p class="em-only_endmatter-idx1">Ambulatory blood pressure mea&#173;sure&#173;ment, 52</p>
			<p class="em-only_endmatter-idx1">Ambulatory surgical center, ocular surgery in, 281</p>
			<p class="em-only_endmatter-idx1">American Acad&#173;emy of Ophthalmology (AAO)</p>
			<p class="em-only_endmatter-idx2">Initiative in Vision Rehabilitation on the ONE&#160;Network, 185</p>
			<p class="em-only_endmatter-idx2">IRIS (Intelligent Research in Sight) Registry of, 26</p>
			<p class="em-only_endmatter-idx2">Preferred Practice Pattern guidelines, 26, 196</p>
			<p class="em-only_endmatter-idx2">wrong-&#173;site surgery checklist, 289</p>
			<p class="em-only_endmatter-idx1">American Cancer Society (ACS)</p>
			<p class="em-only_endmatter-idx2">colorectal cancer screening recommendations <br />of, 219</p>
			<p class="em-only_endmatter-idx2">mammography recommendations of, 217</p>
			<p class="em-only_endmatter-idx1">American College of Cardiology (ACC)</p>
			<p class="em-only_endmatter-idx2">blood pressure classification guidelines, 52</p>
			<p class="em-only_endmatter-idx2">hypertension and</p>
			<p class="em-only_endmatter-idx3">definition of, 214</p>
			<p class="em-only_endmatter-idx3">treatment guidelines, 57</p>
			<p class="em-only_endmatter-idx2">statin guidelines of, 76–77</p>
			<p class="em-only_endmatter-idx1">American Heart Association (AHA)</p>
			<p class="em-only_endmatter-idx2">advanced cardiac life support guidelines, 299</p>
			<p class="em-only_endmatter-idx2">blood pressure classification guidelines, 52</p>
			<p class="em-only_endmatter-idx2">hypertension and</p>
			<p class="em-only_endmatter-idx3">definition of, 214</p>
			<p class="em-only_endmatter-idx3">treatment guidelines, 57</p>
			<p class="em-only_endmatter-idx2">statin guidelines of, 76–77</p>
			<p class="em-only_endmatter-idx1">American Society of Anesthesiologists Physical Status (ASA-&#173;PS), 282</p>
			<p class="em-only_endmatter-idx1">Aminoglycosides, 275</p>
			<p class="em-only_endmatter-idx1">Amiodarone</p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 106, 309<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">optic neuropathy caused by, 106</p>
			<p class="em-only_endmatter-idx1">Amlodipine, for congestive heart failure, 99</p>
			<p class="em-only_endmatter-idx1">Amoxicillin, dental prophylaxis uses of, 248<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Amphotericin&#160;B, for fungal infections, 258, 277</p>
			<p class="em-only_endmatter-idx1">Ampicillin, dental prophylaxis uses of, 248<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Amyloid plaques, in Alzheimer disease, 209</p>
			<p class="em-only_endmatter-idx1">Amyloidosis, 140</p>
			<p class="em-only_endmatter-idx1">ANA. <span class="endmatter-idx1_italic">See</span> Antinuclear antibody (ANA) testing</p>
			<p class="em-only_endmatter-idx1">Anagrelide, for essential thrombocythemia, 143</p>
			<p class="em-only_endmatter-idx1">Anakinra, 180</p>
			<p class="em-only_endmatter-idx1">Analgesics, ocular adverse effects of, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Anaphylactoid reactions, 302</p>
			<p class="em-only_endmatter-idx1">Anaphylaxis, 302–303</p>
			<p class="em-only_endmatter-idx1">Anaplastic carcinoma, 46</p>
			<p class="em-only_endmatter-idx1">ANCA. <span class="endmatter-idx1_italic">See</span> Antineutrophil cytoplasmic autoantibody</p>
			<p class="em-only_endmatter-idx1">Andexanet alfa, 149</p>
			<p class="em-only_endmatter-idx1">Anemia</p>
			<p class="em-only_endmatter-idx2">antibody-&#173;mediated destruction as cause of, 135</p>
			<p class="em-only_endmatter-idx2">aplastic, 137</p>
			<p class="em-only_endmatter-idx2">blood loss as cause of, 132–133</p>
			<p class="em-only_endmatter-idx2">bone marrow disorders as cause of, 137</p>
			<p class="em-only_endmatter-idx2">chronic hemolytic, 135</p>
			<p class="em-only_endmatter-idx2">chronic renal failure as cause of, 137</p>
			<p class="em-only_endmatter-idx2">classification of, 132</p>
			<p class="em-only_endmatter-idx2">in congestive heart failure, 99</p>
			<p class="em-only_endmatter-idx2">Coombs-&#173;positive hemolytic, 135</p>
			<p class="em-only_endmatter-idx2">folate deficiency as cause of, 133–134</p>
			<p class="em-only_endmatter-idx2">hemoglobin synthesis defects as cause of, 134–136</p>
			<p class="em-only_endmatter-idx2">hemolytic, 135–137</p>
			<p class="em-only_endmatter-idx2">inflammatory, 137</p>
			<p class="em-only_endmatter-idx2">iron deficiency, 132–133</p>
			<p class="em-only_endmatter-idx2">macrocytic, 132–133</p>
			<p class="em-only_endmatter-idx2">megaloblastic, 133</p>
			<p class="em-only_endmatter-idx2">microcytic, 132</p>
			<p class="em-only_endmatter-idx2">normocytic, 132</p>
			<p class="em-only_endmatter-idx2">nutritional deficiency as cause of, 132–134</p>
			<p class="em-only_endmatter-idx2">pathophysiology of, 132</p>
			<p class="em-only_endmatter-idx2">pernicious, 133</p>
			<p class="em-only_endmatter-idx2">red blood cell destruction as cause of, 136–137</p>
			<p class="em-only_endmatter-idx2">sickle cell, 135–136</p>
			<p class="em-only_endmatter-idx2">sideroblastic, 137</p>
			<p class="em-only_endmatter-idx2">in thalassemias, 134–135</p>
			<p class="em-only_endmatter-idx2">vitamin B<span class="subscript _idGenCharOverride-1">12</span> deficiency as cause of, 133</p>
			<p class="em-only_endmatter-idx1">Anemia of chronic disease, 159</p>
			<p class="em-only_endmatter-idx1">Anesthesia</p>
			<p class="em-only_endmatter-idx2">general, 289–290</p>
			<p class="em-only_endmatter-idx2">local. <span class="endmatter-idx2_italic">See</span> Local anesthesia</p>
			<p class="em-only_endmatter-idx1">Aneurysmal subarachnoid hemorrhage, 121</p>
			<p class="em-only_endmatter-idx1">Aneurysms, 121–122</p>
			<p class="em-only_endmatter-idx1">Angina pectoris</p>
			<p class="em-only_endmatter-idx2">in congestive heart failure, 95</p>
			<p class="em-only_endmatter-idx2">hypertension and, 65</p>
			<p class="em-only_endmatter-idx2">manifestations of, 82–83</p>
			<p class="em-only_endmatter-idx2">misinterpretation of, 83</p>
			<p class="em-only_endmatter-idx2">Prinzmetal, 83</p>
			<p class="em-only_endmatter-idx2">stable</p>
			<p class="em-only_endmatter-idx3">coronary artery bypass grafting, 91–92</p>
			<p class="em-only_endmatter-idx3">definition of, 83</p>
			<p class="em-only_endmatter-idx3">hypertension and, 65</p>
			<p class="em-only_endmatter-idx3">percutaneous coronary intervention for, 91–92</p>
			<p class="em-only_endmatter-idx3">revascularization for, 91–93</p>
			<p class="em-only_endmatter-idx3">treatment of, 91–93</p>
			<p class="em-only_endmatter-idx2">treatment of, 91–93</p>
			<p class="em-only_endmatter-idx2">unstable, 83</p>
			<p class="em-only_endmatter-idx2">variant, 83</p>
			<p class="em-only_endmatter-idx1">Angioedema</p>
			<p class="em-only_endmatter-idx2">angiotensin-&#173;converting enzyme inhibitors as cause of, 106</p>
			<p class="em-only_endmatter-idx2">description of, 61</p>
			<p class="em-only_endmatter-idx1">Angiogenesis inhibitors, 240<span class="endmatter-idx1_italic">t,</span> 241</p>
			<p class="em-only_endmatter-idx1">Angioid streaks, in pseudoxanthoma elasticum, 141</p>
			<p class="em-only_endmatter-idx1">Angioplasty, for angina pectoris, 92</p>
			<p class="em-only_endmatter-idx1">Angiotensin&#160;I, 61</p>
			<p class="em-only_endmatter-idx1">Angiotensin&#160;II, 61, 301</p>
			<p class="em-only_endmatter-idx1">Angiotensin II receptor blockers (ARBs)</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 61</p>
			<p class="em-only_endmatter-idx2">congestive heart failure treated with, 99</p>
			<p class="em-only_endmatter-idx2">hypertension treated with, 59<span class="endmatter-idx2_italic">t,</span> 61</p>
			<p class="em-only_endmatter-idx2">mechanism of action, 61</p>
			<p class="em-only_endmatter-idx2">pregnancy contraindications for, 68</p>
			<p class="em-only_endmatter-idx1">Angiotensin-&#173;converting enzyme (ACE)</p>
			<p class="em-only_endmatter-idx2">functions of, 61</p>
			<p class="em-only_endmatter-idx2">in sarcoidosis, 163</p>
			<p class="em-only_endmatter-idx1">Angiotensin-&#173;converting enzyme (ACE) inhibitors</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx1_accent">β</span>-&#173;blockers and, in heart failure, 65</p>
			<p class="em-only_endmatter-idx2">congestive heart failure treated with, 98</p>
			<p class="em-only_endmatter-idx2">hypertension treated with, 59<span class="endmatter-idx2_italic">t,</span> 61, 165</p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 106</p>
			<p class="em-only_endmatter-idx2">pregnancy contraindications for, 68</p>
			<p class="em-only_endmatter-idx1">Anhedonia, 195</p>
			<p class="em-only_endmatter-idx1">Ankylosing spondylitis (AS)</p>
			<p class="em-only_endmatter-idx2">description of, 154–155</p>
			<p class="em-only_endmatter-idx2">iridocyclitis in, 157</p>
			<p class="em-only_endmatter-idx1">Antianxiety drugs, 201<span class="endmatter-idx1_italic">t,</span> 201–202</p>
			<p class="em-only_endmatter-idx1">Antiarrhythmic drugs</p>
			<p class="em-only_endmatter-idx2">cardiac rhythm disorders treated with, 102, 102<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">implantable cardioverter-&#173;defibrillator and, combined therapy using, 104</p>
			<p class="em-only_endmatter-idx2">Vaughan Williams classification of, 102, 102<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">ventricular fibrillation treated with, 104</p>
			<p class="em-only_endmatter-idx1">Antibacterial agents</p>
			<p class="em-only_endmatter-idx2">aminoglycosides, 275</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx1_accent">β</span>-&#173;lactam, 271–273</p>
			<p class="em-only_endmatter-idx2">carbapenems, 273</p>
			<p class="em-only_endmatter-idx2">cephalosporins, 272, 272<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">classification of, 270</p>
			<p class="em-only_endmatter-idx2">description of, 270</p>
			<p class="em-only_endmatter-idx2">fluoroquinolones, 274</p>
			<p class="em-only_endmatter-idx2">&#173;future directions for, 276</p>
			<p class="em-only_endmatter-idx2">glycopeptides, 273–274</p>
			<p class="em-only_endmatter-idx2">macrolides, 274–275</p>
			<p class="em-only_endmatter-idx2">mechanism of action, 270</p>
			<p class="em-only_endmatter-idx2">miscellaneous types of, 276</p>
			<p class="em-only_endmatter-idx2">monobactams, 272–273</p>
			<p class="em-only_endmatter-idx2">penicillins, 271–272</p>
			<p class="em-only_endmatter-idx2">tetracyclines, 275–276</p>
			<p class="em-only_endmatter-idx1">Antibiotic Re&#173;sis&#173;tance Monitoring in Ocular Microorganisms (ARMOR) study, 247</p>
			<p class="em-only_endmatter-idx1">Antibiotics. <span class="endmatter-idx1_italic">See also</span> Antibacterial agents</p>
			<p class="em-only_endmatter-idx2">aminoglycosides, 275</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx1_accent">β</span>-&#173;lactam, 271–273</p>
			<p class="em-only_endmatter-idx2">carbapenems, 273</p>
			<p class="em-only_endmatter-idx2">cephalosporins, 272, 272<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">description of, 270</p>
			<p class="em-only_endmatter-idx2">fluoroquinolones, 274</p>
			<p class="em-only_endmatter-idx2">&#173;future directions for, 276</p>
			<p class="em-only_endmatter-idx2">glycopeptides, 273–274</p>
			<p class="em-only_endmatter-idx2">macrolides, 274–275</p>
			<p class="em-only_endmatter-idx2">monobactams, 272–273</p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 308<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">penicillins, 271–272</p>
			<p class="em-only_endmatter-idx2">tetracyclines, 275–276</p>
			<p class="em-only_endmatter-idx1">Antibodies</p>
			<p class="em-only_endmatter-idx2">anticentromere, 165</p>
			<p class="em-only_endmatter-idx2">anti–cyclic citrullinated peptide (CCP), 152–153</p>
			<p class="em-only_endmatter-idx2">anti-&#173;dsDNA, 161</p>
			<p class="em-only_endmatter-idx2">anti-&#173;Smith, 161</p>
			<p class="em-only_endmatter-idx2">monoclonal, 144, 238, 242</p>
			<p class="em-only_endmatter-idx2">thyroglobulin, 42</p>
			<p class="em-only_endmatter-idx1">Anticentromere antibody, 165</p>
			<p class="em-only_endmatter-idx1">Anticholinergics, for lung disease, 128</p>
			<p class="em-only_endmatter-idx1">Anticoagulants</p>
			<p class="em-only_endmatter-idx2">acute coronary syndromes treated with, 93–94</p>
			<p class="em-only_endmatter-idx2">direct oral, 149–150, 286</p>
			<p class="em-only_endmatter-idx2">heparin. <span class="endmatter-idx2_italic">See</span> Heparin</p>
			<p class="em-only_endmatter-idx2">natu&#173;ral, 138–139</p>
			<p class="em-only_endmatter-idx2">ocular surgery and, 286</p>
			<p class="em-only_endmatter-idx2">warfarin. <span class="endmatter-idx2_italic">See</span> Warfarin</p>
			<p class="em-only_endmatter-idx1">Anticoagulation therapy</p>
			<p class="em-only_endmatter-idx2">in atrial fibrillation, 103</p>
			<p class="em-only_endmatter-idx2">dilated cardiomyopathy treated with, 100</p>
			<p class="em-only_endmatter-idx2">unfractionated heparin, 149</p>
			<p class="em-only_endmatter-idx1">Anti–&#173;cyclic citrullinated peptide (CCP) antibodies, 152–153</p>
			<p class="em-only_endmatter-idx1">Antidepressants</p>
			<p class="em-only_endmatter-idx2">description of, 202–203, 203<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 308<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Anti-&#173;dsDNA antibodies, in systemic lupus erythematosus, 161</p>
			<p class="em-only_endmatter-idx1">Antiepileptic drugs, ocular side effects of, 208, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Antifungal agents, 277, 278<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Antihistamines, 302, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Antihypertensive therapy</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_greek">α</span><span class="subscript _idGenCharOverride-1">1</span>-&#173;blockers, 62–63</p>
			<p class="em-only_endmatter-idx2">in &#173;children, 68</p>
			<p class="em-only_endmatter-idx2">combined <span class="endmatter-idx2_greek">α</span>-&#173;adrenergic and <span class="endmatter-idx1_accent">β</span>-&#173;adrenergic <br />antagonists, 63</p>
			<p class="em-only_endmatter-idx2">Conduit Artery Function Endpoint (CAFE) study findings on, 64</p>
			<p class="em-only_endmatter-idx2">direct renin inhibitors, 63</p>
			<p class="em-only_endmatter-idx2">direct vasodilators, 63</p>
			<p class="em-only_endmatter-idx2">diuretics, 59<span class="endmatter-idx2_italic">t,</span> 59–61</p>
			<p class="em-only_endmatter-idx2">drugs used in, 59<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">hypertension treated with, 52, 56–57, 59<span class="endmatter-idx2_italic">t,</span> 59–64</p>
			<p class="em-only_endmatter-idx2">nighttime administration of, 66</p>
			<p class="em-only_endmatter-idx2">in older adults, 67</p>
			<p class="em-only_endmatter-idx2">parenteral, 64</p>
			<p class="em-only_endmatter-idx2">in pregnancy, 68</p>
			<p class="em-only_endmatter-idx2">stroke prevention uses of, 115</p>
			<p class="em-only_endmatter-idx1">Antimetabolites, 240<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Anti–&#173;mutated citrullinated vimentin (anti-&#173;MCV) antibody testing, 153</p>
			<p class="em-only_endmatter-idx1">Antineoplastic drugs, 240<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Antineutrophil cytoplasmic autoantibody (ANCA)–&#173;associated vasculitis, 169<span class="endmatter-idx1_italic">t,</span> 171–173</p>
			<p class="em-only_endmatter-idx1">Antinuclear antibody (ANA) testing</p>
			<p class="em-only_endmatter-idx2">description of, 153</p>
			<p class="em-only_endmatter-idx2">in juvenile idiopathic arthritis, 157</p>
			<p class="em-only_endmatter-idx2">in systemic lupus erythematosus, 160, 160<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in systemic sclerosis, 165</p>
			<p class="em-only_endmatter-idx1">Antiphospholipid syndrome (APS), 148–149, 163–164</p>
			<p class="em-only_endmatter-idx1">Antiplatelet agents</p>
			<p class="em-only_endmatter-idx2">coronary heart disease treated with, 90<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">ocular surgery and, 286</p>
			<p class="em-only_endmatter-idx1">Antipsychotic drugs</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 200</p>
			<p class="em-only_endmatter-idx2">description of, 199–201, 200<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">extrapyramidal side effects of, 200</p>
			<p class="em-only_endmatter-idx2">first-&#173;generation, 199–201, 200<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">second-&#173;generation, 199, 200<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">tardive dyskinesia caused by, 200</p>
			<p class="em-only_endmatter-idx1">Antiretroviral therapy, for &#173;HIV, 268</p>
			<p class="em-only_endmatter-idx1">Anti-&#173;RNA polymerase III, 165</p>
			<p class="em-only_endmatter-idx1">Anti-&#173;Smith antibodies, in systemic lupus <br />erythematosus, 161</p>
			<p class="em-only_endmatter-idx1">Antithrombin</p>
			<p class="em-only_endmatter-idx2">deficiency of, 147</p>
			<p class="em-only_endmatter-idx2">description of, 139</p>
			<p class="em-only_endmatter-idx1">Antithrombotic agents</p>
			<p class="em-only_endmatter-idx2">coronary heart disease treated with, 89–91<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">stroke prevention using, 114–115</p>
			<p class="em-only_endmatter-idx1">Antitumor antibiotics, 240<span class="endmatter-idx1_italic">t,</span> 241</p>
			<p class="em-only_endmatter-idx1">Anti-&#173;vascular endothelial growth &#173;factor agents, 4, 127, 239</p>
			<p class="em-only_endmatter-idx1">Antiviral agents, 277–279</p>
			<p class="em-only_endmatter-idx1">Anxiolytics, ocular adverse effects of, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Apixaban, 149</p>
			<p class="em-only_endmatter-idx1">Aplastic anemia, 137</p>
			<p class="em-only_endmatter-idx1">Apnea. <span class="endmatter-idx2_italic">See</span> Obstructive sleep apnea</p>
			<p class="em-only_endmatter-idx1">Apolipoproteins, 72</p>
			<p class="em-only_endmatter-idx1">Apomorphine, for Parkinson disease, 205</p>
			<p class="em-only_endmatter-idx1">Apparent diffusion coefficient (ADC) mapping, 112</p>
			<p class="em-only_endmatter-idx1">ARR.&#160;<span class="endmatter-idx1_italic">See</span> Absolute risk reduction</p>
			<p class="em-only_endmatter-idx1">Arrhythmias</p>
			<p class="em-only_endmatter-idx2">bradyarrhythmias, 99, 101</p>
			<p class="em-only_endmatter-idx2">in congestive heart failure, 99</p>
			<p class="em-only_endmatter-idx2">tachyarrhythmias. <span class="endmatter-idx2_italic">See</span> Tachyarrhythmias</p>
			<p class="em-only_endmatter-idx1">Arteriovenous malformations (AVMs)</p>
			<p class="em-only_endmatter-idx2">description of, 110</p>
			<p class="em-only_endmatter-idx2">intrace&#173;re&#173;bral hemorrhage from, 120</p>
			<p class="em-only_endmatter-idx2">subarachnoid hemorrhage caused by, 121–122</p>
			<p class="em-only_endmatter-idx2">surgical excision of, 122</p>
			<p class="em-only_endmatter-idx1">Arthritis</p>
			<p class="em-only_endmatter-idx2">enteropathic, 156</p>
			<p class="em-only_endmatter-idx2">enthesitis-&#173;related, 154</p>
			<p class="em-only_endmatter-idx2">juvenile idiopathic, 157–158, 158<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">psoriatic, 156–157</p>
			<p class="em-only_endmatter-idx2">reactive, 155–156<span class="endmatter-idx2_italic">f,</span> 157</p>
			<p class="em-only_endmatter-idx2">rheumatoid. <span class="endmatter-idx2_italic">See</span> Rheumatoid arthritis</p>
			<p class="em-only_endmatter-idx1">Arthritis mutilans, 156</p>
			<p class="em-only_endmatter-idx1">Aspirin</p>
			<p class="em-only_endmatter-idx2">myo&#173;car&#173;dial infarction prophylaxis using, 89</p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 308<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">platelet aggregation inhibition using, 143</p>
			<p class="em-only_endmatter-idx2">stroke prevention uses of, 114</p>
			<p class="em-only_endmatter-idx1">Assessment of Capacity for Everyday Decision-&#173;Making (ACED), 211</p>
			<p class="em-only_endmatter-idx1">Asthma</p>
			<p class="em-only_endmatter-idx2">bronchospasm in, 123–124</p>
			<p class="em-only_endmatter-idx2">description of, 123–124</p>
			<p class="em-only_endmatter-idx2">eosinophilic, 124</p>
			<p class="em-only_endmatter-idx2">precipitating &#173;factors for, 124</p>
			<p class="em-only_endmatter-idx2">treatment of, 128–130, 129<span class="endmatter-idx2_italic">f,</span> 308<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Asymptomatic carotid stenosis, 116–117</p>
			<p class="em-only_endmatter-idx1">Asymptomatic coronary heart disease, 86</p>
			<p class="em-only_endmatter-idx1">Atheromas, 110</p>
			<p class="em-only_endmatter-idx1">Atherosclerosis</p>
			<p class="em-only_endmatter-idx2">carotid</p>
			<p class="em-only_endmatter-idx3">diagnosis of, 116</p>
			<p class="em-only_endmatter-idx3">locations of, 115</p>
			<p class="em-only_endmatter-idx2">definition of, 72</p>
			<p class="em-only_endmatter-idx2">fatty streak associated with, 81</p>
			<p class="em-only_endmatter-idx2">ocular manifestations of, 78</p>
			<p class="em-only_endmatter-idx2">plaque, 81</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 89</p>
			<p class="em-only_endmatter-idx2">screening for, 215</p>
			<p class="em-only_endmatter-idx1">Atorvastatin, 75<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Atrial fibrillation, 102–103, 103<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx2">cardioembolic stroke caused by, 111</p>
			<p class="em-only_endmatter-idx2">perioperative management for ocular surgery in patients with, 284</p>
			<p class="em-only_endmatter-idx2">stroke caused by, 111</p>
			<p class="em-only_endmatter-idx1">Atrial flutter, 102</p>
			<p class="em-only_endmatter-idx1">Atrial thrombi, 102</p>
			<p class="em-only_endmatter-idx1">Atrioventricular (AV) junction, 101</p>
			<p class="em-only_endmatter-idx1">Atropine sulfate, 306</p>
			<p class="em-only_endmatter-idx1">Augmentin, 273</p>
			<p class="em-only_endmatter-idx1">Automated external defibrillator (AED), 296–297, 297<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Automatisms, 207</p>
			<p class="em-only_endmatter-idx1">AVMs. <span class="endmatter-idx1_italic">See</span> Arteriovenous malformations</p>
			<p class="em-only_endmatter-idx1">Azathioprine</p>
			<p class="em-only_endmatter-idx2">dermatomyositis treated with, 168</p>
			<p class="em-only_endmatter-idx2">description of, 179</p>
			<p class="em-only_endmatter-idx2">polymyositis treated with, 168</p>
			<p class="em-only_endmatter-idx1">Azithromycin</p>
			<p class="em-only_endmatter-idx2">dental prophylaxis uses of, 248<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">indications for, 275</p>
			<p class="em-only_endmatter-idx1">Aztreonam, 272–273</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Bacteroides fragilis,</span> 275</p>
			<p class="em-only_endmatter-idx1">Barbiturates, 201–202</p>
			<p class="em-only_endmatter-idx1">Bare-&#173;metal stents, percutaneous coronary intervention with, 92</p>
			<p class="em-only_endmatter-idx1">Baricitinib, 180</p>
			<p class="em-only_endmatter-idx1">Basal ganglia, 204</p>
			<p class="em-only_endmatter-idx1">Baseline probability of the outcome, 22</p>
			<p class="em-only_endmatter-idx1">Basic life support (BLS), 299</p>
			<p class="em-only_endmatter-idx1">Bayes theorem, 19</p>
			<p class="em-only_endmatter-idx1">Behavioral disorders</p>
			<p class="em-only_endmatter-idx2">bipolar disorder, 196, 203</p>
			<p class="em-only_endmatter-idx2">conversion disorder, 197</p>
			<p class="em-only_endmatter-idx2">depression. <span class="endmatter-idx2_italic">See</span> Depression</p>
			<p class="em-only_endmatter-idx2">factitious disorder, 197</p>
			<p class="em-only_endmatter-idx2">generalized anxiety disorder, 197</p>
			<p class="em-only_endmatter-idx2">illness anxiety disorder, 197</p>
			<p class="em-only_endmatter-idx2">informed consent in patients with, 211–212</p>
			<p class="em-only_endmatter-idx2">malingering, 197, 203</p>
			<p class="em-only_endmatter-idx2">mania, 195–196</p>
			<p class="em-only_endmatter-idx2">medical conditions as cause of, 194</p>
			<p class="em-only_endmatter-idx2">mood disorders, 195–196</p>
			<p class="em-only_endmatter-idx2">overview of, 194</p>
			<p class="em-only_endmatter-idx2">panic disorder, 198</p>
			<p class="em-only_endmatter-idx2">personality disorders, 198</p>
			<p class="em-only_endmatter-idx2">pharmacologic treatment of</p>
			<p class="em-only_endmatter-idx3">antianxiety drugs, 201<span class="endmatter-idx3_italic">t,</span> 201–202</p>
			<p class="em-only_endmatter-idx3">antidepressants, 202–203, 203<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">antipsychotic drugs, 199–201, 200<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">barbiturates, 201–202</p>
			<p class="em-only_endmatter-idx3">benzodiazepines, 201–202</p>
			<p class="em-only_endmatter-idx3">hypnotic drugs, 201<span class="endmatter-idx3_italic">t,</span> 201–202</p>
			<p class="em-only_endmatter-idx3">mood stabilizers, 203–204</p>
			<p class="em-only_endmatter-idx2">post-&#173;traumatic stress disorder, 198</p>
			<p class="em-only_endmatter-idx2">prevalence of, 194</p>
			<p class="em-only_endmatter-idx2">schizo&#173;phre&#173;nia, 194–195, 200</p>
			<p class="em-only_endmatter-idx2">somatic symptom and related disorders, 196–197</p>
			<p class="em-only_endmatter-idx2">substance abuse disorders, 198–199</p>
			<p class="em-only_endmatter-idx1">Beh<span class="endmatter-idx1_accent">ç</span>et disease, 173–174</p>
			<p class="em-only_endmatter-idx1">Belimumab, 180</p>
			<p class="em-only_endmatter-idx1">Benzodiazepines, 201–202</p>
			<p class="em-only_endmatter-idx1">Benztropine, 205</p>
			<p class="em-only_endmatter-idx1">Berry aneurysms, 121</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_accent">β</span><span class="subscript _idGenCharOverride-1">2</span>-&#173;adrenergic agonists, for lung disease, 128</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_accent">β</span>-&#173;Blockers</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 62, 309<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">angina pectoris treated with, 91</p>
			<p class="em-only_endmatter-idx2">congestive heart failure treated with, 98–99</p>
			<p class="em-only_endmatter-idx2">hypertension treated with, 62, 69</p>
			<p class="em-only_endmatter-idx2">myo&#173;car&#173;dial infarction treated with, 93</p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 106, 309<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">prophylactic uses of, 285</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_accent">β</span>-lactam antibiotics, 271–273</p>
			<p class="em-only_endmatter-idx1">Bezlotoxumab, 249</p>
			<p class="em-only_endmatter-idx1">Biapenem, 273</p>
			<p class="em-only_endmatter-idx1">Bias</p>
			<p class="em-only_endmatter-idx2">in case series, 9</p>
			<p class="em-only_endmatter-idx2">investigator, 5</p>
			<p class="em-only_endmatter-idx2">missing medical rec&#173;ords and, 26</p>
			<p class="em-only_endmatter-idx2">recall, 11</p>
			<p class="em-only_endmatter-idx2">se&#173;lection, 4, 11</p>
			<p class="em-only_endmatter-idx1">Bile acid sequestrants, for hypercholesterolemia, 75<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Biologic agents, for rheumatoid disease, 153</p>
			<p class="em-only_endmatter-idx1">Biologic response modifiers, 241–242</p>
			<p class="em-only_endmatter-idx1">Biologic therapies, for cancer, 241–243</p>
			<p class="em-only_endmatter-idx1">Biomarkers, of coronary heart disease, 86–87</p>
			<p class="em-only_endmatter-idx1">Biosimilar agents, 180–181</p>
			<p class="em-only_endmatter-idx1">Bipolar disorder, 196, 203</p>
			<p class="em-only_endmatter-idx1">Bisphosphonates, 190, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Biventricular pacing, for congestive heart failure, 100</p>
			<p class="em-only_endmatter-idx1">Bladder cancer screening, 221</p>
			<p class="em-only_endmatter-idx1">Bleeding time, 139</p>
			<p class="em-only_endmatter-idx1">Blood</p>
			<p class="em-only_endmatter-idx2">composition of, 131</p>
			<p class="em-only_endmatter-idx2">formed ele&#173;ments of, 131</p>
			<p class="em-only_endmatter-idx2">plasma of, 131</p>
			<p class="em-only_endmatter-idx1">Blood cells, 131</p>
			<p class="em-only_endmatter-idx1">Blood glucose testing, 40</p>
			<p class="em-only_endmatter-idx1">Blood pressure. <span class="endmatter-idx1_italic">See</span> <span class="endmatter-idx1_italic">also</span> Hypertension</p>
			<p class="em-only_endmatter-idx2">ambulatory mea&#173;sure&#173;ment of, 52</p>
			<p class="em-only_endmatter-idx2">classification of, 52<span class="endmatter-idx2_italic">t,</span> 52–53, 214</p>
			<p class="em-only_endmatter-idx2">coronary heart disease risks, 73<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">diastolic, 52, 56</p>
			<p class="em-only_endmatter-idx2">elevated. <span class="endmatter-idx2_italic">See</span> Hypertension</p>
			<p class="em-only_endmatter-idx2">mea&#173;sure&#173;ment of</p>
			<p class="em-only_endmatter-idx3">ambulatory, 52</p>
			<p class="em-only_endmatter-idx3">in hypertension evaluation, 55</p>
			<p class="em-only_endmatter-idx2">sleep-&#173;related decreases in, 53, 66–67</p>
			<p class="em-only_endmatter-idx2">in stroke prevention, 115</p>
			<p class="em-only_endmatter-idx2">in subarachnoid hemorrhage, 121</p>
			<p class="em-only_endmatter-idx2">systolic, 52, 56</p>
			<p class="em-only_endmatter-idx1">Bodily distress disorder, 196</p>
			<p class="em-only_endmatter-idx1">Body dysmorphic disorder, 197</p>
			<p class="em-only_endmatter-idx1">Bone marrow disorders, anemia caused by, 137</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Borrelia burgdorferi,</span> 254–255</p>
			<p class="em-only_endmatter-idx1">Boutonni<span class="endmatter-idx1_accent">è</span>re deformity, 152</p>
			<p class="em-only_endmatter-idx1">Brachytherapy, 237–238</p>
			<p class="em-only_endmatter-idx1">Bradyarrhythmias</p>
			<p class="em-only_endmatter-idx2">in congestive heart failure, 99</p>
			<p class="em-only_endmatter-idx2">definition of, 101</p>
			<p class="em-only_endmatter-idx1">Brain natriuretic peptide (BNP), 97</p>
			<p class="em-only_endmatter-idx1">Branch ret&#173;i&#173;nal vein occlusion, 148</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">BRCA1,</span> 216–217</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">BRCA2,</span> 216–217</p>
			<p class="em-only_endmatter-idx1">Breast cancer</p>
			<p class="em-only_endmatter-idx2">hormone replacement therapy and, 215</p>
			<p class="em-only_endmatter-idx2">mammographic detection of, 216–217</p>
			<p class="em-only_endmatter-idx2">mortality rates for, 215</p>
			<p class="em-only_endmatter-idx2">prevalence of, 215</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 215–216</p>
			<p class="em-only_endmatter-idx2">screening for, 215–217</p>
			<p class="em-only_endmatter-idx1">Brief psychotic disorder, 195</p>
			<p class="em-only_endmatter-idx1">Brivudine, 279</p>
			<p class="em-only_endmatter-idx1">Bromocriptine, for Parkinson disease, 205</p>
			<p class="em-only_endmatter-idx1">Bronchiectasis, 124</p>
			<p class="em-only_endmatter-idx1">Bronchitis, chronic, 124</p>
			<p class="em-only_endmatter-idx1">Bronchodilators, for lung disease, 128</p>
			<p class="em-only_endmatter-idx1">Bronchospasm, 123–124</p>
			<p class="em-only_endmatter-idx1">Bundle of His, 101</p>
			<p class="em-only_endmatter-idx1">Bupivacaine, 305</p>
			<p class="em-only_endmatter-idx1">Butterfly rash, 158, 159<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Bypass Angioplasty Revascularization Investigation, 92</p>
			<p class="em-only_endmatter-idx1">C cells, 41, 46</p>
			<p class="em-only_endmatter-idx1">C-reactive protein (CRP), 153</p>
			<p class="em-only_endmatter-idx1">Caffeine halothane contracture test, 292</p>
			<p class="em-only_endmatter-idx1">Calcineurin inhibitors, 179</p>
			<p class="em-only_endmatter-idx1">Calcitonin, 41</p>
			<p class="em-only_endmatter-idx1">Calcium channel blockers (CCBs)</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 61–62, 309<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">angina pectoris treated with, 91</p>
			<p class="em-only_endmatter-idx2">classification of, 61</p>
			<p class="em-only_endmatter-idx2">hypertension treated with, 59<span class="endmatter-idx2_italic">t,</span> 61–62</p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 309<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Canakinumab, 180</p>
			<p class="em-only_endmatter-idx1">Cancer. <span class="endmatter-idx1_italic">See also specific cancer</span></p>
			<p class="em-only_endmatter-idx2">in &#173;children, 235</p>
			<p class="em-only_endmatter-idx2">etiology of, 235–236, 237<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">familial clustering of, 236</p>
			<p class="em-only_endmatter-idx2">gene mutations associated with, 236, 237<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">ge&#173;ne&#173;tic profiling of, 242</p>
			<p class="em-only_endmatter-idx2">global incidence of, 235</p>
			<p class="em-only_endmatter-idx2">ionizing radiation exposure as cause of, 236</p>
			<p class="em-only_endmatter-idx2">mortality rates for, 235</p>
			<p class="em-only_endmatter-idx2">screening for, 215–221, 216<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">treatment of</p>
			<p class="em-only_endmatter-idx3">angiogenesis inhibitors, 240<span class="endmatter-idx3_italic">t,</span> 241</p>
			<p class="em-only_endmatter-idx3">biologic therapies, 241–243</p>
			<p class="em-only_endmatter-idx3">chemotherapy, 239–241, 240<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">monoclonal antibodies, 242</p>
			<p class="em-only_endmatter-idx3">radiation therapy, 237–239</p>
			<p class="em-only_endmatter-idx3">vaccines, 242</p>
			<p class="em-only_endmatter-idx2">virus-&#173;associated, 236, 237<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Candida albicans,</span> 258</p>
			<p class="em-only_endmatter-idx1">Capacity to Consent to Treatment Instrument <br />(CCTI), 211</p>
			<p class="em-only_endmatter-idx1">Capillary telangiectasis, 121</p>
			<p class="em-only_endmatter-idx1">Captopril, 309<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Carbamazepine, 203, 207–208</p>
			<p class="em-only_endmatter-idx1">Carbapenems, 273</p>
			<p class="em-only_endmatter-idx1">Carbidopa, for Parkinson disease, 205</p>
			<p class="em-only_endmatter-idx1">Carbonic anhydrase I, 167</p>
			<p class="em-only_endmatter-idx1">Cardiac enzymes, 86–87</p>
			<p class="em-only_endmatter-idx1">Cardiac rhythm disorders</p>
			<p class="em-only_endmatter-idx2">antiarrhythmic drugs for, 102, 102<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">bradyarrhythmias, 99, 101</p>
			<p class="em-only_endmatter-idx2">conduction block, 101</p>
			<p class="em-only_endmatter-idx2">overview of, 101</p>
			<p class="em-only_endmatter-idx2">tachyarrhythmias</p>
			<p class="em-only_endmatter-idx3">atrial fibrillation, 102–103, 103<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">atrial flutter, 102</p>
			<p class="em-only_endmatter-idx3">in congestive heart failure, 99</p>
			<p class="em-only_endmatter-idx3">definition of, 102</p>
			<p class="em-only_endmatter-idx3">implantable cardioverter-&#173;defibrillators for, 104–106</p>
			<p class="em-only_endmatter-idx3">supraventricular tachycardias, 102–103</p>
			<p class="em-only_endmatter-idx3">ventricular, 104</p>
			<p class="em-only_endmatter-idx3">ventricular fibrillation, 104</p>
			<p class="em-only_endmatter-idx1">Cardiac transplantation, for congestive heart failure, 100</p>
			<p class="em-only_endmatter-idx1">Cardioembolic strokes, 111</p>
			<p class="em-only_endmatter-idx1">Cardiogenic shock, 300</p>
			<p class="em-only_endmatter-idx1">Cardiopulmonary arrest, 296–299, 297<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cardiopulmonary resuscitation (CPR)</p>
			<p class="em-only_endmatter-idx2">description of, 296–299, 297<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in ventricular fibrillation, 104</p>
			<p class="em-only_endmatter-idx1">Cardiovascular disease (CVD)</p>
			<p class="em-only_endmatter-idx2">hypertension. <span class="endmatter-idx2_italic">See</span> Hypertension</p>
			<p class="em-only_endmatter-idx2">perioperative management for ocular surgery in patients with, 283</p>
			<p class="em-only_endmatter-idx2">risk assessment for, 73</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors</p>
			<p class="em-only_endmatter-idx3">cholesterol levels, 72</p>
			<p class="em-only_endmatter-idx3">hypertension, 55, 56<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">hypertensive retinopathy and, 69</p>
			<p class="em-only_endmatter-idx3">list of, 56<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx2">screening for, 214–215</p>
			<p class="em-only_endmatter-idx1">Cardiovascular drugs, ocular adverse effects of, 309<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Carotid artery stenting</p>
			<p class="em-only_endmatter-idx2">carotid endarterectomy versus, 118</p>
			<p class="em-only_endmatter-idx2">carotid stenosis treated with, 118</p>
			<p class="em-only_endmatter-idx2">prophylactic uses of, 117</p>
			<p class="em-only_endmatter-idx1">Carotid bruits, asymptomatic, 116–117</p>
			<p class="em-only_endmatter-idx1">Carotid duplex ultrasonography</p>
			<p class="em-only_endmatter-idx2">carotid stenosis diagnosis using, 116</p>
			<p class="em-only_endmatter-idx2">stroke evaluations using, 113</p>
			<p class="em-only_endmatter-idx1">Carotid endarterectomy</p>
			<p class="em-only_endmatter-idx2">carotid artery stenting versus, 118</p>
			<p class="em-only_endmatter-idx2">carotid stenosis treated with, 117–119</p>
			<p class="em-only_endmatter-idx1">Carotid occlusive disease</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 116</p>
			<p class="em-only_endmatter-idx2">ischemic stroke caused by, 115–119</p>
			<p class="em-only_endmatter-idx2">stroke caused by, 115–119</p>
			<p class="em-only_endmatter-idx1">Carotid Revascularization Endarterectomy Versus Stenting Trial-2 (CREST-2), 117</p>
			<p class="em-only_endmatter-idx1">Carotid stenosis</p>
			<p class="em-only_endmatter-idx2">asymptomatic, 116–117</p>
			<p class="em-only_endmatter-idx2">carotid endarterectomy for, 117–119</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 116</p>
			<p class="em-only_endmatter-idx2">ischemic stroke caused by, 115–119</p>
			<p class="em-only_endmatter-idx2">management of, 116–118</p>
			<p class="em-only_endmatter-idx2">stroke caused by, 115–119</p>
			<p class="em-only_endmatter-idx2">symptomatic, 117–118</p>
			<p class="em-only_endmatter-idx2">transient monocular vision loss caused by, 118</p>
			<p class="em-only_endmatter-idx1">Case-&#173;control series, 10–12, 11<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Case reports, 9</p>
			<p class="em-only_endmatter-idx1">Case series, 9–10</p>
			<p class="em-only_endmatter-idx1">Cataract surgery</p>
			<p class="em-only_endmatter-idx2">delirium &#173;after, 187</p>
			<p class="em-only_endmatter-idx2">fall reduction &#173;after, 192</p>
			<p class="em-only_endmatter-idx2">functional visual status &#173;after, 192</p>
			<p class="em-only_endmatter-idx1">Cataracts</p>
			<p class="em-only_endmatter-idx2">radiation therapy as cause of, 239</p>
			<p class="em-only_endmatter-idx2">statins and, 79</p>
			<p class="em-only_endmatter-idx2">visual impairment caused by, 184</p>
			<p class="em-only_endmatter-idx1">Catastrophic antiphospholipid syndrome, 164</p>
			<p class="em-only_endmatter-idx1">Cathepsin, 167</p>
			<p class="em-only_endmatter-idx1">Cause-&#173;and-&#173;effect diagram, 30–31</p>
			<p class="em-only_endmatter-idx1">CCBs. <span class="endmatter-idx1_italic">See</span> Calcium channel blockers</p>
			<p class="em-only_endmatter-idx1">CD52, 180</p>
			<p class="em-only_endmatter-idx1">CD4<span class="endmatter-idx1_symbol">+</span> helper-&#173;induced T lymphocytes, 266</p>
			<p class="em-only_endmatter-idx1">Cefaclor, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cefazolin, for dental prophylaxis, 248<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ceftazidime, for pseudomonal infections, 251</p>
			<p class="em-only_endmatter-idx1">Ceftriaxone</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Borrelia burgdorferi</span> treated with, 255</p>
			<p class="em-only_endmatter-idx2">dental prophylaxis uses of, 248<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">gonococcal infections treated with, 251</p>
			<p class="em-only_endmatter-idx1">Cefuroxime axetil, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">“Ceiling effect,” 25</p>
			<p class="em-only_endmatter-idx1">Cellular immune system, 245</p>
			<p class="em-only_endmatter-idx1">Center for Quality Assessment and Improvement in &#173;Mental Health, 190</p>
			<p class="em-only_endmatter-idx1">Centers for Disease Control (CDC), 223, 226, 227, 232</p>
			<p class="em-only_endmatter-idx1">Central ner&#173;vous system, local anesthesia toxic reactions effect on, 304</p>
			<p class="em-only_endmatter-idx1">Central ret&#173;i&#173;nal vein occlusion, 148</p>
			<p class="em-only_endmatter-idx1">Cephalexin, for dental prophylaxis, 248<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cephalosporins</p>
			<p class="em-only_endmatter-idx2">description of, 272, 272<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Haemophilus influenzae</span> treated with, 250</p>
			<p class="em-only_endmatter-idx1">Ce&#173;re&#173;bral amyloid angiopathy, 120</p>
			<p class="em-only_endmatter-idx1">Ce&#173;re&#173;bral angiography, for carotid stenosis <br />diagnosis, 116</p>
			<p class="em-only_endmatter-idx1">Ce&#173;re&#173;bral autosomal dominant arteriography with subcortical infarcts and leukoencephalopathy (CADASIL), 111</p>
			<p class="em-only_endmatter-idx1">Ce&#173;re&#173;bral circulation, 110</p>
			<p class="em-only_endmatter-idx1">Ce&#173;re&#173;bral hypoperfusion, 299</p>
			<p class="em-only_endmatter-idx1">Ce&#173;re&#173;bral ischemia. <span class="endmatter-idx1_italic">See also</span> Ischemic stroke</p>
			<p class="em-only_endmatter-idx2">&#173;causes of, 110–111</p>
			<p class="em-only_endmatter-idx2">pathogenesis of, 110</p>
			<p class="em-only_endmatter-idx2">transient, 110</p>
			<p class="em-only_endmatter-idx1">Cerebrovascular disease</p>
			<p class="em-only_endmatter-idx2">hyperlipidemia and, 78</p>
			<p class="em-only_endmatter-idx2">hypertension and, 66</p>
			<p class="em-only_endmatter-idx1">Cerivastatin, 77</p>
			<p class="em-only_endmatter-idx1">Certolizumab pegol, 180</p>
			<p class="em-only_endmatter-idx1">Cervical cancer</p>
			<p class="em-only_endmatter-idx2">&#173;human papillomavirus and, 217–218</p>
			<p class="em-only_endmatter-idx2">mortality rates for, 217</p>
			<p class="em-only_endmatter-idx2">prevalence of, 217</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 217–218</p>
			<p class="em-only_endmatter-idx2">screening for, 216<span class="endmatter-idx2_italic">t,</span> 217–218</p>
			<p class="em-only_endmatter-idx1">Cervicitis, 255</p>
			<p class="em-only_endmatter-idx1">CHADS2 risk calculator, 103</p>
			<p class="em-only_endmatter-idx1">Charles Bonnet syndrome, 206</p>
			<p class="em-only_endmatter-idx1">CHD. <span class="endmatter-idx1_italic">See</span> Coronary heart disease</p>
			<p class="em-only_endmatter-idx1">Chemotherapy</p>
			<p class="em-only_endmatter-idx2">adjuvant, 239</p>
			<p class="em-only_endmatter-idx2">cancer treated with, 239–241, 240<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">curative, 239</p>
			<p class="em-only_endmatter-idx2">neoadjuvant, 239</p>
			<p class="em-only_endmatter-idx2">palliative, 239, 241</p>
			<p class="em-only_endmatter-idx1">Chest compressions, 296–297</p>
			<p class="em-only_endmatter-idx1">Chest radiographs</p>
			<p class="em-only_endmatter-idx2">congestive heart failure findings, 97</p>
			<p class="em-only_endmatter-idx2">lung disease evaluations, 126</p>
			<p class="em-only_endmatter-idx1">CHF. <span class="endmatter-idx1_italic">See</span> Congestive heart failure</p>
			<p class="em-only_endmatter-idx1">Chi-&#173;square test, 7</p>
			<p class="em-only_endmatter-idx1">Chickenpox, 260</p>
			<p class="em-only_endmatter-idx1">Childhood absence epilepsy, 207</p>
			<p class="em-only_endmatter-idx1">&#173;Children</p>
			<p class="em-only_endmatter-idx2">cancer in, 235</p>
			<p class="em-only_endmatter-idx2">cardiopulmonary arrest for, 296–299, 297<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">hypertension in, 68</p>
			<p class="em-only_endmatter-idx2">obesity in, 68</p>
			<p class="em-only_endmatter-idx2">perioperative management for ocular surgery in, 283</p>
			<p class="em-only_endmatter-idx2">preoperative fasting by, 287</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Chlamydia pneumoniae,</span> 155</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Chlamydia trachomatis</span></p>
			<p class="em-only_endmatter-idx2">gonorrhea and, 251</p>
			<p class="em-only_endmatter-idx2">reactive arthritis associated with, 155</p>
			<p class="em-only_endmatter-idx2">transmission of, 255</p>
			<p class="em-only_endmatter-idx2">treatment of, 255</p>
			<p class="em-only_endmatter-idx1">Chlorambucil, 179</p>
			<p class="em-only_endmatter-idx1">Chloramphenicol, 276</p>
			<p class="em-only_endmatter-idx1">Chlorthalidone, 59, 65</p>
			<p class="em-only_endmatter-idx1">Choking, 299</p>
			<p class="em-only_endmatter-idx1">Cholera vaccination, 232</p>
			<p class="em-only_endmatter-idx1">Cholesterol</p>
			<p class="em-only_endmatter-idx2">elevated levels of. <span class="endmatter-idx2_italic">See</span> Hypercholesterolemia</p>
			<p class="em-only_endmatter-idx2">lipoprotein transport of, 72</p>
			<p class="em-only_endmatter-idx2">National Cholesterol Education Program guidelines for, 71</p>
			<p class="em-only_endmatter-idx1">Cholesterol absorption inhibitor, for hypercholesterolemia, 75<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cholinesterase inhibitors, for Alzheimer disease, 210</p>
			<p class="em-only_endmatter-idx1">Choroidal vasculitis, 171</p>
			<p class="em-only_endmatter-idx1">Chronic bronchitis, 124</p>
			<p class="em-only_endmatter-idx1">Chronic disseminated intravascular coagulation, 146</p>
			<p class="em-only_endmatter-idx1">Chronic hemolytic anemia, 135</p>
			<p class="em-only_endmatter-idx1">Chronic hypertension, 67–68</p>
			<p class="em-only_endmatter-idx1">Chronic obstructive pulmonary disease (COPD)</p>
			<p class="em-only_endmatter-idx2">description of, 124</p>
			<p class="em-only_endmatter-idx2">Global Initiative for Chronic Obstructive Lung Disease resources on, 124</p>
			<p class="em-only_endmatter-idx2">obstructive sleep apnea and, 124–125</p>
			<p class="em-only_endmatter-idx2">perioperative management for ocular surgery in patients with, 284</p>
			<p class="em-only_endmatter-idx1">Chronic renal disease, 65</p>
			<p class="em-only_endmatter-idx1">Chronic renal failure, 137</p>
			<p class="em-only_endmatter-idx1">Chronic thyroiditis, 45</p>
			<p class="em-only_endmatter-idx1">Churg-&#173;Strauss syndrome. <span class="endmatter-idx1_italic">See</span> Eosinophilic granulomatosis with polyangiitis</p>
			<p class="em-only_endmatter-idx1">Chylomicrons, 72</p>
			<p class="em-only_endmatter-idx1">Cidofovir, for herpes simplex virus, 260</p>
			<p class="em-only_endmatter-idx1">Cilastatin, 273</p>
			<p class="em-only_endmatter-idx1">Ciprofloxacin, 274, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ciraparantag, 149</p>
			<p class="em-only_endmatter-idx1">Circle of Willis, subarachnoid hemorrhage from, 121</p>
			<p class="em-only_endmatter-idx1">Clarithromycin</p>
			<p class="em-only_endmatter-idx2">dental prophylaxis uses of, 248<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">indications for, 275</p>
			<p class="em-only_endmatter-idx1">Clavulanic acid, 273</p>
			<p class="em-only_endmatter-idx1">Clindamycin</p>
			<p class="em-only_endmatter-idx2">dental prophylaxis uses of, 248<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">indications for, 275</p>
			<p class="em-only_endmatter-idx1">Clinical questions</p>
			<p class="em-only_endmatter-idx2">examples of, 3</p>
			<p class="em-only_endmatter-idx2">researching answers to</p>
			<p class="em-only_endmatter-idx3">information sources used in, 3</p>
			<p class="em-only_endmatter-idx3">overview of, 3–4</p>
			<p class="em-only_endmatter-idx1">Clinical studies</p>
			<p class="em-only_endmatter-idx2">absolute risk reduction, 22</p>
			<p class="em-only_endmatter-idx2">case-&#173;control series, 10–12, 11<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">case reports, 9</p>
			<p class="em-only_endmatter-idx2">case series, 9–10</p>
			<p class="em-only_endmatter-idx2">clinical practice mea&#173;sure&#173;ments and <br />improvements using</p>
			<p class="em-only_endmatter-idx3">continuous quality improvement, 28–31</p>
			<p class="em-only_endmatter-idx3">data used in, 23–24</p>
			<p class="em-only_endmatter-idx3">lean techniques for, 31–32</p>
			<p class="em-only_endmatter-idx3">mea&#173;sure&#173;ment system, 24–25</p>
			<p class="em-only_endmatter-idx3">monitoring system implementation, 25–27</p>
			<p class="em-only_endmatter-idx3">quality improvements, 25</p>
			<p class="em-only_endmatter-idx3">results analy&#173;sis, 27–28</p>
			<p class="em-only_endmatter-idx2">cohort studies, 11<span class="endmatter-idx2_italic">f,</span> 12–13</p>
			<p class="em-only_endmatter-idx2">conflict of interest, 7–8</p>
			<p class="em-only_endmatter-idx2">control groups in, 4</p>
			<p class="em-only_endmatter-idx2">critical reading of</p>
			<p class="em-only_endmatter-idx3">recruitment strategy for, 4–5</p>
			<p class="em-only_endmatter-idx3">study population, 4–5</p>
			<p class="em-only_endmatter-idx2">cross-&#173;sectional studies, 12</p>
			<p class="em-only_endmatter-idx2">data from</p>
			<p class="em-only_endmatter-idx3">continuous, 7</p>
			<p class="em-only_endmatter-idx3">extrapolation of, 5</p>
			<p class="em-only_endmatter-idx3">normal distribution of, 7</p>
			<p class="em-only_endmatter-idx2">diagnostic and screening test interpretation</p>
			<p class="em-only_endmatter-idx3">clinical ac&#173;cep&#173;tance, 21</p>
			<p class="em-only_endmatter-idx3">combination use of tests, 20–21</p>
			<p class="em-only_endmatter-idx3">complicating &#173;factors in, 16–21</p>
			<p class="em-only_endmatter-idx3">ethics of testing, 21</p>
			<p class="em-only_endmatter-idx3">generalizability, 21</p>
			<p class="em-only_endmatter-idx3">overview of, 15–16</p>
			<p class="em-only_endmatter-idx3">pretest probability of disease, 18–21, 20<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">receiver operating characteristic curves, 16–18, 18<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx2">experimental, 8</p>
			<p class="em-only_endmatter-idx2">follow-up, 6</p>
			<p class="em-only_endmatter-idx2">hierarchy of, 9<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">“intention to treat” analy&#173;sis, 6</p>
			<p class="em-only_endmatter-idx2">investigator bias in, 5</p>
			<p class="em-only_endmatter-idx2">meta-&#173;analyses, 3, 8</p>
			<p class="em-only_endmatter-idx2">nonexperimental, 8</p>
			<p class="em-only_endmatter-idx2">number needed to treat, 22</p>
			<p class="em-only_endmatter-idx2">observational, 8</p>
			<p class="em-only_endmatter-idx2">odds ratios, 22–23</p>
			<p class="em-only_endmatter-idx2">outcomes of</p>
			<p class="em-only_endmatter-idx3">baseline probability of, 22</p>
			<p class="em-only_endmatter-idx3">as clearly defined, 6</p>
			<p class="em-only_endmatter-idx3">clinical relevance of, 5</p>
			<p class="em-only_endmatter-idx3">reliability of, 6</p>
			<p class="em-only_endmatter-idx2">population used in</p>
			<p class="em-only_endmatter-idx3">evaluation of, 4–5</p>
			<p class="em-only_endmatter-idx3">random assignment of, 4</p>
			<p class="em-only_endmatter-idx3">recruitment strategy for, 4–5</p>
			<p class="em-only_endmatter-idx3">vulnerable, 4</p>
			<p class="em-only_endmatter-idx2">relative risk, 22</p>
			<p class="em-only_endmatter-idx2">reproducibility of, 5</p>
			<p class="em-only_endmatter-idx2">risk difference, 22</p>
			<p class="em-only_endmatter-idx2">sample size of, 5</p>
			<p class="em-only_endmatter-idx2">se&#173;lection bias in, 4</p>
			<p class="em-only_endmatter-idx2">validity of</p>
			<p class="em-only_endmatter-idx3">criteria for, 6</p>
			<p class="em-only_endmatter-idx3">follow-up and, 6</p>
			<p class="em-only_endmatter-idx1">Clinical &#173;trials</p>
			<p class="em-only_endmatter-idx2">case series versus, 9</p>
			<p class="em-only_endmatter-idx2">cohort studies versus, 13, 13<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">evaluation of, 14</p>
			<p class="em-only_endmatter-idx2">meta-&#173;analyses of, 14</p>
			<p class="em-only_endmatter-idx2">random assignment in, 13</p>
			<p class="em-only_endmatter-idx1">Clomiphene, 309<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Clopidogrel, for stroke prevention, 114</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Clostridium difficile,</span> 249</p>
			<p class="em-only_endmatter-idx2">reactive arthritis associated with, 155</p>
			<p class="em-only_endmatter-idx2">vancomycin for, 273</p>
			<p class="em-only_endmatter-idx1">Clozapine, 200</p>
			<p class="em-only_endmatter-idx1">Clusters A, B, and C personality disorders, 198</p>
			<p class="em-only_endmatter-idx1">CMV. <span class="endmatter-idx1_italic">See</span> Cytomegalovirus</p>
			<p class="em-only_endmatter-idx1">CPR. <span class="endmatter-idx1_italic">See</span> Cardiopulmonary resuscitation</p>
			<p class="em-only_endmatter-idx1">Coagulation</p>
			<p class="em-only_endmatter-idx2">disorders of. <span class="endmatter-idx2_italic">See</span> Coagulation disorders</p>
			<p class="em-only_endmatter-idx2">laboratory evaluation of, 139–140</p>
			<p class="em-only_endmatter-idx1">Coagulation cascade</p>
			<p class="em-only_endmatter-idx2">description of, 89, 90<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">extrinsic pathway of, 138<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">intrinsic pathway of, 138<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">schematic diagram of, 138<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Coagulation disorders</p>
			<p class="em-only_endmatter-idx2">acquired, 145–146</p>
			<p class="em-only_endmatter-idx2">disseminated intravascular coagulation, 142, 145–146</p>
			<p class="em-only_endmatter-idx2">hemophilia A, 144</p>
			<p class="em-only_endmatter-idx2">hereditary, 144–145</p>
			<p class="em-only_endmatter-idx2">liver disease, 145</p>
			<p class="em-only_endmatter-idx2">thrombotic disorders, 146</p>
			<p class="em-only_endmatter-idx2">vitamin K deficiency, 145</p>
			<p class="em-only_endmatter-idx2">von Willebrand disease, 144–145</p>
			<p class="em-only_endmatter-idx1">Coagulation &#173;factors, 138</p>
			<p class="em-only_endmatter-idx1">Coarctation of the aorta, 54</p>
			<p class="em-only_endmatter-idx1">Cocaine, optic neuropathy caused by, 199</p>
			<p class="em-only_endmatter-idx1">Cochrane Library, 3</p>
			<p class="em-only_endmatter-idx1">Cogan syndrome, 174</p>
			<p class="em-only_endmatter-idx1">Cohort studies</p>
			<p class="em-only_endmatter-idx2">description of, 12–13</p>
			<p class="em-only_endmatter-idx2">schematic diagram of, 11<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Colchicine, for Beh<span class="endmatter-idx1_accent">ç</span>et disease, 173</p>
			<p class="em-only_endmatter-idx1">Colonoscopy</p>
			<p class="em-only_endmatter-idx2">colorectal cancer screening uses of, 218–219</p>
			<p class="em-only_endmatter-idx2">computed tomography, 219</p>
			<p class="em-only_endmatter-idx1">Colony-&#173;stimulating &#173;factors, 242</p>
			<p class="em-only_endmatter-idx1">Color vision, digoxin effects on, 106</p>
			<p class="em-only_endmatter-idx1">Colorectal cancer</p>
			<p class="em-only_endmatter-idx2">colonoscopy screening for, 218–219</p>
			<p class="em-only_endmatter-idx2">flexible sigmoidoscopy screening for, 218–219</p>
			<p class="em-only_endmatter-idx2">mortality rates for, 218</p>
			<p class="em-only_endmatter-idx2">polyps, 218</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 218</p>
			<p class="em-only_endmatter-idx2">screening for, 216<span class="endmatter-idx2_italic">t,</span> 218–219</p>
			<p class="em-only_endmatter-idx1">Combined <span class="endmatter-idx1_greek">α</span>-&#173;adrenergic and <span class="endmatter-idx1_accent">β</span>-&#173;adrenergic antagonists, 63</p>
			<p class="em-only_endmatter-idx1">Common cause &#173;factors, 28</p>
			<p class="em-only_endmatter-idx1">Complex partial seizures, 206–207</p>
			<p class="em-only_endmatter-idx1">Computed tomography (CT)</p>
			<p class="em-only_endmatter-idx2">in coronary heart disease diagnosis, 88</p>
			<p class="em-only_endmatter-idx2">epilepsy diagnosis using, 207</p>
			<p class="em-only_endmatter-idx2">lung disease evaluations, 126</p>
			<p class="em-only_endmatter-idx2">multimodal, 112</p>
			<p class="em-only_endmatter-idx2">stroke evaluations using, 112</p>
			<p class="em-only_endmatter-idx1">Computed tomography angiography, for carotid stenosis, 116</p>
			<p class="em-only_endmatter-idx1">Computed tomography colonoscopy, for colorectal cancer screening, 219</p>
			<p class="em-only_endmatter-idx1">Concizumab, 144</p>
			<p class="em-only_endmatter-idx1">Conduction block, 101</p>
			<p class="em-only_endmatter-idx1">Conduit Artery Function Endpoint (CAFE) study, 64</p>
			<p class="em-only_endmatter-idx1">Conflict of interest, 7–8</p>
			<p class="em-only_endmatter-idx1">Confounding &#173;factors, 12–13</p>
			<p class="em-only_endmatter-idx1">Confusion, in older adults, 187</p>
			<p class="em-only_endmatter-idx1">Congenital syphilis, 222</p>
			<p class="em-only_endmatter-idx1">Congenital Zika syndrome, 265</p>
			<p class="em-only_endmatter-idx1">Congestive heart failure (CHF)</p>
			<p class="em-only_endmatter-idx2">arrhythmias in, 99</p>
			<p class="em-only_endmatter-idx2">bradyarrhythmias in, 99</p>
			<p class="em-only_endmatter-idx2">brain natriuretic peptide in, 97</p>
			<p class="em-only_endmatter-idx2">cardiac transplantation for, 100</p>
			<p class="em-only_endmatter-idx2">chest radiograph findings in, 97</p>
			<p class="em-only_endmatter-idx2">classification of, 95, 96<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">coronary angiography of, 97</p>
			<p class="em-only_endmatter-idx2">diagnostic evaluation of, 97</p>
			<p class="em-only_endmatter-idx2">echocardiography of, 97</p>
			<p class="em-only_endmatter-idx2">electrocardiography of, 97</p>
			<p class="em-only_endmatter-idx2">epidemiology of, 95</p>
			<p class="em-only_endmatter-idx2">etiology of, 98</p>
			<p class="em-only_endmatter-idx2">hypertension and, 65</p>
			<p class="em-only_endmatter-idx2">left-&#173;sided, 95, 96<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">management of</p>
			<p class="em-only_endmatter-idx3">implantable cardioverter-&#173;defibrillator, 100</p>
			<p class="em-only_endmatter-idx3">invasive, 100</p>
			<p class="em-only_endmatter-idx3">medical, 98–100</p>
			<p class="em-only_endmatter-idx3">nonsurgical, 98–100</p>
			<p class="em-only_endmatter-idx3">surgical, 100</p>
			<p class="em-only_endmatter-idx2">in myo&#173;car&#173;dial infarction, 85</p>
			<p class="em-only_endmatter-idx2">palliative care in, 100</p>
			<p class="em-only_endmatter-idx2">pathophysiology of, 95</p>
			<p class="em-only_endmatter-idx2">perioperative management for ocular surgery in patients with, 283–284</p>
			<p class="em-only_endmatter-idx2">precipitating &#173;factors for, 99</p>
			<p class="em-only_endmatter-idx2">with preserved ejection fraction</p>
			<p class="em-only_endmatter-idx3">description of, 95, 96<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">management of, 99</p>
			<p class="em-only_endmatter-idx2">with reduced ejection fraction</p>
			<p class="em-only_endmatter-idx3">description of, 95, 96<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">management of, 98–99</p>
			<p class="em-only_endmatter-idx2">right-&#173;sided, 95, 96<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">signs and symptoms of, 95, 97</p>
			<p class="em-only_endmatter-idx2">stages of, 95, 96<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">tachyarrhythmias in, 99</p>
			<p class="em-only_endmatter-idx2">in &#173;women, 95</p>
			<p class="em-only_endmatter-idx1">Conjugate nystagmus, 208</p>
			<p class="em-only_endmatter-idx1">Conjunctiva, age-&#173;related changes in, 183</p>
			<p class="em-only_endmatter-idx1">Conjunctivitis</p>
			<p class="em-only_endmatter-idx2">chlamydial, 244</p>
			<p class="em-only_endmatter-idx2">hemorrhagic, 264</p>
			<p class="em-only_endmatter-idx2">neonatal chlamydial, 244</p>
			<p class="em-only_endmatter-idx2">in reactive arthritis, 157</p>
			<p class="em-only_endmatter-idx1">CONSORT (Consolidated Standards of Reporting &#173;Trials) Statement, 14</p>
			<p class="em-only_endmatter-idx1">Contact lenses, 269</p>
			<p class="em-only_endmatter-idx1">Continuous data, 6</p>
			<p class="em-only_endmatter-idx1">Continuous positive airway pressure (CPAP)</p>
			<p class="em-only_endmatter-idx2">description of, 126–127</p>
			<p class="em-only_endmatter-idx2">obstructive sleep apnea treated with, 127</p>
			<p class="em-only_endmatter-idx1">Continuous quality improvement</p>
			<p class="em-only_endmatter-idx2">data pre&#173;sen&#173;ta&#173;tion to facilitate, 28–30<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">features of, 28, 30–31</p>
			<p class="em-only_endmatter-idx2">fishbone for, 30–31</p>
			<p class="em-only_endmatter-idx2">flowchart for, 30–31<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Control charts, 28, 30<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Control group, 4, 5, 6, 11</p>
			<p class="em-only_endmatter-idx1">Convergent nystagmus, 208</p>
			<p class="em-only_endmatter-idx1">Conversion disorder, 197</p>
			<p class="em-only_endmatter-idx1">Coombs-&#173;positive hemolytic anemia, 135</p>
			<p class="em-only_endmatter-idx1">COPD. <span class="endmatter-idx1_italic">See</span> Chronic obstructive pulmonary <br />disease</p>
			<p class="em-only_endmatter-idx1">Copper poisoning, in Wilson disease, 136</p>
			<p class="em-only_endmatter-idx1">Cor pulmonale, 126</p>
			<p class="em-only_endmatter-idx1">Corneal arcus, 78</p>
			<p class="em-only_endmatter-idx1">Corneal nerve enlargement, in multiple endocrine neoplasia type 2B, 50</p>
			<p class="em-only_endmatter-idx1">Coronary angiography, for congestive heart failure, 97</p>
			<p class="em-only_endmatter-idx1">Coronary arteriography, in coronary heart disease diagnosis, 89</p>
			<p class="em-only_endmatter-idx1">Coronary artery bypass grafting (CABG)</p>
			<p class="em-only_endmatter-idx2">angina pectoris treated with, 91–92</p>
			<p class="em-only_endmatter-idx2">percutaneous coronary intervention versus, 92</p>
			<p class="em-only_endmatter-idx1">Coronary artery disease. <span class="endmatter-idx1_italic">See</span> Coronary heart disease</p>
			<p class="em-only_endmatter-idx1">Coronary artery stenosis, 89</p>
			<p class="em-only_endmatter-idx1">Coronary computed tomography angiography, in coronary heart disease diagnosis, 88</p>
			<p class="em-only_endmatter-idx1">Coronary heart disease (CHD), 40, 284</p>
			<p class="em-only_endmatter-idx2">acute coronary syndromes, 83–85</p>
			<p class="em-only_endmatter-idx2">angina pectoris, 82–83</p>
			<p class="em-only_endmatter-idx2">aspirin therapy in, 89</p>
			<p class="em-only_endmatter-idx2">asymptomatic, 86</p>
			<p class="em-only_endmatter-idx2">atherosclerotic</p>
			<p class="em-only_endmatter-idx3">angina pectoris caused by, 83</p>
			<p class="em-only_endmatter-idx3">deaths caused by, 81, 215</p>
			<p class="em-only_endmatter-idx2">clinical syndromes of, 82–86</p>
			<p class="em-only_endmatter-idx2">deaths caused by, 71</p>
			<p class="em-only_endmatter-idx2">diagnosis of</p>
			<p class="em-only_endmatter-idx3">cardiac enzymes, 86–87</p>
			<p class="em-only_endmatter-idx3">computed tomography, 88</p>
			<p class="em-only_endmatter-idx3">coronary arteriography, 89</p>
			<p class="em-only_endmatter-idx3">coronary computed tomography angiography, 88</p>
			<p class="em-only_endmatter-idx3">echocardiography, 87</p>
			<p class="em-only_endmatter-idx3">electrocardiography, 86</p>
			<p class="em-only_endmatter-idx3">electron beam computed tomography, 88</p>
			<p class="em-only_endmatter-idx3">exercise stress testing, 88</p>
			<p class="em-only_endmatter-idx3">intravascular ultrasound, 89</p>
			<p class="em-only_endmatter-idx3">invasive procedures for, 89</p>
			<p class="em-only_endmatter-idx3">magnetic resonance imaging, 88</p>
			<p class="em-only_endmatter-idx3">multiple gated acquisition scans, 89</p>
			<p class="em-only_endmatter-idx3">myoglobin levels, 87</p>
			<p class="em-only_endmatter-idx3">noninvasive procedures for, 86–89</p>
			<p class="em-only_endmatter-idx3">positron emission tomography, 88</p>
			<p class="em-only_endmatter-idx3">radionuclide scintigraphy and scans, 88</p>
			<p class="em-only_endmatter-idx3">serum biomarkers, 86–87</p>
			<p class="em-only_endmatter-idx3">single-&#173;photon emission computed tomography, 88</p>
			<p class="em-only_endmatter-idx3">troponin levels, 87</p>
			<p class="em-only_endmatter-idx3">ventriculography, 89</p>
			<p class="em-only_endmatter-idx2">management of</p>
			<p class="em-only_endmatter-idx3">antithrombotic agents, 89–91<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">direct oral antithrombotic agents, 90<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">goals for, 89</p>
			<p class="em-only_endmatter-idx3">percutaneous coronary intervention, 100</p>
			<p class="em-only_endmatter-idx3">surgery, 100</p>
			<p class="em-only_endmatter-idx2">pathophysiology of, 81–82</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 72, 73<span class="endmatter-idx2_italic">t,</span> 82</p>
			<p class="em-only_endmatter-idx2">screening for, 215</p>
			<p class="em-only_endmatter-idx2">sudden cardiac death, 85–86</p>
			<p class="em-only_endmatter-idx2">in &#173;women, 82</p>
			<p class="em-only_endmatter-idx1">Coronary thrombus, 83</p>
			<p class="em-only_endmatter-idx1">Corticosteroids</p>
			<p class="em-only_endmatter-idx2">adrenal function &#173;after, 175</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 175–176, 308<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">Beh<span class="endmatter-idx2_accent">ç</span>et disease treated with, 173</p>
			<p class="em-only_endmatter-idx2">cessation of, 175</p>
			<p class="em-only_endmatter-idx2">Cogan syndrome treated with, 174</p>
			<p class="em-only_endmatter-idx2">idiopathic thrombocytopenia purpura treated with, 141</p>
			<p class="em-only_endmatter-idx2">inhaled, intraocular pressure affected by, 130</p>
			<p class="em-only_endmatter-idx2">lung disease treated with, 128</p>
			<p class="em-only_endmatter-idx2">monitoring of, 176</p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 308<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">osteoporosis caused by, 175</p>
			<p class="em-only_endmatter-idx2">rheumatic disorders treated with, 174–176, 175<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cortisone, 175<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cough, 124</p>
			<p class="em-only_endmatter-idx1">Crack cocaine, 199</p>
			<p class="em-only_endmatter-idx1">Crash cart, 298</p>
			<p class="em-only_endmatter-idx1">C-&#173;reactive protein (CRP), 153</p>
			<p class="em-only_endmatter-idx1">Creatine kinase MB, 87</p>
			<p class="em-only_endmatter-idx1">CREST syndrome, 164</p>
			<p class="em-only_endmatter-idx1">Cretinism, 41</p>
			<p class="em-only_endmatter-idx1">Creutzfeldt-&#173;Jakob disease (CJD), 211</p>
			<p class="em-only_endmatter-idx1">Cricothyrotomy, 299, 302</p>
			<p class="em-only_endmatter-idx1">Crizanlizumab, for sickle cell disease, 135</p>
			<p class="em-only_endmatter-idx1">Crohn disease, 156</p>
			<p class="em-only_endmatter-idx1">Cromolyn, for lung disease, 128</p>
			<p class="em-only_endmatter-idx1">Cross-&#173;sectional studies, 12</p>
			<p class="em-only_endmatter-idx1">Cryptococcal meningitis, 277</p>
			<p class="em-only_endmatter-idx1">Cryptogenic stroke, 119</p>
			<p class="em-only_endmatter-idx1">CT. <span class="endmatter-idx1_italic">See</span> Computed tomography</p>
			<p class="em-only_endmatter-idx1">Curative chemotherapy, 239</p>
			<p class="em-only_endmatter-idx1">Cushing syndrome</p>
			<p class="em-only_endmatter-idx2">corticotroph adenomas associated with, 48</p>
			<p class="em-only_endmatter-idx2">hypertension associated with, 54</p>
			<p class="em-only_endmatter-idx1">CVD. <span class="endmatter-idx1_italic">See</span> Cardiovascular disease</p>
			<p class="em-only_endmatter-idx1">Cyclin-&#173;dependent kinases, 236</p>
			<p class="em-only_endmatter-idx1">Cyclophosphamide</p>
			<p class="em-only_endmatter-idx2">Beh<span class="endmatter-idx2_accent">ç</span>et disease treated with, 173</p>
			<p class="em-only_endmatter-idx2">description of, 179</p>
			<p class="em-only_endmatter-idx1">Cyclosporine, 179</p>
			<p class="em-only_endmatter-idx1">Cyclothymic disorder, 196</p>
			<p class="em-only_endmatter-idx1">Cystic fibrosis, 124</p>
			<p class="em-only_endmatter-idx1">Cytokines, 241</p>
			<p class="em-only_endmatter-idx1">Cytomegalovirus (CMV), 237<span class="endmatter-idx1_italic">t,</span> 261–262, 279</p>
			<p class="em-only_endmatter-idx1">Dactylitis, 154</p>
			<p class="em-only_endmatter-idx1">Danazol, 309<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Dantrolene, for malignant hyperthermia, 292</p>
			<p class="em-only_endmatter-idx1">DASH diet, 57, 58<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Data</p>
			<p class="em-only_endmatter-idx2">clinical practice improvements using, 23–24</p>
			<p class="em-only_endmatter-idx2">continuous, 6</p>
			<p class="em-only_endmatter-idx2">normal distribution of, 6, 28</p>
			<p class="em-only_endmatter-idx1">Data pre&#173;sen&#173;ta&#173;tion</p>
			<p class="em-only_endmatter-idx2">continuous quality improvement through, 28–30<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">control charts for, 28, 30<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">histograms for, 28, 29<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">Pareto chart for, 28, 30<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">run charts for, 28, 30<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">scatter diagrams for, 28, 29<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Decision-&#173;making capacity assessments, 211</p>
			<p class="em-only_endmatter-idx1">Deep-&#173;brain stimulation, for Parkinson disease, 205</p>
			<p class="em-only_endmatter-idx1">Deep venous thrombosis. <span class="endmatter-idx1_italic">See also</span> Thromboembolism</p>
			<p class="em-only_endmatter-idx2">in activated protein C re&#173;sis&#173;tance, 146–147</p>
			<p class="em-only_endmatter-idx2">in antiphospholipid syndrome, 163–164</p>
			<p class="em-only_endmatter-idx2">treatment of, 139, 164</p>
			<p class="em-only_endmatter-idx1">Delirium, 187</p>
			<p class="em-only_endmatter-idx1">Dementia</p>
			<p class="em-only_endmatter-idx2">Alzheimer disease as cause of, 209–210</p>
			<p class="em-only_endmatter-idx2">Lewy body, 210</p>
			<p class="em-only_endmatter-idx2">vascular, 210</p>
			<p class="em-only_endmatter-idx2">visual symptoms of, 210</p>
			<p class="em-only_endmatter-idx1">Depression</p>
			<p class="em-only_endmatter-idx2">chronic medical conditions as cause of, 194</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Diagnostic and Statistical Manual of &#173;Mental Disorders</span> criteria, 188</p>
			<p class="em-only_endmatter-idx2">medi&#173;cations that cause, 204</p>
			<p class="em-only_endmatter-idx2">in older adults, 188–190, 195–196</p>
			<p class="em-only_endmatter-idx2">Patient Health Questionnaire-2 screening for, 189–190</p>
			<p class="em-only_endmatter-idx2">prevalence of, 196</p>
			<p class="em-only_endmatter-idx2">screening for, 189, 194</p>
			<p class="em-only_endmatter-idx2">signs and symptoms of, 189, 195</p>
			<p class="em-only_endmatter-idx2">subclinical, 189</p>
			<p class="em-only_endmatter-idx1">Dermatomyositis, 167<span class="endmatter-idx1_italic">f,</span> 167–168</p>
			<p class="em-only_endmatter-idx1">Desmopressin, for von Willebrand disease, 144</p>
			<p class="em-only_endmatter-idx1">Dexamethasone, 175<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Diabetes Control and Complications Trial (DCCT), 35</p>
			<p class="em-only_endmatter-idx1">Diabetes mellitus</p>
			<p class="em-only_endmatter-idx2">blood glucose testing in, 40</p>
			<p class="em-only_endmatter-idx2">characteristics of, 33</p>
			<p class="em-only_endmatter-idx2">classification of, 33–34</p>
			<p class="em-only_endmatter-idx2">complications of</p>
			<p class="em-only_endmatter-idx3">acute, 38–39</p>
			<p class="em-only_endmatter-idx3">coronary artery disease, 40</p>
			<p class="em-only_endmatter-idx3">glycemic control effects on, 36</p>
			<p class="em-only_endmatter-idx3">ketoacidosis, 38–39</p>
			<p class="em-only_endmatter-idx3">large-&#173;vessel disease, 40</p>
			<p class="em-only_endmatter-idx3">long-&#173;term, 39–40</p>
			<p class="em-only_endmatter-idx3">macrovascular, 36</p>
			<p class="em-only_endmatter-idx3">myo&#173;car&#173;dial infarction, 40</p>
			<p class="em-only_endmatter-idx3">nephropathy, 39</p>
			<p class="em-only_endmatter-idx3">neuropathy, 39–40</p>
			<p class="em-only_endmatter-idx3">nonketotic hyperglycemic hyperosmolar coma, 38–39</p>
			<p class="em-only_endmatter-idx3">ophthalmic, 40–41</p>
			<p class="em-only_endmatter-idx3">retinopathy, 36, 40</p>
			<p class="em-only_endmatter-idx2">definition of, 33</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 34–35</p>
			<p class="em-only_endmatter-idx2">gestational, 34</p>
			<p class="em-only_endmatter-idx2">glycemic control in, 35–36</p>
			<p class="em-only_endmatter-idx2">hemoglobin A<span class="subscript _idGenCharOverride-1">1c</span> in</p>
			<p class="em-only_endmatter-idx3">as diagnostic marker, 34</p>
			<p class="em-only_endmatter-idx3">retinopathy progression relative to, 36<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx2">hyperglycemia associated with, 33</p>
			<p class="em-only_endmatter-idx2">hypertension in, 56, 65</p>
			<p class="em-only_endmatter-idx2">latent autoimmune diabetes in adults, 34</p>
			<p class="em-only_endmatter-idx2">lifestyle modifications for, 35</p>
			<p class="em-only_endmatter-idx2">metabolic syndrome as risk &#173;factor for, 35</p>
			<p class="em-only_endmatter-idx2">microvascular complications of, 33</p>
			<p class="em-only_endmatter-idx2">ocular surgery considerations in, 284, 286–287</p>
			<p class="em-only_endmatter-idx2">perioperative management for ocular surgery in patients with, 284</p>
			<p class="em-only_endmatter-idx2">prediabetes, 34–35</p>
			<p class="em-only_endmatter-idx2">preoperative fasting considerations in, 287</p>
			<p class="em-only_endmatter-idx2">prevalence of, 33</p>
			<p class="em-only_endmatter-idx2">risk reduction methods, 35–36</p>
			<p class="em-only_endmatter-idx2">signs and symptoms of, 34</p>
			<p class="em-only_endmatter-idx2">treatment of, 36–38, 286–287</p>
			<p class="em-only_endmatter-idx2">type 1</p>
			<p class="em-only_endmatter-idx3">glycemic control in, 35–36</p>
			<p class="em-only_endmatter-idx3">insulin administration for, 37</p>
			<p class="em-only_endmatter-idx3">pancreas transplantation for, 37–38</p>
			<p class="em-only_endmatter-idx3">pathogenesis of, 33–34</p>
			<p class="em-only_endmatter-idx3">prevalence of, 33</p>
			<p class="em-only_endmatter-idx3">quality-of-life improvements in, 37</p>
			<p class="em-only_endmatter-idx3">treatment of, 36–38</p>
			<p class="em-only_endmatter-idx2">type 2</p>
			<p class="em-only_endmatter-idx3">cardiovascular risk reduction in, 36</p>
			<p class="em-only_endmatter-idx3">characteristics of, 34</p>
			<p class="em-only_endmatter-idx3">in &#173;children, 34</p>
			<p class="em-only_endmatter-idx3">glycemic control in, 35–36</p>
			<p class="em-only_endmatter-idx3">hypertension associated with, 33</p>
			<p class="em-only_endmatter-idx3">impaired glucose tolerance progression to, 35</p>
			<p class="em-only_endmatter-idx3">insulin re&#173;sis&#173;tance associated with, 34</p>
			<p class="em-only_endmatter-idx3">metformin for, 38</p>
			<p class="em-only_endmatter-idx3">noninsulin therapy for, 38</p>
			<p class="em-only_endmatter-idx3">prevalence of, 33</p>
			<p class="em-only_endmatter-idx3">thiazolidinediones for, 38</p>
			<p class="em-only_endmatter-idx3">treatment of, 38</p>
			<p class="em-only_endmatter-idx2">types of, 34</p>
			<p class="em-only_endmatter-idx1">Diabetic ketoacidosis, 38–39</p>
			<p class="em-only_endmatter-idx1">Diabetic retinopathy</p>
			<p class="em-only_endmatter-idx2">ischemic heart disease and, 105</p>
			<p class="em-only_endmatter-idx2">in older adults, 184</p>
			<p class="em-only_endmatter-idx2">prevalence of, 184</p>
			<p class="em-only_endmatter-idx2">progression of, 36, 40</p>
			<p class="em-only_endmatter-idx2">studies of, 78</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Diagnostic and Statistical Manual of &#173;Mental Disorders</span> depression criteria, 188</p>
			<p class="em-only_endmatter-idx1">Diarrhea, <span class="endmatter-idx1_italic">Clostridium difficile,</span> 249</p>
			<p class="em-only_endmatter-idx1">Diastolic blood pressure, 52, 56, 214</p>
			<p class="em-only_endmatter-idx1">Diastolic dysfunction, 99</p>
			<p class="em-only_endmatter-idx1">Diazoxide, 64</p>
			<p class="em-only_endmatter-idx1">Diet</p>
			<p class="em-only_endmatter-idx2">DASH, 57, 58<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">hypercholesterolemia managed with, 74</p>
			<p class="em-only_endmatter-idx1">Diffuse toxic goiter, 43</p>
			<p class="em-only_endmatter-idx1">Diffusion-&#173;weighted magnetic resonance imaging, <br />112</p>
			<p class="em-only_endmatter-idx1">Digital rectal examination (DRE), for prostate cancer, 221</p>
			<p class="em-only_endmatter-idx1">Digitalis glycosides, 309<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Digoxin, ocular adverse effects of, 106</p>
			<p class="em-only_endmatter-idx1">Dihydropyridine calcium channel blockers, 61</p>
			<p class="em-only_endmatter-idx1">Dilated cardiomyopathy, anticoagulation therapy for, 100</p>
			<p class="em-only_endmatter-idx1">Diphenhydramine hydrochloride, 302</p>
			<p class="em-only_endmatter-idx1">Diphtheria-&#173;tetanus-&#173;pertussis (DTP), 229</p>
			<p class="em-only_endmatter-idx1">Direct-&#173;current (DC) cardioversion</p>
			<p class="em-only_endmatter-idx2">atrial fibrillation treated with, 103</p>
			<p class="em-only_endmatter-idx2">ventricular tachycardia treated with, 104</p>
			<p class="em-only_endmatter-idx1">Direct oral anticoagulants, 149–150, 286</p>
			<p class="em-only_endmatter-idx1">Direct oral antithrombotic agents, for coronary heart disease, 90<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Direct renin inhibitors, for hypertension, 63</p>
			<p class="em-only_endmatter-idx1">Direct thrombin inhibitors</p>
			<p class="em-only_endmatter-idx2">coronary heart disease treated with, 90–91<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">indications for, 149</p>
			<p class="em-only_endmatter-idx1">Direct vasodilators, for hypertension, 63</p>
			<p class="em-only_endmatter-idx1">Disability-&#173;adjusted life years (DALYs), 193</p>
			<p class="em-only_endmatter-idx1">Disease</p>
			<p class="em-only_endmatter-idx2">posttest probability of, 19–20</p>
			<p class="em-only_endmatter-idx2">pretest probability of, 18–21, 20<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">risk &#173;factors and, cohort studies regarding associations between, 13</p>
			<p class="em-only_endmatter-idx1">Disease-&#173;modifying antirheumatic drugs (DMARDs)</p>
			<p class="em-only_endmatter-idx2">alkylating agents, 179</p>
			<p class="em-only_endmatter-idx2">ankylosing spondylitis treated with, 155</p>
			<p class="em-only_endmatter-idx2">azathioprine, 179</p>
			<p class="em-only_endmatter-idx2">biologic, 177<span class="endmatter-idx2_italic">t,</span> 180–181</p>
			<p class="em-only_endmatter-idx2">biosimilar agents, 180–181</p>
			<p class="em-only_endmatter-idx2">calcineurin inhibitors, 179</p>
			<p class="em-only_endmatter-idx2">hydroxychloroquine, 178–179</p>
			<p class="em-only_endmatter-idx2">interleukin inhibitors, 180</p>
			<p class="em-only_endmatter-idx2">Janus kinase inhibitors, 180</p>
			<p class="em-only_endmatter-idx2">leflunomide, 178</p>
			<p class="em-only_endmatter-idx2">methotrexate, 178</p>
			<p class="em-only_endmatter-idx2">mycophenolate mofetil, 179</p>
			<p class="em-only_endmatter-idx2">nonbiologic, 177<span class="endmatter-idx2_italic">t,</span> 178–179</p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 308<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">rheumatoid disease treated with, 153</p>
			<p class="em-only_endmatter-idx2">sulfasalazine, 179</p>
			<p class="em-only_endmatter-idx2">tumor necrosis factor-&#173;<span class="endmatter-idx2_greek">α</span> inhibitors, 180</p>
			<p class="em-only_endmatter-idx2">types of, 177<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Disk-&#173;diffusion susceptibility testing, 271</p>
			<p class="em-only_endmatter-idx1">Disseminated intravascular coagulation (DIC), 142, 145–146</p>
			<p class="em-only_endmatter-idx1">Distributive shock, 300. <span class="endmatter-idx1_italic">See also</span> Shock</p>
			<p class="em-only_endmatter-idx1">Diuretics</p>
			<p class="em-only_endmatter-idx2">hypertension treated with, 59<span class="endmatter-idx2_italic">t,</span> 59–61</p>
			<p class="em-only_endmatter-idx2">loop, 59<span class="endmatter-idx2_italic">t,</span> 59–60</p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 309<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">potassium-&#173;sparing, 59<span class="endmatter-idx2_italic">t,</span> 60</p>
			<p class="em-only_endmatter-idx2">side effects of, 60–61</p>
			<p class="em-only_endmatter-idx2">thiazide-&#173;type, 59, 59<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">DNA viruses, 236, 237<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Donepezil, for Alzheimer disease, 210</p>
			<p class="em-only_endmatter-idx1">Dopamine agonists, for Parkinson disease, 205</p>
			<p class="em-only_endmatter-idx1">Dopamine–norepinephrine reuptake inhibitors, 203<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Doripenem, 273</p>
			<p class="em-only_endmatter-idx1">Doxycycline, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Drug dependence, 198–199</p>
			<p class="em-only_endmatter-idx1">Drug-&#173;eluting stents, percutaneous coronary intervention with, 92</p>
			<p class="em-only_endmatter-idx1">Drug-&#173;induced thrombocytopenia, 141–142</p>
			<p class="em-only_endmatter-idx1">Drug withdrawal syndromes, 68–69</p>
			<p class="em-only_endmatter-idx1">Dual antiplatelet therapy (DAT)</p>
			<p class="em-only_endmatter-idx2">for angina pectoris, 91–92</p>
			<p class="em-only_endmatter-idx2">ocular surgery considerations, 286</p>
			<p class="em-only_endmatter-idx1">Duke Activity Status Index, 283</p>
			<p class="em-only_endmatter-idx1">Dysplastic nevi, 220</p>
			<p class="em-only_endmatter-idx1">Dyspnea, 124</p>
			<p class="em-only_endmatter-idx1">Dysthymic disorder, 195</p>
			<p class="em-only_endmatter-idx1">Ebola virus, 264–265</p>
			<p class="em-only_endmatter-idx1">EBV. <span class="endmatter-idx1_italic">See</span> Epstein-Barr virus</p>
			<p class="em-only_endmatter-idx1">Echocardiography</p>
			<p class="em-only_endmatter-idx2">congestive heart failure evaluations, 97</p>
			<p class="em-only_endmatter-idx2">coronary heart disease diagnosis using, 87</p>
			<p class="em-only_endmatter-idx2">ejection fraction evaluations, 97</p>
			<p class="em-only_endmatter-idx2">stress, 87</p>
			<p class="em-only_endmatter-idx2">stroke evaluations, 112</p>
			<p class="em-only_endmatter-idx1">Eclampsia, 67</p>
			<p class="em-only_endmatter-idx1">Ectopia lentis</p>
			<p class="em-only_endmatter-idx2">in Ehlers-&#173;Danlos syndrome, 141</p>
			<p class="em-only_endmatter-idx2">in Marfan syndrome, 141</p>
			<p class="em-only_endmatter-idx1">Edrophonium chloride, 305</p>
			<p class="em-only_endmatter-idx1">Ehlers-&#173;Danlos syndrome, 140–141</p>
			<p class="em-only_endmatter-idx1">Ejection fraction (EF)</p>
			<p class="em-only_endmatter-idx2">in congestive heart failure, 95, 96<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">echocardiography of, 97</p>
			<p class="em-only_endmatter-idx1">Elder abuse, 185–187</p>
			<p class="em-only_endmatter-idx1">El&#173;derly. <span class="endmatter-idx1_italic">See</span> Older adults</p>
			<p class="em-only_endmatter-idx1">Electrocardiography/electrocardiogram</p>
			<p class="em-only_endmatter-idx2">atrial fibrillation findings, 103<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">congestive heart failure evaluations, 97</p>
			<p class="em-only_endmatter-idx2">myo&#173;car&#173;dial infarction findings, 83–84, 86</p>
			<p class="em-only_endmatter-idx2">nomenclature of, 84–85<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">non–&#173;ST-&#173;segment elevation myo&#173;car&#173;dial infarction findings, 83–84</p>
			<p class="em-only_endmatter-idx2">ST-&#173;segment elevation myo&#173;car&#173;dial infarction <br />findings, 84</p>
			<p class="em-only_endmatter-idx2">unstable angina findings, 83</p>
			<p class="em-only_endmatter-idx1">Electroencephalography (EEG), epilepsy diagnosis using, 207</p>
			<p class="em-only_endmatter-idx1">Electron beam computed tomography, in coronary heart disease diagnosis, 88</p>
			<p class="em-only_endmatter-idx1">Electrophysiologic testing, in ventricular <br />arrhythmias, 104</p>
			<p class="em-only_endmatter-idx1">ELISA. <span class="endmatter-idx1_italic">See</span> Enzyme-linked immunosorbent assay</p>
			<p class="em-only_endmatter-idx1">Emergency Medical Ser&#173;vices (EMS), 296</p>
			<p class="em-only_endmatter-idx1">Emicipizumab, 144</p>
			<p class="em-only_endmatter-idx1">Emphysema, 124</p>
			<p class="em-only_endmatter-idx1">Emtansine, 242</p>
			<p class="em-only_endmatter-idx1">Enalapril, 64, 309<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">End-&#173;stage renal disease</p>
			<p class="em-only_endmatter-idx2">diabetic nephropathy as cause of, 39</p>
			<p class="em-only_endmatter-idx2">hypertension as cause of, 214</p>
			<p class="em-only_endmatter-idx1">Endophthalmitis, 199</p>
			<p class="em-only_endmatter-idx1">Entacapone, for Parkinson disease, 205</p>
			<p class="em-only_endmatter-idx1">Enteropancreatic tumors, 50</p>
			<p class="em-only_endmatter-idx1">Enteropathic arthritis, 156</p>
			<p class="em-only_endmatter-idx1">Enthesitis, 154</p>
			<p class="em-only_endmatter-idx1">Enthesitis-&#173;related arthritis, 154</p>
			<p class="em-only_endmatter-idx1">Enzyme-&#173;linked immunosorbent assay (ELISA)</p>
			<p class="em-only_endmatter-idx2">for <span class="endmatter-idx2_italic">Borrelia burgdorferi,</span> 254</p>
			<p class="em-only_endmatter-idx2">for &#173;HIV, 267</p>
			<p class="em-only_endmatter-idx1">Eosinophilic airway inflammation, 124</p>
			<p class="em-only_endmatter-idx1">Eosinophilic granulomatosis with polyangiitis <br />(EGPA), 172</p>
			<p class="em-only_endmatter-idx1">Epigastric thrusts, 299</p>
			<p class="em-only_endmatter-idx1">Epilepsy</p>
			<p class="em-only_endmatter-idx2">characteristics of, 206</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 207</p>
			<p class="em-only_endmatter-idx2">etiology of, 206–207</p>
			<p class="em-only_endmatter-idx2">seizures associated with, 206–209</p>
			<p class="em-only_endmatter-idx2">surgery for, 208</p>
			<p class="em-only_endmatter-idx2">treatment of, 207–209</p>
			<p class="em-only_endmatter-idx1">Epinephrine</p>
			<p class="em-only_endmatter-idx2">acute allergic reaction treated with, 302–303</p>
			<p class="em-only_endmatter-idx2">acute asthma attacks treated with, 128</p>
			<p class="em-only_endmatter-idx2">local anesthesia uses of, 305</p>
			<p class="em-only_endmatter-idx1">Episcleral implants, radioactive, 238</p>
			<p class="em-only_endmatter-idx1">Epstein-&#173;Barr virus (EBV), 237<span class="endmatter-idx1_italic">t,</span> 262</p>
			<p class="em-only_endmatter-idx1">Epstein-&#173;Barr virus-&#173;associated hemophagocytic lymphohistiocytosis (EBV-&#173;HLH), 262</p>
			<p class="em-only_endmatter-idx1">Ertapenem, 273</p>
			<p class="em-only_endmatter-idx1">Erythema nodosum, 155, 156<span class="endmatter-idx1_italic">f,</span> 162</p>
			<p class="em-only_endmatter-idx1">Erythrocyte sedimentation rate (ESR), 153</p>
			<p class="em-only_endmatter-idx1">Erythrocytes, mean corpuscular volume of, 132. <span class="endmatter-idx1_italic">See also</span> Red blood cell(s)</p>
			<p class="em-only_endmatter-idx1">Erythromycin, 274–275</p>
			<p class="em-only_endmatter-idx1">Erythropoiesis, 131</p>
			<p class="em-only_endmatter-idx1">Erythropoietin, 136</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Escherichia coli</span></p>
			<p class="em-only_endmatter-idx2">reactive arthritis associated with, 155</p>
			<p class="em-only_endmatter-idx2">Shiga toxin-&#173;producing, 142</p>
			<p class="em-only_endmatter-idx1">Esmolol, 64</p>
			<p class="em-only_endmatter-idx1">Esophageal cancer, 219</p>
			<p class="em-only_endmatter-idx1">Essential thrombocythemia (ET), 142–143</p>
			<p class="em-only_endmatter-idx1">Estradiol, 309<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Etanercept, 180</p>
			<p class="em-only_endmatter-idx1">Ethambutol</p>
			<p class="em-only_endmatter-idx2">screening recommendations for, 257</p>
			<p class="em-only_endmatter-idx2">tuberculosis treated with, 257</p>
			<p class="em-only_endmatter-idx1">Ethosuximide, 207</p>
			<p class="em-only_endmatter-idx1">Etoricoxib, 176</p>
			<p class="em-only_endmatter-idx1">Eu&#173;ro&#173;pean Centre for Disease Prevention and Control (ECDC), 224</p>
			<p class="em-only_endmatter-idx1">Exenatide, 205</p>
			<p class="em-only_endmatter-idx1">Exercise stress testing, for coronary heart disease diagnosis, 88</p>
			<p class="em-only_endmatter-idx1">Experimental studies, 8</p>
			<p class="em-only_endmatter-idx1">External beam radiotherapy, 237–238</p>
			<p class="em-only_endmatter-idx1">External validity, 26</p>
			<p class="em-only_endmatter-idx1">Extrinsic pathway, of coagulation cascade, 138<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Eye, age-&#173;related changes in, 183–184</p>
			<p class="em-only_endmatter-idx1">Eyelids</p>
			<p class="em-only_endmatter-idx2">age-&#173;related changes in, 183</p>
			<p class="em-only_endmatter-idx2">in Parkinson disease patients, 206</p>
			<p class="em-only_endmatter-idx1">Factitious disorder, 197</p>
			<p class="em-only_endmatter-idx1">&#173;Factor&#160;IX</p>
			<p class="em-only_endmatter-idx2">activation of, 138</p>
			<p class="em-only_endmatter-idx2">deficiency of, 144</p>
			<p class="em-only_endmatter-idx1">&#173;Factor&#160;V, 146</p>
			<p class="em-only_endmatter-idx1">&#173;Factor V&#160;Leiden, 146–147</p>
			<p class="em-only_endmatter-idx1">&#173;Factor&#160;VII, 138</p>
			<p class="em-only_endmatter-idx1">&#173;Factor VIII deficiency. <span class="endmatter-idx1_italic">See</span> Hemophilia&#160;A</p>
			<p class="em-only_endmatter-idx1">&#173;Factor Xa inhibitors, 90<span class="endmatter-idx1_italic">t,</span> 149</p>
			<p class="em-only_endmatter-idx1">Falls, 191–192</p>
			<p class="em-only_endmatter-idx1">Famciclovir</p>
			<p class="em-only_endmatter-idx2">herpes simplex virus treated with, 260, 278</p>
			<p class="em-only_endmatter-idx2">varicella-&#173;zoster treated with, 261</p>
			<p class="em-only_endmatter-idx1">Famotidine, 288</p>
			<p class="em-only_endmatter-idx1">Faropenem, 273</p>
			<p class="em-only_endmatter-idx1">Fasting, preoperative, 287–288</p>
			<p class="em-only_endmatter-idx1">Fasting hypoglycemia, 300</p>
			<p class="em-only_endmatter-idx1">Fasting plasma glucose (FPG), in diabetes mellitus diagnosis, 34</p>
			<p class="em-only_endmatter-idx1">Fatal familial insomnia (FFI), 211</p>
			<p class="em-only_endmatter-idx1">Fatty streak, 81</p>
			<p class="em-only_endmatter-idx1">Fecal immunochemical test (FIT), for colorectal cancer screening, 218–219</p>
			<p class="em-only_endmatter-idx1">Felty syndrome, 152</p>
			<p class="em-only_endmatter-idx1">Fenoterol, 128</p>
			<p class="em-only_endmatter-idx1">Fentanyl, 290, 306</p>
			<p class="em-only_endmatter-idx1">Ferrous sulfate, for iron deficiency anemia, 133</p>
			<p class="em-only_endmatter-idx1">Fetal alcohol syndrome (FAS), 199</p>
			<p class="em-only_endmatter-idx1">Fetus, irradiation effects on, 239</p>
			<p class="em-only_endmatter-idx1">Fibric acids, for hypercholesterolemia, 75<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Fibrin, 146</p>
			<p class="em-only_endmatter-idx1">Fibrin degradation products, 146</p>
			<p class="em-only_endmatter-idx1">First-&#173;generation antipsychotics, 199–201, 200<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Fishbone diagram, 30–31</p>
			<p class="em-only_endmatter-idx1">Flavivirus, 265</p>
			<p class="em-only_endmatter-idx1">Flecainide, 309<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Flexible sigmoidoscopy, for colorectal cancer screening, 218–219</p>
			<p class="em-only_endmatter-idx1">“Floor effect,” 25</p>
			<p class="em-only_endmatter-idx1">Flowchart, 30–31<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Fluo&#173;rescent treponemal antibody absorption <br />(FTA-&#173;ABS), 253</p>
			<p class="em-only_endmatter-idx1">Fluoroquinolones</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 274</p>
			<p class="em-only_endmatter-idx2">description of, 274</p>
			<p class="em-only_endmatter-idx2">gonococcal infections treated with, 251</p>
			<p class="em-only_endmatter-idx1">Fluoxetine, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Fluvastatin, 75<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Fms-&#173;like tyrosine kinase 3 ligand (Flt-3L), 167</p>
			<p class="em-only_endmatter-idx1">Foam cells, 81</p>
			<p class="em-only_endmatter-idx1">Folate deficiency</p>
			<p class="em-only_endmatter-idx2">anemia caused by, 133–134</p>
			<p class="em-only_endmatter-idx2">&#173;causes of, 134</p>
			<p class="em-only_endmatter-idx2">vitamin B<span class="subscript _idGenCharOverride-1">12</span> deficiency versus, 134</p>
			<p class="em-only_endmatter-idx1">Folic acid deficiency, 133–134</p>
			<p class="em-only_endmatter-idx1">Follicular carcinoma, 46</p>
			<p class="em-only_endmatter-idx1">Fondaparinux, 149</p>
			<p class="em-only_endmatter-idx1">Forced expiratory volume over 1 second (FEV<span class="subscript _idGenCharOverride-1">1</span>), 126</p>
			<p class="em-only_endmatter-idx1">Forced expiratory volume over 1 second/forced vital capacity (FEV<span class="subscript _idGenCharOverride-1">1</span>/FVC) ratio, 126</p>
			<p class="em-only_endmatter-idx1">Forced vital capacity (FVC), 126</p>
			<p class="em-only_endmatter-idx1">Formoterol, 128</p>
			<p class="em-only_endmatter-idx1">Foscarnet, for herpes simplex virus, 260</p>
			<p class="em-only_endmatter-idx1">Fostamatinib, 141</p>
			<p class="em-only_endmatter-idx1">Fractures, osteoporotic, 190</p>
			<p class="em-only_endmatter-idx1">Fungal infections</p>
			<p class="em-only_endmatter-idx2">antifungal agents for, 277, 278<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">description of, 258</p>
			<p class="em-only_endmatter-idx1">Gail model, 217</p>
			<p class="em-only_endmatter-idx1">Ganciclovir, for Epstein-&#173;Barr virus, 261</p>
			<p class="em-only_endmatter-idx1">Ganglioneuromas, 50</p>
			<p class="em-only_endmatter-idx1">Gastric cancer, 219</p>
			<p class="em-only_endmatter-idx1">Gastrinomas, 50</p>
			<p class="em-only_endmatter-idx1">Gastroenteritis, 230</p>
			<p class="em-only_endmatter-idx1">Gastroesophageal reflux disease (GERD), 219</p>
			<p class="em-only_endmatter-idx1">Gastrointestinal cancer screening, 219–220</p>
			<p class="em-only_endmatter-idx1">Gaze deviations, 208</p>
			<p class="em-only_endmatter-idx1">Gaze-&#173;evoked nystagmus, substance abuse as <br />cause of, 199</p>
			<p class="em-only_endmatter-idx1">General anesthesia, 289–290</p>
			<p class="em-only_endmatter-idx1">Generalized anxiety disorder (GAD), 197</p>
			<p class="em-only_endmatter-idx1">Generalized seizures, 207</p>
			<p class="em-only_endmatter-idx1">Generalized tonic-&#173;clonic seizures, 207</p>
			<p class="em-only_endmatter-idx1">Geriatrics. <span class="endmatter-idx1_italic">See</span> Older adults</p>
			<p class="em-only_endmatter-idx1">Gerstmann-&#173;Str<span class="endmatter-idx1_accent">ä</span>ussler-&#173;Scheinker (GSS) syndrome, <br />211</p>
			<p class="em-only_endmatter-idx1">Gestational diabetes mellitus, 34</p>
			<p class="em-only_endmatter-idx1">&#173;Giant cell arteritis (GCA)</p>
			<p class="em-only_endmatter-idx2">description of, 168</p>
			<p class="em-only_endmatter-idx2">polymyalgia rheumatica associated with, 168</p>
			<p class="em-only_endmatter-idx2">transient monocular visual loss and, 119</p>
			<p class="em-only_endmatter-idx1">Gigantism, 47</p>
			<p class="em-only_endmatter-idx1">Glare, digoxin as cause of, 106</p>
			<p class="em-only_endmatter-idx1">Glaucoma</p>
			<p class="em-only_endmatter-idx2">incidence of, 184</p>
			<p class="em-only_endmatter-idx2">intraocular pressure monitoring in, 130</p>
			<p class="em-only_endmatter-idx2">low-&#173;tension, systemic nocturnal hypotension as risk &#173;factor for, 66–67</p>
			<p class="em-only_endmatter-idx1">Global Burden of Disease Study (GBD), 193</p>
			<p class="em-only_endmatter-idx1">Global Initiative for Chronic Obstructive Lung Disease (GOLD), 124</p>
			<p class="em-only_endmatter-idx1">Glucagon-&#173;like peptide-1 (GLP-1), 205</p>
			<p class="em-only_endmatter-idx1">Glucocorticoids</p>
			<p class="em-only_endmatter-idx2">granulomatosis with polyangiitis treated with, 172</p>
			<p class="em-only_endmatter-idx2">potency of, 175<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">rheumatic disorders treated with, 174–176, 175<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Glucose-6-&#173;phosphate dehydrogenase (G6PD) deficiency, 136</p>
			<p class="em-only_endmatter-idx1">Glycemic control, in diabetes mellitus, 35–36</p>
			<p class="em-only_endmatter-idx1">Glycopeptides, 273–274</p>
			<p class="em-only_endmatter-idx1">Glycoprotein IIb/IIIa inhibitors</p>
			<p class="em-only_endmatter-idx2">coronary heart disease treated with, 91<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">myo&#173;car&#173;dial infarction treated with, 94</p>
			<p class="em-only_endmatter-idx1">Goiter, in Graves hyperthyroidism, 43</p>
			<p class="em-only_endmatter-idx1">Gold standard, 15–16</p>
			<p class="em-only_endmatter-idx1">Golimumab, 180</p>
			<p class="em-only_endmatter-idx1">Gonadotroph adenomas, 48</p>
			<p class="em-only_endmatter-idx1">Gonadotropin-&#173;producing pituitary tumors, 48</p>
			<p class="em-only_endmatter-idx1">Gonococcal infections, 250–251</p>
			<p class="em-only_endmatter-idx1">Gottron sign, 167</p>
			<p class="em-only_endmatter-idx1">Granulomatosis with polyangiitis (GPA), 171–172</p>
			<p class="em-only_endmatter-idx1">Granulomatous colitis. <span class="endmatter-idx1_italic">See</span> Crohn disease</p>
			<p class="em-only_endmatter-idx1">Granulomatous hypersensitivity reaction, 125</p>
			<p class="em-only_endmatter-idx1">Granulomatous ileocolitis. <span class="endmatter-idx1_italic">See</span> Crohn disease</p>
			<p class="em-only_endmatter-idx1">Graves disease</p>
			<p class="em-only_endmatter-idx2">hyperthyroidism associated with, 43–44</p>
			<p class="em-only_endmatter-idx2">radioactive iodine uptake testing for, 42</p>
			<p class="em-only_endmatter-idx2">thyroid-&#173;stimulating immunoglobulins in, 42</p>
			<p class="em-only_endmatter-idx1">Gray (Gy), 237</p>
			<p class="em-only_endmatter-idx1">Group A <span class="endmatter-idx1_accent">β</span>-&#173;hemolytic streptococci, 247</p>
			<p class="em-only_endmatter-idx1">Guaiac-&#173;based fecal occult blood test, for colorectal cancer screening, 218–219</p>
			<p class="em-only_endmatter-idx1">Guillain-Barré syndrome, 223</p>
			<p class="em-only_endmatter-idx1">H<span class="subscript _idGenCharOverride-1">2</span> blockers, 288</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Haemophilus influenzae</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 249–250</p>
			<p class="em-only_endmatter-idx2">treatment of, 250</p>
			<p class="em-only_endmatter-idx2">vaccines for, 231, 250</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Haemophilus influenzae</span> type B, 249–250</p>
			<p class="em-only_endmatter-idx1">Hand deformities, rheumatoid arthritis-&#173;related, <br />152, 152<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Hashimoto thyroiditis, 45–46</p>
			<p class="em-only_endmatter-idx1">HDL-C. <span class="endmatter-idx1_italic">See</span> High-density-lipoprotein cholesterol</p>
			<p class="em-only_endmatter-idx1">Headache, in subarachnoid hemorrhage, 121</p>
			<p class="em-only_endmatter-idx1">Head-&#173;tilt, chin-&#173;lift maneuver, 297</p>
			<p class="em-only_endmatter-idx1">Heart block, 101</p>
			<p class="em-only_endmatter-idx1">Heart disease. <span class="endmatter-idx1_italic">See</span> Coronary heart disease; Ischemic heart disease</p>
			<p class="em-only_endmatter-idx1">Heart failure. <span class="endmatter-idx1_italic">See</span> Congestive heart failure</p>
			<p class="em-only_endmatter-idx1">Heerfordt-&#173;Waldenstr<span class="endmatter-idx1_accent">ö</span>m syndrome, 162</p>
			<p class="em-only_endmatter-idx1">Heimlich maneuver, 299</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Helicobacter pylori,</span> gastric cancer and, 219</p>
			<p class="em-only_endmatter-idx1">Heliotrope rash, 167, 167<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Hemagglutination treponemal test for syphilis (HATTS), 253</p>
			<p class="em-only_endmatter-idx1">Hematologic disorders</p>
			<p class="em-only_endmatter-idx2">anemia. <span class="endmatter-idx2_italic">See</span> Anemia</p>
			<p class="em-only_endmatter-idx2">blood composition, 131</p>
			<p class="em-only_endmatter-idx2">erythropoiesis, 131</p>
			<p class="em-only_endmatter-idx2">hemostasis disorders. <span class="endmatter-idx2_italic">See</span> Hemostasis disorders</p>
			<p class="em-only_endmatter-idx1">Hematopoietic growth &#173;factors, 242</p>
			<p class="em-only_endmatter-idx1">Hematopoietic stem cell transplantation (HCT)</p>
			<p class="em-only_endmatter-idx2">allogeneic, for thalassemias, 134</p>
			<p class="em-only_endmatter-idx2">complications of, 135</p>
			<p class="em-only_endmatter-idx2">sickle cell disease treated with, 135</p>
			<p class="em-only_endmatter-idx1">Hemoglobin</p>
			<p class="em-only_endmatter-idx2">normal level of, 132</p>
			<p class="em-only_endmatter-idx2">synthesis defects involving, 134–136</p>
			<p class="em-only_endmatter-idx1">Hemoglobin A<span class="subscript _idGenCharOverride-1">1c</span>, in diabetes mellitus, 34</p>
			<p class="em-only_endmatter-idx1">Hemoglobin&#160;S, 135</p>
			<p class="em-only_endmatter-idx1">Hemolysis, renal response to, 136</p>
			<p class="em-only_endmatter-idx1">Hemolytic anemia</p>
			<p class="em-only_endmatter-idx2">characteristics of, 135–137</p>
			<p class="em-only_endmatter-idx2">microangiopathic, 142</p>
			<p class="em-only_endmatter-idx1">Hemolytic-&#173;uremic syndrome (HUS), 136, 142</p>
			<p class="em-only_endmatter-idx1">Hemophilia&#160;A, 144</p>
			<p class="em-only_endmatter-idx1">Hemophilia&#160;B, 144</p>
			<p class="em-only_endmatter-idx1">Hemorrhage</p>
			<p class="em-only_endmatter-idx2">intrace&#173;re&#173;bral, 120</p>
			<p class="em-only_endmatter-idx2">intracranial, 120–122</p>
			<p class="em-only_endmatter-idx2">intraventricular, 120–121</p>
			<p class="em-only_endmatter-idx2">subarachnoid, 121</p>
			<p class="em-only_endmatter-idx1">Hemorrhagic conjunctivitis, 264</p>
			<p class="em-only_endmatter-idx1">Hemorrhagic disease of the newborn, 145</p>
			<p class="em-only_endmatter-idx1">Hemostasis</p>
			<p class="em-only_endmatter-idx2">clot formation in, 138</p>
			<p class="em-only_endmatter-idx2">laboratory evaluation of, 139–140</p>
			<p class="em-only_endmatter-idx2">pathways of, 138<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">physiology of, 138–139</p>
			<p class="em-only_endmatter-idx1">Hemostasis disorders</p>
			<p class="em-only_endmatter-idx2">amyloidosis, 140</p>
			<p class="em-only_endmatter-idx2">&#173;causes of, 138</p>
			<p class="em-only_endmatter-idx2">clinical manifestations of, 140</p>
			<p class="em-only_endmatter-idx2">Ehlers-&#173;Danlos syndrome, 140</p>
			<p class="em-only_endmatter-idx2">essential thrombocythemia, 142–143</p>
			<p class="em-only_endmatter-idx2">essential thrombocytopenia, 142–143</p>
			<p class="em-only_endmatter-idx2">hemophilia A, 144</p>
			<p class="em-only_endmatter-idx2">hemophilia B, 144</p>
			<p class="em-only_endmatter-idx2">hereditary hemorrhagic telangiectasia, 140</p>
			<p class="em-only_endmatter-idx2">idiopathic thrombocytopenic purpura, 141</p>
			<p class="em-only_endmatter-idx2">laboratory tests for, 139–140</p>
			<p class="em-only_endmatter-idx2">Marfan syndrome, 140–141</p>
			<p class="em-only_endmatter-idx2">osteogenesis imperfecta, 140</p>
			<p class="em-only_endmatter-idx2">platelet disorders, 141–144</p>
			<p class="em-only_endmatter-idx2">pseudoxanthoma elasticum, 140</p>
			<p class="em-only_endmatter-idx2">scurvy, 140</p>
			<p class="em-only_endmatter-idx2">thrombocytopenia, 141–142</p>
			<p class="em-only_endmatter-idx2">thrombocytosis, 142–143</p>
			<p class="em-only_endmatter-idx2">thrombotic thrombocytopenic purpura, 142</p>
			<p class="em-only_endmatter-idx2">vascular disorders, 140–141</p>
			<p class="em-only_endmatter-idx2">von Willebrand disease, 144–145</p>
			<p class="em-only_endmatter-idx1">Heparin</p>
			<p class="em-only_endmatter-idx2">coronary heart disease treated with, 91<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">indications for, 150</p>
			<p class="em-only_endmatter-idx2">low-&#173;molecular-&#173;weight</p>
			<p class="em-only_endmatter-idx3">coronary heart disease treated with, 91<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">description of, 149</p>
			<p class="em-only_endmatter-idx2">stroke prevention uses of, 114</p>
			<p class="em-only_endmatter-idx2">unfractionated, 149</p>
			<p class="em-only_endmatter-idx1">Hepatitis</p>
			<p class="em-only_endmatter-idx2">A, 224, 232</p>
			<p class="em-only_endmatter-idx2">B, 224, 226, 232, 237<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">C, 226, 237<span class="endmatter-idx2_italic">t,</span> 263</p>
			<p class="em-only_endmatter-idx2">D, 263</p>
			<p class="em-only_endmatter-idx2">E, 263</p>
			<p class="em-only_endmatter-idx2">G, 263</p>
			<p class="em-only_endmatter-idx2">immunization for, 224–226, 225<span class="endmatter-idx2_italic">t,</span> 232</p>
			<p class="em-only_endmatter-idx1">Hepatocellular cancer, 220, 224</p>
			<p class="em-only_endmatter-idx1">Hepcidin</p>
			<p class="em-only_endmatter-idx2">ferrous sulfate effects on, 133</p>
			<p class="em-only_endmatter-idx2">in iron deficiency anemia, 132</p>
			<p class="em-only_endmatter-idx1">Hereditary hemorrhagic telangiectasia, 140</p>
			<p class="em-only_endmatter-idx1">Hereditary spherocytosis, 136</p>
			<p class="em-only_endmatter-idx1">Hermansky-&#173;Pudlak syndrome, 144</p>
			<p class="em-only_endmatter-idx1">Herpes simplex virus</p>
			<p class="em-only_endmatter-idx2">characteristics of, 259–260</p>
			<p class="em-only_endmatter-idx2">type 1, 237<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">type 2, 237<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Herpes zoster. <span class="endmatter-idx1_italic">See</span> Varicella-&#173;zoster</p>
			<p class="em-only_endmatter-idx1">Herpes zoster ophthalmicus, 278</p>
			<p class="em-only_endmatter-idx1">Herpesviruses</p>
			<p class="em-only_endmatter-idx2">cytomegalovirus, 237<span class="endmatter-idx2_italic">t,</span> 261–262, 279</p>
			<p class="em-only_endmatter-idx2">Epstein-&#173;Barr virus, 262</p>
			<p class="em-only_endmatter-idx2">herpes simplex virus. <span class="endmatter-idx2_italic">See</span> Herpes simplex virus</p>
			<p class="em-only_endmatter-idx2">types of, 259</p>
			<p class="em-only_endmatter-idx2">varicella-&#173;zoster, 260–261</p>
			<p class="em-only_endmatter-idx1">High-&#173;density-&#173;lipoprotein cholesterol (HDL-&#173;C)</p>
			<p class="em-only_endmatter-idx2">coronary heart disease prevention in, 71</p>
			<p class="em-only_endmatter-idx2">pathogenesis of, 72</p>
			<p class="em-only_endmatter-idx1">Hip fractures, 190</p>
			<p class="em-only_endmatter-idx1">Histograms, 28, 29<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">HIV (human immunodeficiency virus)</p>
			<p class="em-only_endmatter-idx2">antiretroviral therapy for, 268</p>
			<p class="em-only_endmatter-idx2">clinical syndromes of, 267</p>
			<p class="em-only_endmatter-idx2">description of, 266</p>
			<p class="em-only_endmatter-idx2">etiology of, 266–267</p>
			<p class="em-only_endmatter-idx2">opportunistic infections in, 269</p>
			<p class="em-only_endmatter-idx2">pathogenesis of, 266–267</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 267</p>
			<p class="em-only_endmatter-idx2">syphilis involvement in, 253</p>
			<p class="em-only_endmatter-idx2">treatment of, 268</p>
			<p class="em-only_endmatter-idx1">HLA-&#173;B27, 154, 156</p>
			<p class="em-only_endmatter-idx1">HMG-&#173;CoA reductase inhibitors</p>
			<p class="em-only_endmatter-idx2">hypercholesterolemia treated with, 75<span class="endmatter-idx2_italic">t,</span> 76</p>
			<p class="em-only_endmatter-idx2">lipid-&#173;lowering uses of, 75<span class="endmatter-idx2_italic">t,</span> 76</p>
			<p class="em-only_endmatter-idx1">Homocysteine, 148</p>
			<p class="em-only_endmatter-idx1">Horizontal gaze deviation, seizures and, 208</p>
			<p class="em-only_endmatter-idx1">Hormone(s)</p>
			<p class="em-only_endmatter-idx2">hypothalamic, 47, 47<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 309<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">thyroid. <span class="endmatter-idx2_italic">See</span> Thyroid hormones</p>
			<p class="em-only_endmatter-idx1">Hormone replacement therapy, breast cancer and, 215</p>
			<p class="em-only_endmatter-idx1">Host–&#173;microbe interactions, 245</p>
			<p class="em-only_endmatter-idx1">Hot nodules, 44</p>
			<p class="em-only_endmatter-idx1">&#173;Human papillomavirus (HPV)</p>
			<p class="em-only_endmatter-idx2">cervical cancer and, 217–218, 237<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 264</p>
			<p class="em-only_endmatter-idx2">transmission of, 231</p>
			<p class="em-only_endmatter-idx2">vaccination for, 225<span class="endmatter-idx2_italic">t,</span> 231–232, 236</p>
			<p class="em-only_endmatter-idx1">&#173;Human T lymphotropic virus type 1, 237<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Humoral immune system, 245</p>
			<p class="em-only_endmatter-idx1">Hybridomas, 242</p>
			<p class="em-only_endmatter-idx1">Hydralazine, 64</p>
			<p class="em-only_endmatter-idx1">Hydrocortisone, 175<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Hydroxychloroquine, 164, 178–179, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Hydroxyurea</p>
			<p class="em-only_endmatter-idx2">essential thrombocythemia treated with, 143</p>
			<p class="em-only_endmatter-idx2">sickle cell disease treated with, 135</p>
			<p class="em-only_endmatter-idx1">Hyperaldosteronism, hypertension caused by, 54</p>
			<p class="em-only_endmatter-idx1">Hypercapnia, 124</p>
			<p class="em-only_endmatter-idx1">Hypercholesterolemia. <span class="endmatter-idx1_italic">See</span> Hyperlipidemia</p>
			<p class="em-only_endmatter-idx1">Hypercoagulable states</p>
			<p class="em-only_endmatter-idx2">description of, 146</p>
			<p class="em-only_endmatter-idx2">in pregnancy, 148</p>
			<p class="em-only_endmatter-idx2">primary, 146–148</p>
			<p class="em-only_endmatter-idx2">secondary, 146, 148</p>
			<p class="em-only_endmatter-idx1">Hyperglycemia, in diabetes mellitus, 33</p>
			<p class="em-only_endmatter-idx1">Hyperhomocysteinemia, 148</p>
			<p class="em-only_endmatter-idx1">Hyperlipidemia</p>
			<p class="em-only_endmatter-idx2">cerebrovascular disease and, 78</p>
			<p class="em-only_endmatter-idx2">ischemic heart disease and, 78</p>
			<p class="em-only_endmatter-idx2">lifestyle modifications for, 74</p>
			<p class="em-only_endmatter-idx2">management of, 74–79</p>
			<p class="em-only_endmatter-idx2">peripheral arterial disease and, 78</p>
			<p class="em-only_endmatter-idx2">statins for, 75<span class="endmatter-idx2_italic">t</span>, 76–77</p>
			<p class="em-only_endmatter-idx1">Hyperprolactinemia, 48</p>
			<p class="em-only_endmatter-idx1">Hypersplenism, 134, 136</p>
			<p class="em-only_endmatter-idx1">Hypertension. <span class="endmatter-idx1_italic">See also</span> Pulmonary hypertension</p>
			<p class="em-only_endmatter-idx2">in adolescents, 68</p>
			<p class="em-only_endmatter-idx2">ambulatory blood pressure monitoring in, 53</p>
			<p class="em-only_endmatter-idx2">angina pectoris and, 65</p>
			<p class="em-only_endmatter-idx2">in black patients, 52, 57</p>
			<p class="em-only_endmatter-idx2">blood pressure in</p>
			<p class="em-only_endmatter-idx3">ambulatory monitoring of, 53</p>
			<p class="em-only_endmatter-idx3">classifications of, 52<span class="endmatter-idx3_italic">t,</span> 52–53, 214</p>
			<p class="em-only_endmatter-idx2">as cardiovascular risk &#173;factor, 55, 56<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">cerebrovascular disease and, 66</p>
			<p class="em-only_endmatter-idx2">characteristics of, 51–52</p>
			<p class="em-only_endmatter-idx2">in &#173;children, 68</p>
			<p class="em-only_endmatter-idx2">chronic, 67–68</p>
			<p class="em-only_endmatter-idx2">chronic renal disease and, 65</p>
			<p class="em-only_endmatter-idx2">coronary heart disease risks, 73<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">definition of, 214</p>
			<p class="em-only_endmatter-idx2">in diabetes mellitus, 56, 65</p>
			<p class="em-only_endmatter-idx2">end-&#173;stage renal disease secondary to, 214</p>
			<p class="em-only_endmatter-idx2">etiology of, 53–55</p>
			<p class="em-only_endmatter-idx2">evaluation of, 55–56</p>
			<p class="em-only_endmatter-idx2">health risks associated with, 51, 214</p>
			<p class="em-only_endmatter-idx2">heart failure and, 65</p>
			<p class="em-only_endmatter-idx2">intrace&#173;re&#173;bral bleeding secondary to, 120</p>
			<p class="em-only_endmatter-idx2">in intraventricular hemorrhage, 120</p>
			<p class="em-only_endmatter-idx2">left ventricular hypertrophy and, 66</p>
			<p class="em-only_endmatter-idx2">lifestyle modifications for, 57, 58<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">masked, 51, 53</p>
			<p class="em-only_endmatter-idx2">metabolic syndrome and, 66</p>
			<p class="em-only_endmatter-idx2">obesity as risk &#173;factor for, 66, 68</p>
			<p class="em-only_endmatter-idx2">obstructive sleep apnea syndrome and, 66</p>
			<p class="em-only_endmatter-idx2">in older adults, 67</p>
			<p class="em-only_endmatter-idx2">oral contraceptives and, 67</p>
			<p class="em-only_endmatter-idx2">pathogenesis of, 53–55</p>
			<p class="em-only_endmatter-idx2">patient education and assessment in, 69–70</p>
			<p class="em-only_endmatter-idx2">perioperative management for ocular surgery in patients with, 284</p>
			<p class="em-only_endmatter-idx2">peripheral arterial disease and, 66</p>
			<p class="em-only_endmatter-idx2">physical examination of, 55</p>
			<p class="em-only_endmatter-idx2">in pregnancy, 67–68</p>
			<p class="em-only_endmatter-idx2">prevalence of, 51, 214</p>
			<p class="em-only_endmatter-idx2">primary, 53</p>
			<p class="em-only_endmatter-idx2">race and, 51–52</p>
			<p class="em-only_endmatter-idx2">rebound, 69</p>
			<p class="em-only_endmatter-idx2">renin-&#173;angiotensin-&#173;aldosterone system in, 53, 54<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">resistant, 54, 55<span class="endmatter-idx2_italic">t,</span> 64</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal complications of, 69–70, 70<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">screening for, 214</p>
			<p class="em-only_endmatter-idx2">secondary</p>
			<p class="em-only_endmatter-idx3">&#173;causes of, 53–54, 55<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">in &#173;children, 68</p>
			<p class="em-only_endmatter-idx3">laboratory tests for, 55</p>
			<p class="em-only_endmatter-idx2">stage 1, 52</p>
			<p class="em-only_endmatter-idx2">stage 2, 52–53</p>
			<p class="em-only_endmatter-idx2">stroke and, 66, 115</p>
			<p class="em-only_endmatter-idx2">transient, 68</p>
			<p class="em-only_endmatter-idx2">treatment of</p>
			<p class="em-only_endmatter-idx3">advanced glycation cross-&#173;link breakers, 65</p>
			<p class="em-only_endmatter-idx3">algorithm for, 60<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3"><span class="endmatter-idx3_greek">α</span><span class="subscript _idGenCharOverride-1">1</span>-&#173;blockers, 62–63</p>
			<p class="em-only_endmatter-idx3">angiotensin II receptor blockers, 59<span class="endmatter-idx3_italic">t,</span> 61</p>
			<p class="em-only_endmatter-idx3">angiotensin-&#173;converting enzyme inhibitors, 59<span class="endmatter-idx3_italic">t,</span> 61, 165</p>
			<p class="em-only_endmatter-idx3">antihypertensives, 52, 56–57, 59–64</p>
			<p class="em-only_endmatter-idx3"><span class="endmatter-idx1_accent">β</span>-&#173;blockers, 62, 69</p>
			<p class="em-only_endmatter-idx3">blood pressure thresholds as guidelines <br />for, 60<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">calcium channel blockers, 59<span class="endmatter-idx3_italic">t,</span> 61–62</p>
			<p class="em-only_endmatter-idx3">combination therapy, 63</p>
			<p class="em-only_endmatter-idx3">combined <span class="endmatter-idx3_greek">α</span>-&#173;adrenergic and <span class="endmatter-idx1_accent">β</span>-&#173;adrenergic antagonists, 63</p>
			<p class="em-only_endmatter-idx3">comorbidities, 65–66</p>
			<p class="em-only_endmatter-idx3">considerations in, 57</p>
			<p class="em-only_endmatter-idx3">DASH diet, 57, 58<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">direct renin inhibitors, 63</p>
			<p class="em-only_endmatter-idx3">direct vasodilators, 63</p>
			<p class="em-only_endmatter-idx3">diuretics, 59<span class="endmatter-idx3_italic">t,</span> 59–61</p>
			<p class="em-only_endmatter-idx3">&#173;future, 64–65</p>
			<p class="em-only_endmatter-idx3">lifestyle modifications, 57, 58<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">nonpharmacologic, 57, 58<span class="endmatter-idx3_italic">t,</span> 64</p>
			<p class="em-only_endmatter-idx3">in older adults, 67</p>
			<p class="em-only_endmatter-idx3">pharmacologic, 51–52</p>
			<p class="em-only_endmatter-idx3">radiofrequency ablation, 64–65</p>
			<p class="em-only_endmatter-idx2">ventricular dysfunction and, 65</p>
			<p class="em-only_endmatter-idx2">“white coat,” 53</p>
			<p class="em-only_endmatter-idx2">withdrawal syndromes as cause of, 68–69</p>
			<p class="em-only_endmatter-idx2">in &#173;women, 67–68</p>
			<p class="em-only_endmatter-idx1">Hypertensive crisis, 69</p>
			<p class="em-only_endmatter-idx1">Hypertensive retinopathy, 69, 70<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Hyperthyroidism, Graves, 43–44</p>
			<p class="em-only_endmatter-idx1">Hypnotic drugs, 201<span class="endmatter-idx1_italic">t,</span> 201–202</p>
			<p class="em-only_endmatter-idx1">Hypoglycemia, 300</p>
			<p class="em-only_endmatter-idx1">Hypothalamic-&#173;pituitary axis</p>
			<p class="em-only_endmatter-idx2">disorders of, 46–49</p>
			<p class="em-only_endmatter-idx2">functions of, 46–47</p>
			<p class="em-only_endmatter-idx1">Hypothalamic-&#173;pituitary-&#173;adrenal suppression, 175</p>
			<p class="em-only_endmatter-idx1">Hypothalamus</p>
			<p class="em-only_endmatter-idx2">functions of, 46</p>
			<p class="em-only_endmatter-idx2">hormones secreted from, 47, 47<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Hypothyroidism, 44–45</p>
			<p class="em-only_endmatter-idx1">Hypovolemic shock, 300</p>
			<p class="em-only_endmatter-idx1">Hypoxemia, 124</p>
			<p class="em-only_endmatter-idx1">Ibuprofen, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Idarucizumab, 149</p>
			<p class="em-only_endmatter-idx1">Idiopathic thrombocytopenic purpura (ITP), 141</p>
			<p class="em-only_endmatter-idx1">Illness anxiety disorder, 197</p>
			<p class="em-only_endmatter-idx1">Imipenem/cilastatin, 273</p>
			<p class="em-only_endmatter-idx1">Imipramine, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Immune reconstitution inflammatory syndrome (IRIS), 269–270</p>
			<p class="em-only_endmatter-idx1">Immune recovery uveitis (IRU), 269</p>
			<p class="em-only_endmatter-idx1">Immunity</p>
			<p class="em-only_endmatter-idx2">adaptive, 246</p>
			<p class="em-only_endmatter-idx2">innate, 245</p>
			<p class="em-only_endmatter-idx1">Immunization schedules, 223</p>
			<p class="em-only_endmatter-idx1">Immunizations. <span class="endmatter-idx1_italic">See also</span> Vaccines/vaccinations</p>
			<p class="em-only_endmatter-idx2">active, 223</p>
			<p class="em-only_endmatter-idx2">contraindications for, 223–224</p>
			<p class="em-only_endmatter-idx2">development of, 223</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Haemophilus influenzae,</span> 231–232</p>
			<p class="em-only_endmatter-idx2">hepatitis, 224–226, 225<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">hepatitis A, 224</p>
			<p class="em-only_endmatter-idx2">hepatitis B, 224, 226, 232</p>
			<p class="em-only_endmatter-idx2">hepatitis C, 226</p>
			<p class="em-only_endmatter-idx2">influenza, 225<span class="endmatter-idx2_italic">t,</span> 226–227</p>
			<p class="em-only_endmatter-idx2">measles/mumps/rubella, 225<span class="endmatter-idx2_italic">t,</span> 228–229</p>
			<p class="em-only_endmatter-idx2">meningococcal, 231</p>
			<p class="em-only_endmatter-idx2">passive, 223, 233</p>
			<p class="em-only_endmatter-idx2">pneumococcal pneumonia, 230–231</p>
			<p class="em-only_endmatter-idx2">polio, 229</p>
			<p class="em-only_endmatter-idx2">in pregnancy, 224</p>
			<p class="em-only_endmatter-idx2">recommendations for, 225<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">rotavirus, 230</p>
			<p class="em-only_endmatter-idx2">tetanus and diphtheria, 225<span class="endmatter-idx2_italic">t,</span> 229–230</p>
			<p class="em-only_endmatter-idx2">travel-&#173;related, 232</p>
			<p class="em-only_endmatter-idx2">varicella-&#173;zoster, 225<span class="endmatter-idx2_italic">t,</span> 227–228</p>
			<p class="em-only_endmatter-idx2">yellow fever, 232</p>
			<p class="em-only_endmatter-idx1">Immunosuppressive agents</p>
			<p class="em-only_endmatter-idx2">Cogan syndrome treated with, 174</p>
			<p class="em-only_endmatter-idx2">dermatomyositis treated with, 168</p>
			<p class="em-only_endmatter-idx2">polymyositis treated with, 168</p>
			<p class="em-only_endmatter-idx2">systemic sclerosis treated with, 166</p>
			<p class="em-only_endmatter-idx1">Immunotherapy, for lung disease, 128</p>
			<p class="em-only_endmatter-idx1">Impaired glucose tolerance, 35</p>
			<p class="em-only_endmatter-idx1">Implantable cardioverter-&#173;defibrillator (ICD)</p>
			<p class="em-only_endmatter-idx2">antiarrhythmic therapy with, 105</p>
			<p class="em-only_endmatter-idx2">congestive heart failure treated with, 100</p>
			<p class="em-only_endmatter-idx2">current-&#173;generation, 105</p>
			<p class="em-only_endmatter-idx2">ocular surgery preoperative discussions, 282</p>
			<p class="em-only_endmatter-idx2">sudden cardiac death prevention using, 86, 105</p>
			<p class="em-only_endmatter-idx2">tachyarrhythmias treated with, 104–106</p>
			<p class="em-only_endmatter-idx2">transvenous system, 105</p>
			<p class="em-only_endmatter-idx1">Inactivated influenza vaccines (IIVs), 227</p>
			<p class="em-only_endmatter-idx1">Infectious diseases</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Borrelia burgdorferi,</span> 254–255</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Candida albicans,</span> 258</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Chlamydia trachomatis. See Chlamydia trachomatis</span></p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Clostridium difficile,</span> 249</p>
			<p class="em-only_endmatter-idx2">cytomegalovirus, 237<span class="endmatter-idx2_italic">t,</span> 261–262, 279</p>
			<p class="em-only_endmatter-idx2">Ebola virus, 264–265</p>
			<p class="em-only_endmatter-idx2">fungal, 258</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Haemophilus influenzae,</span> 231, 249–250</p>
			<p class="em-only_endmatter-idx2">hepatitis. <span class="endmatter-idx2_italic">See</span> Hepatitis</p>
			<p class="em-only_endmatter-idx2">herpes simplex virus. <span class="endmatter-idx2_italic">See</span> Herpes simplex virus</p>
			<p class="em-only_endmatter-idx2">&#173;human papillomavirus. <span class="endmatter-idx2_italic">See</span> &#173;Human papillomavirus</p>
			<p class="em-only_endmatter-idx2">influenza, 225<span class="endmatter-idx2_italic">t,</span> 226–227</p>
			<p class="em-only_endmatter-idx2">measles, 228–229</p>
			<p class="em-only_endmatter-idx2">meningococcus, 231</p>
			<p class="em-only_endmatter-idx2">microbiology of, 245–246</p>
			<p class="em-only_endmatter-idx2">mumps, 228–229</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Mycobacterium tuberculosis,</span> 222, 256–257</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Mycoplasma pneumoniae,</span> 256</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Neisseria,</span> 250–251, 276</p>
			<p class="em-only_endmatter-idx2">polio, 229</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Pseudomonas aeruginosa,</span> 251–252</p>
			<p class="em-only_endmatter-idx2">rotavirus, 230</p>
			<p class="em-only_endmatter-idx2">rubella, 229</p>
			<p class="em-only_endmatter-idx2">screening for, 222–223</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Staphylococcus,</span> 246–247</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Streptococcus,</span> 247–249, 248<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">syphilis. <span class="endmatter-idx2_italic">See</span> Syphilis</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Toxoplasma gondii,</span> 258–259</p>
			<p class="em-only_endmatter-idx2">varicella-&#173;zoster, 225<span class="endmatter-idx2_italic">t,</span> 227–228</p>
			<p class="em-only_endmatter-idx2">Zika virus, 265–266</p>
			<p class="em-only_endmatter-idx1">Infectious endocarditis, community-&#173;acquired, <br />248</p>
			<p class="em-only_endmatter-idx1">Inflammatory anemia, 137</p>
			<p class="em-only_endmatter-idx1">Inflammatory bowel disease (IBD)</p>
			<p class="em-only_endmatter-idx2">ocular manifestations of, 157</p>
			<p class="em-only_endmatter-idx2">spondylarthritis associated with, 156</p>
			<p class="em-only_endmatter-idx1">Infliximab, 180</p>
			<p class="em-only_endmatter-idx1">Infliximab-&#173;dyyb, 181</p>
			<p class="em-only_endmatter-idx1">Influenza</p>
			<p class="em-only_endmatter-idx2">antiviral agents for, 279</p>
			<p class="em-only_endmatter-idx2">immunization for, 225<span class="endmatter-idx2_italic">t,</span> 226–227</p>
			<p class="em-only_endmatter-idx1">Informed consent</p>
			<p class="em-only_endmatter-idx2">in behavioral disorder patients, 211–212</p>
			<p class="em-only_endmatter-idx2">ethical considerations in, 212</p>
			<p class="em-only_endmatter-idx2">in neurologic disorder patients, 211–212</p>
			<p class="em-only_endmatter-idx2">before ocular surgery, 282</p>
			<p class="em-only_endmatter-idx2">in older adults, 187</p>
			<p class="em-only_endmatter-idx1">Initiative in Vision Rehabilitation on the ONE&#160;<br />Network, 185</p>
			<p class="em-only_endmatter-idx1">Innate immunity, 245</p>
			<p class="em-only_endmatter-idx1">Instrumental activities of daily living (IADLs), <br />187</p>
			<p class="em-only_endmatter-idx1">Insulin</p>
			<p class="em-only_endmatter-idx2">continuous subcutaneous infusion of, 37</p>
			<p class="em-only_endmatter-idx2">type 1 diabetes mellitus treated with, 37</p>
			<p class="em-only_endmatter-idx1">Insulin re&#173;sis&#173;tance</p>
			<p class="em-only_endmatter-idx2">metabolic syndrome and, 77</p>
			<p class="em-only_endmatter-idx2">in type 2 diabetes mellitus, 34</p>
			<p class="em-only_endmatter-idx1">Insulinomas, 50</p>
			<p class="em-only_endmatter-idx1">“Intention to treat” analy&#173;sis, 6</p>
			<p class="em-only_endmatter-idx1">Interferon, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Interferon-&#173;<span class="endmatter-idx1_greek">α</span><span class="subscript _idGenCharOverride-1">2a</span>, 261</p>
			<p class="em-only_endmatter-idx1">Interferon-&#173;gamma release assay (IGRA), for tuberculosis detection, 222</p>
			<p class="em-only_endmatter-idx1">INTERHEART study, 72</p>
			<p class="em-only_endmatter-idx1">Interleukin inhibitors, 180</p>
			<p class="em-only_endmatter-idx1">Interleukins, 242</p>
			<p class="em-only_endmatter-idx1">International League of Associations of Rheumatology, 157, 158<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">International normalized ratio (INR), 140, 276</p>
			<p class="em-only_endmatter-idx1">Interrater reliability, 24</p>
			<p class="em-only_endmatter-idx1">Intrace&#173;re&#173;bral hemorrhage, 120</p>
			<p class="em-only_endmatter-idx1">Intracranial hemorrhage, 120–122</p>
			<p class="em-only_endmatter-idx1">Intraocular pressure</p>
			<p class="em-only_endmatter-idx2">inhaled corticosteroids’ effect on, 130</p>
			<p class="em-only_endmatter-idx2">monitoring of, in glaucoma patients using corticosteroids, 130</p>
			<p class="em-only_endmatter-idx2">statins and, 78</p>
			<p class="em-only_endmatter-idx1">Intraparenchymal hematomas, 122</p>
			<p class="em-only_endmatter-idx1">Intrarater reliability, 24</p>
			<p class="em-only_endmatter-idx1">Intravascular ultrasound, in coronary heart disease diagnosis, 89</p>
			<p class="em-only_endmatter-idx1">Intraventricular hemorrhage (IVH), 120–121</p>
			<p class="em-only_endmatter-idx1">Intrinsic pathway, of coagulation cascade, 138<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Intrinsic sympathomimetic activity, 62</p>
			<p class="em-only_endmatter-idx1">Investigator bias, 5</p>
			<p class="em-only_endmatter-idx1">Iodine-131, for Graves hyperthyroidism, 44</p>
			<p class="em-only_endmatter-idx1">Ionizing radiation. <span class="endmatter-idx1_italic">See also</span> Radiation therapy</p>
			<p class="em-only_endmatter-idx2">cancer caused by exposure to, 236</p>
			<p class="em-only_endmatter-idx2">ocular effects of, 238, 238<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">tissue damage caused by, 238<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">treatment uses of, 237</p>
			<p class="em-only_endmatter-idx1">Ipratropium bromide, 128</p>
			<p class="em-only_endmatter-idx1">Iridocyclitis</p>
			<p class="em-only_endmatter-idx2">in ankylosing spondylitis, 157</p>
			<p class="em-only_endmatter-idx2">in Beh<span class="endmatter-idx2_accent">ç</span>et disease, 174</p>
			<p class="em-only_endmatter-idx1">IRIS (Intelligent Research in Sight) Registry, 26</p>
			<p class="em-only_endmatter-idx1">Iron chelation, for thalassemias, 134</p>
			<p class="em-only_endmatter-idx1">Iron deficiency anemia, 132–133</p>
			<p class="em-only_endmatter-idx1">Irreversible obstructive lung diseases, 124</p>
			<p class="em-only_endmatter-idx1">Ischemia, 81</p>
			<p class="em-only_endmatter-idx1">Ischemic heart disease</p>
			<p class="em-only_endmatter-idx2">asymptomatic, 86</p>
			<p class="em-only_endmatter-idx2">clinical syndromes associated with, 82–86</p>
			<p class="em-only_endmatter-idx2">diabetic retinopathy and, 105</p>
			<p class="em-only_endmatter-idx2">diagnosis of</p>
			<p class="em-only_endmatter-idx3">cardiac enzymes, 86–87</p>
			<p class="em-only_endmatter-idx3">computed tomography, 88</p>
			<p class="em-only_endmatter-idx3">coronary arteriography, 89</p>
			<p class="em-only_endmatter-idx3">coronary computed tomography angiography, 88</p>
			<p class="em-only_endmatter-idx3">echocardiography, 87</p>
			<p class="em-only_endmatter-idx3">electrocardiography, 86</p>
			<p class="em-only_endmatter-idx3">electron beam computed tomography, 88</p>
			<p class="em-only_endmatter-idx3">exercise stress testing, 88</p>
			<p class="em-only_endmatter-idx3">intravascular ultrasound, 89</p>
			<p class="em-only_endmatter-idx3">invasive procedures for, 89</p>
			<p class="em-only_endmatter-idx3">magnetic resonance imaging, 88</p>
			<p class="em-only_endmatter-idx3">multiple gated acquisition scans, 89</p>
			<p class="em-only_endmatter-idx3">myoglobin levels, 87</p>
			<p class="em-only_endmatter-idx3">noninvasive procedures for, 86–89</p>
			<p class="em-only_endmatter-idx3">positron emission tomography, 88</p>
			<p class="em-only_endmatter-idx3">radionuclide scintigraphy and scans, 88</p>
			<p class="em-only_endmatter-idx3">serum biomarkers, 86–87</p>
			<p class="em-only_endmatter-idx3">single-&#173;photon emission computed tomography, 88</p>
			<p class="em-only_endmatter-idx3">troponin levels, 87</p>
			<p class="em-only_endmatter-idx3">ventriculography, 89</p>
			<p class="em-only_endmatter-idx2">hyperlipidemia and, 78</p>
			<p class="em-only_endmatter-idx2">management of</p>
			<p class="em-only_endmatter-idx3">antithrombotic agents, 89–91<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">direct oral antithrombotic agents, 90<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">goals for, 89</p>
			<p class="em-only_endmatter-idx2">pathophysiology of, 81–82</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 82</p>
			<p class="em-only_endmatter-idx1">Ischemic stroke. <span class="endmatter-idx1_italic">See also</span> Ce&#173;re&#173;bral ischemia</p>
			<p class="em-only_endmatter-idx2">blood pressure control for prevention of, 115</p>
			<p class="em-only_endmatter-idx2">cardioaortic &#173;causes of, 118–119</p>
			<p class="em-only_endmatter-idx2">carotid duplex ultrasonography for, 113</p>
			<p class="em-only_endmatter-idx2">carotid occlusive disease as cause of, 115–119</p>
			<p class="em-only_endmatter-idx2">&#173;causes of, 111</p>
			<p class="em-only_endmatter-idx2">ce&#173;re&#173;bral arteriography for, 113</p>
			<p class="em-only_endmatter-idx2">clinical manifestations of, 110–111</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 111–112</p>
			<p class="em-only_endmatter-idx2">helical computed tomography angiography for, 113</p>
			<p class="em-only_endmatter-idx2">imaging studies for, 112–113</p>
			<p class="em-only_endmatter-idx2">magnetic resonance angiography evaluations, <br />112–113</p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging evaluations, 112–113</p>
			<p class="em-only_endmatter-idx2">management of, 111–112</p>
			<p class="em-only_endmatter-idx2">mechanical thrombectomy for, 113–114</p>
			<p class="em-only_endmatter-idx2">multimodal computed tomography for, 112</p>
			<p class="em-only_endmatter-idx2">nonarteriosclerotic &#173;causes of, 111</p>
			<p class="em-only_endmatter-idx2">penumbra, 110</p>
			<p class="em-only_endmatter-idx2">prevention of, 114–115</p>
			<p class="em-only_endmatter-idx2">recombinant tissue plasminogen activator for, 113</p>
			<p class="em-only_endmatter-idx2">reperfusion techniques, 114</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 111</p>
			<p class="em-only_endmatter-idx2">statins for prevention of, 115</p>
			<p class="em-only_endmatter-idx2">thrombolytic agents, 113</p>
			<p class="em-only_endmatter-idx2">transcranial Doppler ultrasonography for, 113</p>
			<p class="em-only_endmatter-idx2">treatment of, 113–114</p>
			<p class="em-only_endmatter-idx1">Islet cell transplantation, 37</p>
			<p class="em-only_endmatter-idx1">Isoetharine, 128</p>
			<p class="em-only_endmatter-idx1">Isoniazid, for tuberculosis, 257</p>
			<p class="em-only_endmatter-idx1">Isotretinoin, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ixekizumab, 180</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Ixodes,</span> 254</p>
			<p class="em-only_endmatter-idx1">Janus kinase inhibitors</p>
			<p class="em-only_endmatter-idx2">description of, 180</p>
			<p class="em-only_endmatter-idx2">rheumatoid disease treated with, 153</p>
			<p class="em-only_endmatter-idx1">Jenner, Edward, 223</p>
			<p class="em-only_endmatter-idx1">Joint National Committee on Prevention, Detection, Evaluation, and Treatment of Blood <br />Pressure (JNC 7)</p>
			<p class="em-only_endmatter-idx2">blood pressure classification, 52</p>
			<p class="em-only_endmatter-idx2">hypertension treatment guidelines, 57</p>
			<p class="em-only_endmatter-idx1">Juvenile idiopathic arthritis (JIA), 157–158, 158<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Kartagener syndrome, 124</p>
			<p class="em-only_endmatter-idx1">Kawasaki disease, 171</p>
			<p class="em-only_endmatter-idx1">Keratoconjunctivitis sicca, in systemic lupus erythematosus, 161</p>
			<p class="em-only_endmatter-idx1">Keratoconjunctivitis sicca-&#173;like syndrome, 106</p>
			<p class="em-only_endmatter-idx1">Keratoderma blennorrhagicum, 155, 155<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ketoconazole, 277</p>
			<p class="em-only_endmatter-idx1">Ketorolac, 289–290</p>
			<p class="em-only_endmatter-idx1">Kinase inhibitors, 177<span class="endmatter-idx1_italic">t,</span> 180</p>
			<p class="em-only_endmatter-idx1">Kuru, 211</p>
			<p class="em-only_endmatter-idx1">Labetalol, 64</p>
			<p class="em-only_endmatter-idx1">Lamotrigine, 203, 207</p>
			<p class="em-only_endmatter-idx1">Large-&#173;vessel vasculitis, 169<span class="endmatter-idx1_italic">t,</span> 170</p>
			<p class="em-only_endmatter-idx1">Laryngotracheobronchial disease, in relapsing polychondritis, 168</p>
			<p class="em-only_endmatter-idx1">Latent autoimmune diabetes in adults (LADA), 34</p>
			<p class="em-only_endmatter-idx1">Latent syphilis, 252</p>
			<p class="em-only_endmatter-idx1">Latex allergies, 288</p>
			<p class="em-only_endmatter-idx1">Lean techniques, 31–32</p>
			<p class="em-only_endmatter-idx1">Ledipasvir/sofosbuvir, 261</p>
			<p class="em-only_endmatter-idx1">Left ventricular hypertrophy, hypertension and, 66</p>
			<p class="em-only_endmatter-idx1">Lens, radiation sensitivity of, 238–239</p>
			<p class="em-only_endmatter-idx1">Leukemia, essential thrombocythemia transformation into, 143</p>
			<p class="em-only_endmatter-idx1">Leukotriene inhibitors, for lung disease, 128</p>
			<p class="em-only_endmatter-idx1">Leuprolide, 309<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Levodopa, for Parkinson disease, 205</p>
			<p class="em-only_endmatter-idx1">Levothyroxine, for hypothyroidism, 45</p>
			<p class="em-only_endmatter-idx1">Lewy body dementia, 210</p>
			<p class="em-only_endmatter-idx1">Libman-&#173;Sacks endocarditis, 163</p>
			<p class="em-only_endmatter-idx1">Lidocaine, 291</p>
			<p class="em-only_endmatter-idx1">Lifestyle modifications</p>
			<p class="em-only_endmatter-idx2">for congestive heart failure, 99</p>
			<p class="em-only_endmatter-idx2">for diabetes mellitus, 35</p>
			<p class="em-only_endmatter-idx2">for hyperlipidemia, 74</p>
			<p class="em-only_endmatter-idx2">for hypertension, 57, 58<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Life-&#173;support techniques, 295</p>
			<p class="em-only_endmatter-idx1">Likelihood ratio, 19</p>
			<p class="em-only_endmatter-idx1">Lipid management, coronary heart disease risk modification using, 73<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Lipid-&#173;lowering therapy</p>
			<p class="em-only_endmatter-idx2">agents used in, 75<span class="endmatter-idx2_italic">t,</span> 76–77</p>
			<p class="em-only_endmatter-idx2">atherosclerotic lesions reduced with, 89</p>
			<p class="em-only_endmatter-idx2">low-&#173;density-&#173;lipoprotein cholesterol reductions using, 74, 75<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">statins for, 75<span class="endmatter-idx2_italic">t,</span> 76–77</p>
			<p class="em-only_endmatter-idx1">Lipoproteins</p>
			<p class="em-only_endmatter-idx2">cholesterol transport by, 72</p>
			<p class="em-only_endmatter-idx2">definition of, 72</p>
			<p class="em-only_endmatter-idx1">Lithium carbonate, 203</p>
			<p class="em-only_endmatter-idx1">Live-&#173;attenuated influenza vaccine (LAIV), 227</p>
			<p class="em-only_endmatter-idx1">Liver disease, 145</p>
			<p class="em-only_endmatter-idx1">Liver transplantation, 226</p>
			<p class="em-only_endmatter-idx1">Local anesthesia</p>
			<p class="em-only_endmatter-idx2">agents for</p>
			<p class="em-only_endmatter-idx3">description of, 290–291</p>
			<p class="em-only_endmatter-idx3">dosing of, 305<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">toxic reactions to, 304–306</p>
			<p class="em-only_endmatter-idx2">epinephrine added to, 305</p>
			<p class="em-only_endmatter-idx2">intraoperative considerations for, 290–291</p>
			<p class="em-only_endmatter-idx2">peribulbar injection of, 304</p>
			<p class="em-only_endmatter-idx2">retrobulbar injection of, 290–291, 304</p>
			<p class="em-only_endmatter-idx1">L<span class="endmatter-idx1_accent">ö</span>fgren syndrome, 162</p>
			<p class="em-only_endmatter-idx1">Loop diuretics, 59<span class="endmatter-idx1_italic">t,</span> 59–60</p>
			<p class="em-only_endmatter-idx1">Loracarbef, 273</p>
			<p class="em-only_endmatter-idx1">Los Angeles Latino Eye Study, 12</p>
			<p class="em-only_endmatter-idx1">Lovastatin, 75<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Low-&#173;density-&#173;lipoprotein cholesterol (LDL-&#173;C)</p>
			<p class="em-only_endmatter-idx2">coronary heart disease prevention in, 71</p>
			<p class="em-only_endmatter-idx2">lipid-&#173;lowering therapies for, 74–77, 75<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">pathogenesis of, 72</p>
			<p class="em-only_endmatter-idx1">Low-&#173;molecular-&#173;weight heparin (LMWH)</p>
			<p class="em-only_endmatter-idx2">coronary heart disease treated with, 91<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">description of, 149</p>
			<p class="em-only_endmatter-idx1">Low-&#173;tension glaucoma, 66–67</p>
			<p class="em-only_endmatter-idx1">Lung(s), pathologic pro&#173;cesses that affect, 123</p>
			<p class="em-only_endmatter-idx1">Lung cancer</p>
			<p class="em-only_endmatter-idx2">mortality rates for, 220</p>
			<p class="em-only_endmatter-idx2">screening for, 216<span class="endmatter-idx2_italic">t,</span> 220</p>
			<p class="em-only_endmatter-idx1">Lung diseases</p>
			<p class="em-only_endmatter-idx2">asthma, 123–124, 128–130, 129<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">evaluation of, 125–126</p>
			<p class="em-only_endmatter-idx2">obstructive, 123–125</p>
			<p class="em-only_endmatter-idx3">chronic obstructive pulmonary disease, 124, 285</p>
			<p class="em-only_endmatter-idx3">description of, 123</p>
			<p class="em-only_endmatter-idx3">irreversible, 124</p>
			<p class="em-only_endmatter-idx3">reversible, 123–124</p>
			<p class="em-only_endmatter-idx2">perioperative management for ocular surgery in patients with, 284</p>
			<p class="em-only_endmatter-idx2">restrictive, 125</p>
			<p class="em-only_endmatter-idx2">symptoms of, 124</p>
			<p class="em-only_endmatter-idx2">treatment of</p>
			<p class="em-only_endmatter-idx3">algorithm for, 129<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">anticholinergics, 128</p>
			<p class="em-only_endmatter-idx3"><span class="endmatter-idx1_accent">β</span><span class="subscript _idGenCharOverride-1">2</span>-&#173;adrenergic agonists, 128</p>
			<p class="em-only_endmatter-idx3">bronchodilators, 128</p>
			<p class="em-only_endmatter-idx3">corticosteroids, 128</p>
			<p class="em-only_endmatter-idx3">inflammation inhibitors, 128</p>
			<p class="em-only_endmatter-idx3">leukotriene inhibitors, 128</p>
			<p class="em-only_endmatter-idx3">noninvasive pressure support ventilation, <br />126–127</p>
			<p class="em-only_endmatter-idx3">nonpharmacologic, 126–127</p>
			<p class="em-only_endmatter-idx3 ParaOverride-2">pharmacologic, 127–130</p>
			<p class="em-only_endmatter-idx1">M2 protein inhibitors, 279</p>
			<p class="em-only_endmatter-idx1">MacArthur Competence Assessment Tool for Treatment (MacCAT-&#173;T), 211</p>
			<p class="em-only_endmatter-idx1">Macroadenomas, pituitary, 47</p>
			<p class="em-only_endmatter-idx1">Macroalbuminuria, 39</p>
			<p class="em-only_endmatter-idx1">Macrocytic anemia, 132–133</p>
			<p class="em-only_endmatter-idx1">Macrolides, 274–275</p>
			<p class="em-only_endmatter-idx1">Macular degeneration</p>
			<p class="em-only_endmatter-idx2">age-&#173;related. <span class="endmatter-idx2_italic">See</span> Age-&#173;related macular degeneration</p>
			<p class="em-only_endmatter-idx2">fall risks associated with, 191</p>
			<p class="em-only_endmatter-idx1">Magnetic resonance angiography</p>
			<p class="em-only_endmatter-idx2">carotid stenosis diagnosis using, 116</p>
			<p class="em-only_endmatter-idx2">stroke evaluations, 112–113</p>
			<p class="em-only_endmatter-idx1">Magnetic resonance imaging (MRI)</p>
			<p class="em-only_endmatter-idx2">in coronary heart disease diagnosis, 88</p>
			<p class="em-only_endmatter-idx2">diffusion-&#173;weighted, 112</p>
			<p class="em-only_endmatter-idx2">perfusion-&#173;weighted imaging, 113</p>
			<p class="em-only_endmatter-idx2">pituitary tumor evaluations using, 48</p>
			<p class="em-only_endmatter-idx2">stroke evaluations, 112–113</p>
			<p class="em-only_endmatter-idx1">Magnetic resonance imaging, epilepsy diagnosis <br />using, 207</p>
			<p class="em-only_endmatter-idx1">Major depressive disorder, 189, 195, 202</p>
			<p class="em-only_endmatter-idx1">Malabsorption, folate deficiency caused by, 134</p>
			<p class="em-only_endmatter-idx1">Malar rash, in systemic lupus erythematosus, 158, <br />159<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Malaria vaccination, 232</p>
			<p class="em-only_endmatter-idx1">Malignant Hyperthermia Association of the United States (MHAUS), 292, 293<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Malignant hyperthermia (MH), 291–292, 293<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Malingering, 197, 203</p>
			<p class="em-only_endmatter-idx1">Mammography, breast cancer detection using, <br />216–217</p>
			<p class="em-only_endmatter-idx1">Mania, 195–196</p>
			<p class="em-only_endmatter-idx1">Mann-&#173;Whitney U test, 7</p>
			<p class="em-only_endmatter-idx1">Marfan syndrome, 140–141</p>
			<p class="em-only_endmatter-idx1">Masked hypertension, 51, 53</p>
			<p class="em-only_endmatter-idx1">Maze procedure, 103</p>
			<p class="em-only_endmatter-idx1">Mean corpuscular volume (MCV), 132</p>
			<p class="em-only_endmatter-idx1">Measles/mumps/rubella vaccination, 225<span class="endmatter-idx1_italic">t,</span> 228–229</p>
			<p class="em-only_endmatter-idx1">Mechanical thrombectomy, for stroke, 113–114</p>
			<p class="em-only_endmatter-idx1">Medical emergencies</p>
			<p class="em-only_endmatter-idx2">anaphylaxis, 302–303</p>
			<p class="em-only_endmatter-idx2">cardiopulmonary arrest, 296–299, 297<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">crash cart for, 298</p>
			<p class="em-only_endmatter-idx2">hypoglycemia, 300</p>
			<p class="em-only_endmatter-idx2">opioid overdose, 306–307</p>
			<p class="em-only_endmatter-idx2">seizures. <span class="endmatter-idx2_italic">See</span> Seizures</p>
			<p class="em-only_endmatter-idx2">shock. <span class="endmatter-idx2_italic">See</span> Shock</p>
			<p class="em-only_endmatter-idx2">status epilepticus, 303–304</p>
			<p class="em-only_endmatter-idx2">syncope, 299</p>
			<p class="em-only_endmatter-idx1">Medicare Access and CHIP Reauthorization Act (MACRA), 32</p>
			<p class="em-only_endmatter-idx1">Medi&#173;cations. <span class="endmatter-idx1_italic">See also specific medi&#173;cation</span></p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 307–309<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">thrombocytopenia induced by, 141–142</p>
			<p class="em-only_endmatter-idx1">Medium-&#173;sized–&#173;vessel vasculitis, 169<span class="endmatter-idx1_italic">t,</span> 170–171</p>
			<p class="em-only_endmatter-idx1">Medullary thyroid cancer, 46, 50</p>
			<p class="em-only_endmatter-idx1">Megaloblastic anemia, 133</p>
			<p class="em-only_endmatter-idx1">Melanoma</p>
			<p class="em-only_endmatter-idx2">oncolytic virus treatment for, 242</p>
			<p class="em-only_endmatter-idx2">screening for, 220–221</p>
			<p class="em-only_endmatter-idx1">Memantine, 210</p>
			<p class="em-only_endmatter-idx1">MEN.&#160;<span class="endmatter-idx1_italic">See</span> Multiple endocrine neoplasia</p>
			<p class="em-only_endmatter-idx1">Meningitis</p>
			<p class="em-only_endmatter-idx2">cryptococcal, 277</p>
			<p class="em-only_endmatter-idx2">meningococcal, 250</p>
			<p class="em-only_endmatter-idx1">Meningococcal meningitis, 250</p>
			<p class="em-only_endmatter-idx1">Meningococcal vaccinations, 231</p>
			<p class="em-only_endmatter-idx1">Mepolizumab, for eosinophilic asthma, 124</p>
			<p class="em-only_endmatter-idx1">Merit-&#173;based Incentive Payment System (MIPS), 32</p>
			<p class="em-only_endmatter-idx1">Meta-&#173;analyses, 3, 8, 14</p>
			<p class="em-only_endmatter-idx1">Metabolic syndrome</p>
			<p class="em-only_endmatter-idx2">definition of, 77</p>
			<p class="em-only_endmatter-idx2">diabetes mellitus risks, 35</p>
			<p class="em-only_endmatter-idx2">diagnostic criteria for, 35</p>
			<p class="em-only_endmatter-idx2">hypertension and, 66</p>
			<p class="em-only_endmatter-idx2">insulin re&#173;sis&#173;tance and, 77</p>
			<p class="em-only_endmatter-idx2">management of, 77–78</p>
			<p class="em-only_endmatter-idx1">Metformin, 38</p>
			<p class="em-only_endmatter-idx1">Methicillin-&#173;resistant <span class="endmatter-idx1_italic">Staphylococcus aureus </span>(MRSA), <br />246</p>
			<p class="em-only_endmatter-idx1">Methimazole, thyroid secretion suppression using, 44</p>
			<p class="em-only_endmatter-idx1">Methotrexate</p>
			<p class="em-only_endmatter-idx2">dermatomyositis treated with, 168</p>
			<p class="em-only_endmatter-idx2">description of, 178</p>
			<p class="em-only_endmatter-idx2">dosing of, 178</p>
			<p class="em-only_endmatter-idx2">polymyalgia rheumatica treated with, 168</p>
			<p class="em-only_endmatter-idx2">polymyositis treated with, 168</p>
			<p class="em-only_endmatter-idx2">rheumatoid disease treated with, 153</p>
			<p class="em-only_endmatter-idx1">Methyldopa, 63</p>
			<p class="em-only_endmatter-idx1">Methylenetetrahydrofolate reductase gene, 148</p>
			<p class="em-only_endmatter-idx1">Methylmalonic acid, 133</p>
			<p class="em-only_endmatter-idx1">Methylprednisolone</p>
			<p class="em-only_endmatter-idx2">acute allergic reaction treated with, 302</p>
			<p class="em-only_endmatter-idx2">potency of, 175<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Microadenomas, pituitary, 47</p>
			<p class="em-only_endmatter-idx1">Microalbuminuria, 39</p>
			<p class="em-only_endmatter-idx1">Microangiopathic hemolytic anemia (MAHA), 142</p>
			<p class="em-only_endmatter-idx1">Microbiology, 245–246</p>
			<p class="em-only_endmatter-idx1">Microcornea, in Ehlers-&#173;Danlos syndrome, 141</p>
			<p class="em-only_endmatter-idx1">Microcytic anemia, 132</p>
			<p class="em-only_endmatter-idx1">Microscopic polyangiitis (MPA), 172–173</p>
			<p class="em-only_endmatter-idx1">Midazolam, 290</p>
			<p class="em-only_endmatter-idx1">&#173;Middle ce&#173;re&#173;bral artery aneurysms, 122</p>
			<p class="em-only_endmatter-idx1">Mikulicz syndrome, 166</p>
			<p class="em-only_endmatter-idx1">Minimal inhibitory concentration (MIC), 271</p>
			<p class="em-only_endmatter-idx1">Minimal lethal concentration (MLC), 271</p>
			<p class="em-only_endmatter-idx1">Minocycline, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Mitotic inhibitors, 240<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Monitoring system, for clinical practice, 25–27</p>
			<p class="em-only_endmatter-idx1">Monoamine oxidase inhibitors</p>
			<p class="em-only_endmatter-idx2">Parkinson disease treated with, 205</p>
			<p class="em-only_endmatter-idx2">types of, 203<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Monobactams, 272–273</p>
			<p class="em-only_endmatter-idx1">Monoclonal antibodies (mAbs), 144, 238, 242</p>
			<p class="em-only_endmatter-idx1">Monocular nystagmus, seizures and, 208</p>
			<p class="em-only_endmatter-idx1">Mononeuritis multiplex, 171</p>
			<p class="em-only_endmatter-idx1">Mood disorders, 195–196. <span class="endmatter-idx1_italic">See also</span> Depression</p>
			<p class="em-only_endmatter-idx1">Mood stabilizers, 203–204</p>
			<p class="em-only_endmatter-idx1">Mouth-&#173;to-&#173;mouth ventilation, 298</p>
			<p class="em-only_endmatter-idx1">Moxifloxacin, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">MRI. <span class="endmatter-idx1_italic">See</span> Magnetic resonance imaging</p>
			<p class="em-only_endmatter-idx1">Mucocutaneous lymph node syndrome. <span class="endmatter-idx1_italic">See</span> Kawasaki disease</p>
			<p class="em-only_endmatter-idx1">Mucopolysaccharides, in hypothyroidism, 45</p>
			<p class="em-only_endmatter-idx1">Multidrug-&#173;resistant tuberculosis (MDRTB), 257</p>
			<p class="em-only_endmatter-idx1">Multimodal computed tomography, stroke <br />evaluations, 112</p>
			<p class="em-only_endmatter-idx1">Multiple endocrine neoplasia (MEN)</p>
			<p class="em-only_endmatter-idx2">MEN1, 49–50, 236</p>
			<p class="em-only_endmatter-idx2">MEN2, 49–50, 236</p>
			<p class="em-only_endmatter-idx2">ophthalmologic findings in, 49<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Multiple gated acquisition scans, in coronary heart disease diagnosis, 89</p>
			<p class="em-only_endmatter-idx1">Mumps, 228–229</p>
			<p class="em-only_endmatter-idx1">Munchausen syndrome. <span class="endmatter-idx1_italic">See</span> Factitious disorder</p>
			<p class="em-only_endmatter-idx1">Mycobacteria, 256–257</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Mycobacterium abscessus,</span> 256</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Mycobacterium leprae,</span> 256</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Mycobacterium lepromatosis,</span> 256</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Mycobacterium tuberculosis,</span> 222, 256–257</p>
			<p class="em-only_endmatter-idx1">Mycophenolate mofetil, 179</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Mycoplasma pneumoniae,</span> 256</p>
			<p class="em-only_endmatter-idx1">Mydriasis, seizures and, 208</p>
			<p class="em-only_endmatter-idx1">Myelodysplastic syndrome, 137</p>
			<p class="em-only_endmatter-idx1">Myeloid stem cells, 131</p>
			<p class="em-only_endmatter-idx1">Myeloproliferative disorders, 142, 148</p>
			<p class="em-only_endmatter-idx1">Myo&#173;car&#173;dial infarction (MI)</p>
			<p class="em-only_endmatter-idx2">aspirin prophylaxis in, 89</p>
			<p class="em-only_endmatter-idx2">complications of, 85</p>
			<p class="em-only_endmatter-idx2">congestive heart failure &#173;after, 85</p>
			<p class="em-only_endmatter-idx2">coronary thrombus as cause of, 83</p>
			<p class="em-only_endmatter-idx2">definition of, 83</p>
			<p class="em-only_endmatter-idx2">in diabetes mellitus, 40</p>
			<p class="em-only_endmatter-idx2">diagnosis of</p>
			<p class="em-only_endmatter-idx3">biomarkers, 86–87</p>
			<p class="em-only_endmatter-idx3">cardiac enzymes, 86</p>
			<p class="em-only_endmatter-idx3">electrocardiogram, 83–84, 85<span class="endmatter-idx3_italic">f,</span> 86</p>
			<p class="em-only_endmatter-idx3">myoglobin levels, 87</p>
			<p class="em-only_endmatter-idx3">troponin levels, 87</p>
			<p class="em-only_endmatter-idx2">mortality rate for, 85</p>
			<p class="em-only_endmatter-idx2">non–&#173;ST-&#173;segment elevation</p>
			<p class="em-only_endmatter-idx3">description of, 83</p>
			<p class="em-only_endmatter-idx3">treatment of, 93–94</p>
			<p class="em-only_endmatter-idx2">onset of, 83</p>
			<p class="em-only_endmatter-idx2">prognosis for, 84–85</p>
			<p class="em-only_endmatter-idx2">signs and symptoms of, 84</p>
			<p class="em-only_endmatter-idx2">ST-&#173;segment elevation</p>
			<p class="em-only_endmatter-idx3">description of, 83</p>
			<p class="em-only_endmatter-idx3">reperfusion therapies for, 94</p>
			<p class="em-only_endmatter-idx3">thrombolysis for, 94–95</p>
			<p class="em-only_endmatter-idx3">treatment of, 94</p>
			<p class="em-only_endmatter-idx2">treatment of</p>
			<p class="em-only_endmatter-idx3">medical therapy, 93–94</p>
			<p class="em-only_endmatter-idx3">percutaneous coronary intervention, 85, 94</p>
			<p class="em-only_endmatter-idx3">thrombolysis, 94–95</p>
			<p class="em-only_endmatter-idx1">Myo&#173;car&#173;dial ischemia, 83</p>
			<p class="em-only_endmatter-idx1">Myo&#173;car&#173;dial oxygen demand, 81</p>
			<p class="em-only_endmatter-idx1">Myoglobin, serum, 87</p>
			<p class="em-only_endmatter-idx1">Myxedema, 44</p>
			<p class="em-only_endmatter-idx1">Nadbath facial nerve block, 291</p>
			<p class="em-only_endmatter-idx1">Naproxen, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">NAION. <span class="endmatter-idx1_italic">See</span> Nonarteritic anterior ischemic optic neuropathy</p>
			<p class="em-only_endmatter-idx1">Narrow complex tachycardias, 102</p>
			<p class="em-only_endmatter-idx1">National Cholesterol Education Program (NCEP)</p>
			<p class="em-only_endmatter-idx2">Adult Treatment Panel, 71, 74</p>
			<p class="em-only_endmatter-idx2">blood cholesterol guidelines, 71</p>
			<p class="em-only_endmatter-idx1">National Elder Abuse Incidence Study, 185</p>
			<p class="em-only_endmatter-idx1">National Health and Nutrition Examination Surveys (NHANES), 52</p>
			<p class="em-only_endmatter-idx1">National Institutes of Health Stroke Scale (NIHSS), <br />111</p>
			<p class="em-only_endmatter-idx1">National Registry of Drug-&#173;Induced Ocular <br />Side Effects, 309</p>
			<p class="em-only_endmatter-idx1">Negative likelihood ratio, 19</p>
			<p class="em-only_endmatter-idx1">Negative predictive value (NPV)</p>
			<p class="em-only_endmatter-idx2">of diagnostic and screening test, 15–16</p>
			<p class="em-only_endmatter-idx2">pretest probability effects on, 20<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Neisseria</span> spp., 250–251, 276</p>
			<p class="em-only_endmatter-idx1">Neoadjuvant chemotherapy, 239</p>
			<p class="em-only_endmatter-idx1">Neonates</p>
			<p class="em-only_endmatter-idx2">chlamydial conjunctivitis in, 244</p>
			<p class="em-only_endmatter-idx2">herpes infection in, 260</p>
			<p class="em-only_endmatter-idx1">Nephropathy, diabetic, 39</p>
			<p class="em-only_endmatter-idx1">Neuroleptic malignant syndrome (NMS), 200</p>
			<p class="em-only_endmatter-idx1">Neurologic disorders</p>
			<p class="em-only_endmatter-idx2">Alzheimer disease, 209–210</p>
			<p class="em-only_endmatter-idx2">behavioral changes caused by, 194</p>
			<p class="em-only_endmatter-idx2">decision-&#173;making capacity assessments in, 211</p>
			<p class="em-only_endmatter-idx2">epilepsy. <span class="endmatter-idx2_italic">See</span> Epilepsy</p>
			<p class="em-only_endmatter-idx2">informed consent in patients with, 211–212</p>
			<p class="em-only_endmatter-idx2">Lewy body dementia, 210</p>
			<p class="em-only_endmatter-idx2">Parkinson disease, 204–205</p>
			<p class="em-only_endmatter-idx2">prion-&#173;associated, 211</p>
			<p class="em-only_endmatter-idx2">stroke. <span class="endmatter-idx2_italic">See</span> Stroke</p>
			<p class="em-only_endmatter-idx2">vascular dementia, 210</p>
			<p class="em-only_endmatter-idx1">Neuropathic pain, 40</p>
			<p class="em-only_endmatter-idx1">Neuropathy, diabetic, 39–40</p>
			<p class="em-only_endmatter-idx1">Neurosyphilis, 252–253</p>
			<p class="em-only_endmatter-idx1">Nicotinic acid, for hypercholesterolemia, 75<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Nitrates, 91</p>
			<p class="em-only_endmatter-idx1">Nitric oxide, in eosinophilic airway inflammation, 124</p>
			<p class="em-only_endmatter-idx1">Nitroglycerin, 64, 91</p>
			<p class="em-only_endmatter-idx1">Nitrosoureas, 240<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Nocturnal arterial hypotension, 66–67</p>
			<p class="em-only_endmatter-idx1">Non–&#173;ST-&#173;segment elevation myo&#173;car&#173;dial infarction (NSTEMI)</p>
			<p class="em-only_endmatter-idx2">description of, 83</p>
			<p class="em-only_endmatter-idx2">treatment of, 93–94</p>
			<p class="em-only_endmatter-idx1">Nonarteritic anterior ischemic optic neuropathy (NAION), nocturnal arterial hypotension and, 67</p>
			<p class="em-only_endmatter-idx1">Nondihydropyridine calcium channel blockers, 61</p>
			<p class="em-only_endmatter-idx1">Nonexperimental studies, 8</p>
			<p class="em-only_endmatter-idx1">Noninvasive pressure support ventilation, 126–127</p>
			<p class="em-only_endmatter-idx1">Nonketotic hyperglycemic hyperosmolar coma, 38–39</p>
			<p class="em-only_endmatter-idx1">Nonsteroidal anti-&#173;inflammatory drugs (NSAIDs)</p>
			<p class="em-only_endmatter-idx2">ankylosing spondylitis treated with, 155</p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 308<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">platelet function inhibition using, 143</p>
			<p class="em-only_endmatter-idx2">rheumatic disorders treated with, 176</p>
			<p class="em-only_endmatter-idx2">rheumatoid arthritis treated with, 153</p>
			<p class="em-only_endmatter-idx1">Normal distribution, 6</p>
			<p class="em-only_endmatter-idx1">Normocytic anemia, 132</p>
			<p class="em-only_endmatter-idx1">Null-&#173;cell adenomas, 48</p>
			<p class="em-only_endmatter-idx1">Null hypothesis</p>
			<p class="em-only_endmatter-idx2">definition of, 5</p>
			<p class="em-only_endmatter-idx2">rejection of, 5</p>
			<p class="em-only_endmatter-idx1">Number needed to treat (NNT), 22</p>
			<p class="em-only_endmatter-idx1">Nutritional deficiency, anemia caused by, 132–134</p>
			<p class="em-only_endmatter-idx1">Nystatin, 277</p>
			<p class="em-only_endmatter-idx1 ParaOverride-3">Obesity</p>
			<p class="em-only_endmatter-idx2">in &#173;children, 68</p>
			<p class="em-only_endmatter-idx2">hypertension risks associated with, 66, 68</p>
			<p class="em-only_endmatter-idx1">Observational studies, 8</p>
			<p class="em-only_endmatter-idx1">Obstructive lung diseases</p>
			<p class="em-only_endmatter-idx2">chronic obstructive pulmonary disease, 124</p>
			<p class="em-only_endmatter-idx2">description of, 123</p>
			<p class="em-only_endmatter-idx2">irreversible, 124</p>
			<p class="em-only_endmatter-idx2">reversible, 123–124</p>
			<p class="em-only_endmatter-idx1">Obstructive shock, 300</p>
			<p class="em-only_endmatter-idx1">Obstructive sleep apnea (OSA)</p>
			<p class="em-only_endmatter-idx2">characteristics of, 124–125</p>
			<p class="em-only_endmatter-idx2">continuous positive airway pressure for, 127</p>
			<p class="em-only_endmatter-idx2">ocular conditions associated with, 127</p>
			<p class="em-only_endmatter-idx1">Obstructive sleep apnea syndrome (OSAS)</p>
			<p class="em-only_endmatter-idx2">hypertension and, 66</p>
			<p class="em-only_endmatter-idx2">nonarteritic anterior ischemic optic neuropathy associated with, 67</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal findings secondary to, 67</p>
			<p class="em-only_endmatter-idx1">Ocular Hypertension Treatment Study, 22–23</p>
			<p class="em-only_endmatter-idx1">Ocular surgery. <span class="endmatter-idx1_italic">See also</span> Cataract surgery</p>
			<p class="em-only_endmatter-idx2">in ambulatory surgical center, 281</p>
			<p class="em-only_endmatter-idx2">American Society of Anesthesiologists Physical Status, 282</p>
			<p class="em-only_endmatter-idx2">fasting before, 287–288</p>
			<p class="em-only_endmatter-idx2">informed consent before, 282</p>
			<p class="em-only_endmatter-idx2">intraoperative considerations</p>
			<p class="em-only_endmatter-idx3">general anesthesia, 289–290</p>
			<p class="em-only_endmatter-idx3">local anesthesia, 290–291</p>
			<p class="em-only_endmatter-idx3">malignant hyperthermia, 291–292, 293<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx2">perioperative management in</p>
			<p class="em-only_endmatter-idx3">in adolescents, 283</p>
			<p class="em-only_endmatter-idx3">anticoagulants, 286</p>
			<p class="em-only_endmatter-idx3">antiplatelet agents, 286</p>
			<p class="em-only_endmatter-idx3">atrial fibrillation, 284</p>
			<p class="em-only_endmatter-idx3">cardiovascular disease, 283–284</p>
			<p class="em-only_endmatter-idx3">in &#173;children, 283</p>
			<p class="em-only_endmatter-idx3">complications prevention as focus of, 282</p>
			<p class="em-only_endmatter-idx3">diabetes mellitus, 284, 286–287</p>
			<p class="em-only_endmatter-idx3">fasting, 287–288</p>
			<p class="em-only_endmatter-idx3">hypertension, 284</p>
			<p class="em-only_endmatter-idx3">implantable cardioverter-&#173;defibrillator, 282</p>
			<p class="em-only_endmatter-idx3">latex allergies, 288</p>
			<p class="em-only_endmatter-idx3">medi&#173;cations, 285–287</p>
			<p class="em-only_endmatter-idx3">preoperative assessment, 281–283</p>
			<p class="em-only_endmatter-idx3">pulmonary medi&#173;cations, 287</p>
			<p class="em-only_endmatter-idx3">respiratory diseases, 284–285</p>
			<p class="em-only_endmatter-idx3">risk status assessments, 281</p>
			<p class="em-only_endmatter-idx3">Universal Protocol, 288–289</p>
			<p class="em-only_endmatter-idx1">Odds ratios, 22–23</p>
			<p class="em-only_endmatter-idx1">“Off-&#173;pump bypass surgery,” 92</p>
			<p class="em-only_endmatter-idx1">Olanzapine, 200</p>
			<p class="em-only_endmatter-idx1">Older adults</p>
			<p class="em-only_endmatter-idx2">abuse of, 185–187</p>
			<p class="em-only_endmatter-idx2">antihypertensive therapy in, 67</p>
			<p class="em-only_endmatter-idx2">cataracts in, 184</p>
			<p class="em-only_endmatter-idx2">confusion in, 187</p>
			<p class="em-only_endmatter-idx2">delirium in, 187</p>
			<p class="em-only_endmatter-idx2">depression in, 188–190, 195</p>
			<p class="em-only_endmatter-idx2">diabetic retinopathy in, 184</p>
			<p class="em-only_endmatter-idx2">falls in, 191–192</p>
			<p class="em-only_endmatter-idx2">financial abuse of, 186</p>
			<p class="em-only_endmatter-idx2">functional assessment of, 187</p>
			<p class="em-only_endmatter-idx2">glaucoma in, 184</p>
			<p class="em-only_endmatter-idx2">global statistics regarding, 183</p>
			<p class="em-only_endmatter-idx2">hip fractures in, 190</p>
			<p class="em-only_endmatter-idx2">hypertension in, 67</p>
			<p class="em-only_endmatter-idx2">informed consent in, 187</p>
			<p class="em-only_endmatter-idx2">instrumental activities of daily living assessment <br />in, 187</p>
			<p class="em-only_endmatter-idx2">losses experienced by, 188</p>
			<p class="em-only_endmatter-idx2">maltreatment of, 185</p>
			<p class="em-only_endmatter-idx2">office environment for, 184–185</p>
			<p class="em-only_endmatter-idx2">orthostatic hypotension in, 67</p>
			<p class="em-only_endmatter-idx2">osteoporosis in, 190</p>
			<p class="em-only_endmatter-idx2">perioperative considerations in, 187–188</p>
			<p class="em-only_endmatter-idx2">physical abuse of, 186</p>
			<p class="em-only_endmatter-idx2">physiologic aging in, 183–184</p>
			<p class="em-only_endmatter-idx2">population growth, 183</p>
			<p class="em-only_endmatter-idx2">preoperative discussions with, 188</p>
			<p class="em-only_endmatter-idx2">psychological abuse of, 186</p>
			<p class="em-only_endmatter-idx2">sensory systems in, 184</p>
			<p class="em-only_endmatter-idx2">suicide rates in, 188</p>
			<p class="em-only_endmatter-idx2">varicella-&#173;zoster virus in, 228</p>
			<p class="em-only_endmatter-idx2">vision loss in, 184</p>
			<p class="em-only_endmatter-idx1">Oncogenes, 235</p>
			<p class="em-only_endmatter-idx1">Opioid crisis, 306–307</p>
			<p class="em-only_endmatter-idx1">Opportunistic infections, 269</p>
			<p class="em-only_endmatter-idx1">Optic neuropathy</p>
			<p class="em-only_endmatter-idx2">amiodarone, 106</p>
			<p class="em-only_endmatter-idx2">cocaine use as cause of, 199</p>
			<p class="em-only_endmatter-idx2">radiation, 239</p>
			<p class="em-only_endmatter-idx2">toxic, 199</p>
			<p class="em-only_endmatter-idx1">Oral contraceptives</p>
			<p class="em-only_endmatter-idx2">disseminated intravascular coagulation and, <br />148</p>
			<p class="em-only_endmatter-idx2">hypertension and, 67</p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 309<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Oral glucose tolerance test (OGTT), diabetes mellitus diagnosis using, 34</p>
			<p class="em-only_endmatter-idx1">Orbit, radiation sensitivity of, 238</p>
			<p class="em-only_endmatter-idx1">Orthostatic hypotension, 67</p>
			<p class="em-only_endmatter-idx1">OSA. <span class="endmatter-idx1_italic">See</span> Obstructive sleep apnea</p>
			<p class="em-only_endmatter-idx1">Oseltamivir, 279</p>
			<p class="em-only_endmatter-idx1">Osteogenesis imperfecta, 140</p>
			<p class="em-only_endmatter-idx1">Osteoporosis</p>
			<p class="em-only_endmatter-idx2">bisphosphonates for, 190</p>
			<p class="em-only_endmatter-idx2">corticosteroids as cause of, 175</p>
			<p class="em-only_endmatter-idx2">in Cushing syndrome, 48</p>
			<p class="em-only_endmatter-idx2">definition of, 190</p>
			<p class="em-only_endmatter-idx2">fractures secondary to, 190</p>
			<p class="em-only_endmatter-idx2">incidence of, 190</p>
			<p class="em-only_endmatter-idx1">Otosclerosis, 140</p>
			<p class="em-only_endmatter-idx1">Oxcarbazepine, 207</p>
			<p class="em-only_endmatter-idx1">Oxitropium bromide, 128</p>
			<p class="em-only_endmatter-idx1">Oxytocin, 47</p>
			<p class="em-only_endmatter-idx1">p53, 242</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">P</span> value, 7</p>
			<p class="em-only_endmatter-idx1">Pain</p>
			<p class="em-only_endmatter-idx2">angina pectoris-&#173;related, 82–83</p>
			<p class="em-only_endmatter-idx2">neuropathic, 40</p>
			<p class="em-only_endmatter-idx1">“Painless” thyroiditis, 45</p>
			<p class="em-only_endmatter-idx1">Palliative chemotherapy, 239, 241</p>
			<p class="em-only_endmatter-idx1">Pallidotomy, for Parkinson disease, 205</p>
			<p class="em-only_endmatter-idx1">PAN. <span class="endmatter-idx1_italic">See</span> Polyarteritis nodosa</p>
			<p class="em-only_endmatter-idx1">Pancreas</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx1_accent">β</span> cells of, 33</p>
			<p class="em-only_endmatter-idx2">cancer of, 220</p>
			<p class="em-only_endmatter-idx2">transplantation of, 37–38</p>
			<p class="em-only_endmatter-idx1">Panic disorder, 198</p>
			<p class="em-only_endmatter-idx1">Panipenem, 273</p>
			<p class="em-only_endmatter-idx1">Panret&#173;i&#173;nal photocoagulation, for radiation <br />retinopathy, 239</p>
			<p class="em-only_endmatter-idx1">Papanicolaou test (“Pap smear”), cervical cancer screening using, 218</p>
			<p class="em-only_endmatter-idx1">Papillary cancer, 46</p>
			<p class="em-only_endmatter-idx1">Parafollicular cells, 41</p>
			<p class="em-only_endmatter-idx1">Paralysis agitans. <span class="endmatter-idx1_italic">See</span> Parkinson disease</p>
			<p class="em-only_endmatter-idx1">Parecoxib, 176</p>
			<p class="em-only_endmatter-idx1">Parenteral antihypertensives, 64</p>
			<p class="em-only_endmatter-idx1">Pareto chart, 28, 30<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Parkinson disease (PD), 204–205</p>
			<p class="em-only_endmatter-idx1">Paroxysmal nocturnal hemoglobinuria (PNH), 136, 148</p>
			<p class="em-only_endmatter-idx1">Partial seizures, 206–207</p>
			<p class="em-only_endmatter-idx1">Parvoviruses, 236</p>
			<p class="em-only_endmatter-idx1">Passive immunization, 223, 233</p>
			<p class="em-only_endmatter-idx1">Patient Health Questionnaire-2 (PHQ-2), 189–190</p>
			<p class="em-only_endmatter-idx1">Pediatric life support (PLS), 299</p>
			<p class="em-only_endmatter-idx1">Penicillin&#160;G</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Borrelia burgdorferi</span> treated with, 255</p>
			<p class="em-only_endmatter-idx2">syphilis treated with, 253</p>
			<p class="em-only_endmatter-idx1">Penicillinase-&#173;resistant penicillins, 246, 271</p>
			<p class="em-only_endmatter-idx1">Penumbra, 110</p>
			<p class="em-only_endmatter-idx1">Peramivir, 279</p>
			<p class="em-only_endmatter-idx1">&#173;Percent agreement, 25</p>
			<p class="em-only_endmatter-idx1">Percutaneous coronary intervention (PCI)</p>
			<p class="em-only_endmatter-idx2">angina pectoris treated with, 91–92</p>
			<p class="em-only_endmatter-idx2">angioplasty, 92</p>
			<p class="em-only_endmatter-idx2">coronary heart disease treated with, 100</p>
			<p class="em-only_endmatter-idx2">drug-&#173;eluting stents with, 92</p>
			<p class="em-only_endmatter-idx2">myo&#173;car&#173;dial infarction treated with, 85, 94</p>
			<p class="em-only_endmatter-idx1">Per&#173;for&#173;mance indicators, 28</p>
			<p class="em-only_endmatter-idx1">Peripheral airway disease, 124</p>
			<p class="em-only_endmatter-idx1">Peripheral arterial disease</p>
			<p class="em-only_endmatter-idx2">hyperlipidemia and, 78</p>
			<p class="em-only_endmatter-idx2">hypertension and, 66</p>
			<p class="em-only_endmatter-idx1">Pernicious anemia, 133</p>
			<p class="em-only_endmatter-idx1">Personality disorders, 198</p>
			<p class="em-only_endmatter-idx1">Pertussis vaccination, 225<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">PET. <span class="endmatter-idx1_italic">See</span> Positron emission tomography</p>
			<p class="em-only_endmatter-idx1">Petechiae, 140</p>
			<p class="em-only_endmatter-idx1">Pharyngitis, 247</p>
			<p class="em-only_endmatter-idx1">Phentolamine, 64</p>
			<p class="em-only_endmatter-idx1">Phenytoin, 207–208</p>
			<p class="em-only_endmatter-idx1">Pheochromocytoma</p>
			<p class="em-only_endmatter-idx2">hypertension caused by, 54</p>
			<p class="em-only_endmatter-idx2">in multiple endocrine neoplasia, 50</p>
			<p class="em-only_endmatter-idx1">Physical activity, coronary heart disease risk modification using, 73<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Pitavastatin, 75<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Pituitary apoplexy, 49</p>
			<p class="em-only_endmatter-idx1">Pituitary gland</p>
			<p class="em-only_endmatter-idx2">adenomas of, 47–49</p>
			<p class="em-only_endmatter-idx2">thyrotropin-&#173;releasing hormone secretion by, 42</p>
			<p class="em-only_endmatter-idx1">Plant alkaloids, 240<span class="endmatter-idx1_italic">t,</span> 241</p>
			<p class="em-only_endmatter-idx1">Plasma, 131</p>
			<p class="em-only_endmatter-idx1">Plasma exchange, for granulomatosis with polyangiitis, 172</p>
			<p class="em-only_endmatter-idx1">Plasmid re&#173;sis&#173;tance, 270–271</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Plasmodium falciparum,</span> 232</p>
			<p class="em-only_endmatter-idx1">Platelet(s)</p>
			<p class="em-only_endmatter-idx2">dysfunction of, 143–144</p>
			<p class="em-only_endmatter-idx2">function of, laboratory evaluation of, 139</p>
			<p class="em-only_endmatter-idx1">Platelet aggregation</p>
			<p class="em-only_endmatter-idx2">aspirin effects on, 143</p>
			<p class="em-only_endmatter-idx2">inhibition of, 89, 90<span class="endmatter-idx2_italic">f,</span> 143</p>
			<p class="em-only_endmatter-idx1">Platelet aggregometry, 139</p>
			<p class="em-only_endmatter-idx1">Platelet count, 139</p>
			<p class="em-only_endmatter-idx1">Platelet disorders</p>
			<p class="em-only_endmatter-idx2">essential thrombocytopenia, 142–143</p>
			<p class="em-only_endmatter-idx2">thrombocytopenia, 141–142</p>
			<p class="em-only_endmatter-idx2">thrombocytosis, 142–143</p>
			<p class="em-only_endmatter-idx1">Platelet function analyzer, 139</p>
			<p class="em-only_endmatter-idx1">Plurihormonal adenomas, 48</p>
			<p class="em-only_endmatter-idx1">Pneumococcal pneumonia, 230–231</p>
			<p class="em-only_endmatter-idx1">Pneumococcal polysaccharide vaccine 13-&#173;valent, 230</p>
			<p class="em-only_endmatter-idx1">Pneumococcal polysaccharide vaccine 23-&#173;valent, 230</p>
			<p class="em-only_endmatter-idx1">Pneumococcal vaccination, 225<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Pneumocystis jiroveci,</span> 266</p>
			<p class="em-only_endmatter-idx1">Pneumonia, pneumococcal, 230–231</p>
			<p class="em-only_endmatter-idx1">Polio vaccine, 229</p>
			<p class="em-only_endmatter-idx1">Polyarteritis nodosa (PAN), 170–171</p>
			<p class="em-only_endmatter-idx1">Polycystic kidney disease, 53</p>
			<p class="em-only_endmatter-idx1">Polymyalgia rheumatica (PMR), 168</p>
			<p class="em-only_endmatter-idx1">Polymyositis, 167–168</p>
			<p class="em-only_endmatter-idx1">Population, for clinical studies</p>
			<p class="em-only_endmatter-idx2">evaluation of, 4–5</p>
			<p class="em-only_endmatter-idx2">random assignment of, 4</p>
			<p class="em-only_endmatter-idx2">recruitment strategy for, 4–5</p>
			<p class="em-only_endmatter-idx2">vulnerable, 4</p>
			<p class="em-only_endmatter-idx1">Positive likelihood ratio, 19</p>
			<p class="em-only_endmatter-idx1">Positive predictive value (PPV)</p>
			<p class="em-only_endmatter-idx2">of diagnostic and screening test, 15–16</p>
			<p class="em-only_endmatter-idx2">pretest probability effects on, 20<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Positron emission tomography (PET)</p>
			<p class="em-only_endmatter-idx2">in coronary heart disease diagnosis, 88</p>
			<p class="em-only_endmatter-idx2">epilepsy diagnosis using, 207</p>
			<p class="em-only_endmatter-idx2">lung cancer screening uses of, 220</p>
			<p class="em-only_endmatter-idx1">Posterior pituitary gland hormones, 47</p>
			<p class="em-only_endmatter-idx1">Postexposure prophylaxis, 226, 268</p>
			<p class="em-only_endmatter-idx1">Postherpetic neuralgia, 261, 278</p>
			<p class="em-only_endmatter-idx1">Postictal paresis, 207</p>
			<p class="em-only_endmatter-idx1">Postictal period, 207</p>
			<p class="em-only_endmatter-idx1">Postoperative nausea and vomiting, 289</p>
			<p class="em-only_endmatter-idx1">Postpartum thyroiditis, 46</p>
			<p class="em-only_endmatter-idx1">Postprandial hypoglycemia, 300</p>
			<p class="em-only_endmatter-idx1">Posttest probability of disease, 19–20</p>
			<p class="em-only_endmatter-idx1">Post-&#173;traumatic stress disorder (PTSD), 198</p>
			<p class="em-only_endmatter-idx1">Potassium-&#173;sparing diuretics, 59<span class="endmatter-idx1_italic">t,</span> 60</p>
			<p class="em-only_endmatter-idx1">Power, sample size and, 5</p>
			<p class="em-only_endmatter-idx1">Power calculations, 26</p>
			<p class="em-only_endmatter-idx1">PR interval, 84<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">PR segment, 84<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Pramipexole, for Parkinson disease, 205</p>
			<p class="em-only_endmatter-idx1">Pravastatin, 75<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Prediabetes, 34–35</p>
			<p class="em-only_endmatter-idx1">Prednisolone, 175<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Prednisone</p>
			<p class="em-only_endmatter-idx2">polymyalgia rheumatica treated with, 168</p>
			<p class="em-only_endmatter-idx2">potency of, 175<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Preeclampsia, 67</p>
			<p class="em-only_endmatter-idx1">Pre-&#173;exposure prophylaxis, 268</p>
			<p class="em-only_endmatter-idx1">Preferred Practice Pattern guidelines, 26</p>
			<p class="em-only_endmatter-idx1">Pregnancy</p>
			<p class="em-only_endmatter-idx2">angiotensin-&#173;converting enzyme inhibitor contraindications in, 61</p>
			<p class="em-only_endmatter-idx2">antihypertensive therapy in, 68</p>
			<p class="em-only_endmatter-idx2">antiphospholipid syndrome in, 163</p>
			<p class="em-only_endmatter-idx2">cocaine use during, 199</p>
			<p class="em-only_endmatter-idx2">hypercoagulability associated with, 148</p>
			<p class="em-only_endmatter-idx2">hypertension in, 67–68</p>
			<p class="em-only_endmatter-idx2">immunizations in, 224</p>
			<p class="em-only_endmatter-idx2">statins contraindications in, 77</p>
			<p class="em-only_endmatter-idx2">thyrotropin-&#173;releasing hormone levels in, 42</p>
			<p class="em-only_endmatter-idx2">thyroxine levels in, 42</p>
			<p class="em-only_endmatter-idx1">Preload, 99</p>
			<p class="em-only_endmatter-idx1">Premature contractions, 101–102</p>
			<p class="em-only_endmatter-idx2">atrial, 101</p>
			<p class="em-only_endmatter-idx2">junctional, 101</p>
			<p class="em-only_endmatter-idx2">ventricular, 101</p>
			<p class="em-only_endmatter-idx1">Preoperative assessment, 281–283</p>
			<p class="em-only_endmatter-idx1">Pretest probability of disease, 18–21, 20<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Preventive medicine</p>
			<p class="em-only_endmatter-idx2">immunizations. <span class="endmatter-idx2_italic">See</span> Immunizations</p>
			<p class="em-only_endmatter-idx2">screenings. <span class="endmatter-idx2_italic">See</span> Screening</p>
			<p class="em-only_endmatter-idx1">Primary hypercoagulable states, 146–148</p>
			<p class="em-only_endmatter-idx1">Primary hypothyroidism, 45</p>
			<p class="em-only_endmatter-idx1">Prinzmetal angina, 83</p>
			<p class="em-only_endmatter-idx1">Prion-&#173;associated neurologic disorders, 211</p>
			<p class="em-only_endmatter-idx1">Procaine penicillin, for syphilis, 253</p>
			<p class="em-only_endmatter-idx1">Pro&#173;cess quality, 25</p>
			<p class="em-only_endmatter-idx1">Profilin, 167</p>
			<p class="em-only_endmatter-idx1">Prolactinomas, 47, 50</p>
			<p class="em-only_endmatter-idx1">Proliferative diabetic retinopathy, ischemic heart disease and, 105</p>
			<p class="em-only_endmatter-idx1">Propofol, 290</p>
			<p class="em-only_endmatter-idx1">Proprotein convertase subtilisin kexin 9, 77</p>
			<p class="em-only_endmatter-idx1">Propylthiouracil, for thyroid secretion suppression, <br />44</p>
			<p class="em-only_endmatter-idx1">Prostate cancer</p>
			<p class="em-only_endmatter-idx2">digital rectal examination for, 221</p>
			<p class="em-only_endmatter-idx2">screening for, 216<span class="endmatter-idx2_italic">t,</span> 221</p>
			<p class="em-only_endmatter-idx1">Prostate-&#173;specific antigen (PSA), 221</p>
			<p class="em-only_endmatter-idx1">Protein&#160;C</p>
			<p class="em-only_endmatter-idx2">deficiency of, 147</p>
			<p class="em-only_endmatter-idx2">description of, 139</p>
			<p class="em-only_endmatter-idx1">Protein&#160;S</p>
			<p class="em-only_endmatter-idx2">deficiency of, 147</p>
			<p class="em-only_endmatter-idx2">description of, 139</p>
			<p class="em-only_endmatter-idx1">Proteinuria, 56</p>
			<p class="em-only_endmatter-idx1">Prothrombin G20210A gene mutation, 147</p>
			<p class="em-only_endmatter-idx1">Prothrombin time (PT), 139</p>
			<p class="em-only_endmatter-idx1">Pseudomembranous colitis, 273</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Pseudomonas aeruginosa,</span> 251–252</p>
			<p class="em-only_endmatter-idx1">Pseudoxanthoma elasticum, 140</p>
			<p class="em-only_endmatter-idx1">Psoriatic arthritis, 156–157</p>
			<p class="em-only_endmatter-idx1">Psychiatric disorders. <span class="endmatter-idx1_italic">See</span> Behavioral disorders</p>
			<p class="em-only_endmatter-idx1">Psychotherapy, 198</p>
			<p class="em-only_endmatter-idx1">PubMed, 3–4</p>
			<p class="em-only_endmatter-idx1">Pulmonary diseases</p>
			<p class="em-only_endmatter-idx2">asthma, 123–124, 128–130, 129<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">evaluation of, 125–126</p>
			<p class="em-only_endmatter-idx2">obstructive, 123–125</p>
			<p class="em-only_endmatter-idx3">chronic obstructive pulmonary disease, 124</p>
			<p class="em-only_endmatter-idx3">description of, 123</p>
			<p class="em-only_endmatter-idx3">irreversible, 124</p>
			<p class="em-only_endmatter-idx3">reversible, 123–124</p>
			<p class="em-only_endmatter-idx2">perioperative management for ocular surgery in patients with, 284</p>
			<p class="em-only_endmatter-idx2">restrictive, 125</p>
			<p class="em-only_endmatter-idx2">symptoms of, 124</p>
			<p class="em-only_endmatter-idx2">treatment of</p>
			<p class="em-only_endmatter-idx3">algorithm for, 129<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">anticholinergics, 128</p>
			<p class="em-only_endmatter-idx3"><span class="endmatter-idx1_accent">β</span><span class="subscript _idGenCharOverride-1">2</span>-&#173;adrenergic agonists, 128</p>
			<p class="em-only_endmatter-idx3">bronchodilators, 128</p>
			<p class="em-only_endmatter-idx3">corticosteroids, 128</p>
			<p class="em-only_endmatter-idx3">inflammation inhibitors, 128</p>
			<p class="em-only_endmatter-idx3">leukotriene inhibitors, 128</p>
			<p class="em-only_endmatter-idx3">noninvasive pressure support ventilation, 126–127</p>
			<p class="em-only_endmatter-idx3">nonpharmacologic, 126–127</p>
			<p class="em-only_endmatter-idx3">pharmacologic, 127–130</p>
			<p class="em-only_endmatter-idx1">Pulmonary embolism, in activated protein C <br />re&#173;sis&#173;tance, 147</p>
			<p class="em-only_endmatter-idx1">Pulmonary function tests, 126</p>
			<p class="em-only_endmatter-idx1">Pulmonary hypertension</p>
			<p class="em-only_endmatter-idx2">oxygen supplementation in, 126</p>
			<p class="em-only_endmatter-idx2">sildenafil for, 130</p>
			<p class="em-only_endmatter-idx2">in systemic sclerosis, 165</p>
			<p class="em-only_endmatter-idx2">treatment of, 165</p>
			<p class="em-only_endmatter-idx1">Pupils</p>
			<p class="em-only_endmatter-idx2">age-&#173;related changes in, 183</p>
			<p class="em-only_endmatter-idx2">substance abuse effects on, 199</p>
			<p class="em-only_endmatter-idx1">Purified protein derivative (PPD) tuberculin skin test, 256–257</p>
			<p class="em-only_endmatter-idx1">Purpura, 140</p>
			<p class="em-only_endmatter-idx1">Pyruvate kinase deficiency, 136</p>
			<p class="em-only_endmatter-idx1">Q waves, 84</p>
			<p class="em-only_endmatter-idx1">QRS complex, 84<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">QT interval</p>
			<p class="em-only_endmatter-idx2">illustration of, 84<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">prolongation of, in myo&#173;car&#173;dial infarction, 86</p>
			<p class="em-only_endmatter-idx1">Quality indicators, 24</p>
			<p class="em-only_endmatter-idx1">Quetiapine, 200</p>
			<p class="em-only_endmatter-idx1">RA. <span class="endmatter-idx1_italic">See</span> Rheumatoid arthritis</p>
			<p class="em-only_endmatter-idx1">Rabies vaccination, 232</p>
			<p class="em-only_endmatter-idx1">Radiation exposure, cancer caused by, 236</p>
			<p class="em-only_endmatter-idx1">Radiation therapy</p>
			<p class="em-only_endmatter-idx2">brachytherapy, 237–238</p>
			<p class="em-only_endmatter-idx2">cancer treated with, 237–239</p>
			<p class="em-only_endmatter-idx2">cataracts caused by, 239</p>
			<p class="em-only_endmatter-idx2">external beam, 237–238</p>
			<p class="em-only_endmatter-idx2">monoclonal antibody use in, 238</p>
			<p class="em-only_endmatter-idx2">ocular effects of, 238, 238<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">optic neuropathy caused by, 239</p>
			<p class="em-only_endmatter-idx2">retinopathy caused by, 239</p>
			<p class="em-only_endmatter-idx1">Radioactive iodine uptake testing, for Graves disease, 42</p>
			<p class="em-only_endmatter-idx1">Radiofrequency ablation, catheter-&#173;based, 64–65</p>
			<p class="em-only_endmatter-idx1">Radionuclide scintigraphy and scans</p>
			<p class="em-only_endmatter-idx2">in coronary heart disease diagnosis, 88</p>
			<p class="em-only_endmatter-idx2">technetium-99m, 88</p>
			<p class="em-only_endmatter-idx2">thallium-201, 88</p>
			<p class="em-only_endmatter-idx1">Random assignment, 4</p>
			<p class="em-only_endmatter-idx1">Randomized controlled &#173;trials</p>
			<p class="em-only_endmatter-idx2">features of, 14</p>
			<p class="em-only_endmatter-idx2">schematic diagram of, 13<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ranitidine, 288</p>
			<p class="em-only_endmatter-idx1">Rapid plasma reagin (RPR) test, 252</p>
			<p class="em-only_endmatter-idx1">Rasagiline, 205</p>
			<p class="em-only_endmatter-idx1">Raynaud phenomenon</p>
			<p class="em-only_endmatter-idx2">in systemic lupus erythematosus, 159, 159<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in systemic sclerosis, 165–166</p>
			<p class="em-only_endmatter-idx2">treatment of, 166</p>
			<p class="em-only_endmatter-idx1">Reactive arthritis</p>
			<p class="em-only_endmatter-idx2">conjunctivitis in, 157</p>
			<p class="em-only_endmatter-idx2">description of, 155–156<span class="endmatter-idx2_italic">f,</span> 157</p>
			<p class="em-only_endmatter-idx2">iridocyclitis associated with, 157</p>
			<p class="em-only_endmatter-idx1">Reactive thrombocytosis, 142</p>
			<p class="em-only_endmatter-idx1">Rebound hypertension, 69</p>
			<p class="em-only_endmatter-idx1">Recall bias, 11</p>
			<p class="em-only_endmatter-idx1">Receiver operating characteristic (ROC) curves, 16–18, 18<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Recombinant tissue plasminogen activator (rtPA), 113</p>
			<p class="em-only_endmatter-idx1">Rec&#173;ord review, 25–26</p>
			<p class="em-only_endmatter-idx1">Red blood cells (RBCs)</p>
			<p class="em-only_endmatter-idx2">anemia caused by destruction of, 136–137</p>
			<p class="em-only_endmatter-idx2">life span of, 131, 136</p>
			<p class="em-only_endmatter-idx2">precursors of, 131</p>
			<p class="em-only_endmatter-idx1">Red blood cell (RBC) indexes, 132</p>
			<p class="em-only_endmatter-idx1">Red cell distribution width (RDW), 132</p>
			<p class="em-only_endmatter-idx1">Regional enteritis. <span class="endmatter-idx1_italic">See</span> Crohn disease</p>
			<p class="em-only_endmatter-idx1">Regression analy&#173;sis, 12</p>
			<p class="em-only_endmatter-idx1">Reiter syndrome, 155</p>
			<p class="em-only_endmatter-idx1">Relapsing polychondritis, 168–169</p>
			<p class="em-only_endmatter-idx1">Relative risk, 22–23, 214</p>
			<p class="em-only_endmatter-idx1">Reliability, 24</p>
			<p class="em-only_endmatter-idx1">Renal artery stenosis, angiotensin-&#173;converting enzyme inhibitor contraindications in, 61</p>
			<p class="em-only_endmatter-idx1">Renal disease, chronic, 65</p>
			<p class="em-only_endmatter-idx1">Renal sympathetic nerves, catheter-&#173;based radiofrequency ablation of, 64–65</p>
			<p class="em-only_endmatter-idx1">Rendu-&#173;Osler-&#173;Weber disease, 140</p>
			<p class="em-only_endmatter-idx1">Renin-&#173;angiotensin-&#173;aldosterone system</p>
			<p class="em-only_endmatter-idx2">angiotensin II, 61</p>
			<p class="em-only_endmatter-idx2">in hypertension, 53, 54<span class="endmatter-idx2_italic">f,</span> 69</p>
			<p class="em-only_endmatter-idx2">in ocular tissues, 69</p>
			<p class="em-only_endmatter-idx2">schematic diagram of, 54<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Renovascular disease, hypertension caused by, 53</p>
			<p class="em-only_endmatter-idx1">Rescue breathing, 297</p>
			<p class="em-only_endmatter-idx1">Resistant hypertension, 54, 55<span class="endmatter-idx1_italic">t,</span> 64</p>
			<p class="em-only_endmatter-idx1">Respiratory obstruction, 301</p>
			<p class="em-only_endmatter-idx1">Restrictive lung diseases, 125</p>
			<p class="em-only_endmatter-idx1">Reticulocyte count, 132</p>
			<p class="em-only_endmatter-idx1">Ret&#173;ina, hypertension-&#173;related complications of, 69–70, 70<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal arteriovenous anastomoses, in Takayasu arteritis, 170</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal vasculitis, 9</p>
			<p class="em-only_endmatter-idx1">Retinitis, cytomegalovirus, 262, 279</p>
			<p class="em-only_endmatter-idx1">Retinopathy</p>
			<p class="em-only_endmatter-idx2">diabetic</p>
			<p class="em-only_endmatter-idx3">ischemic heart disease and, 105</p>
			<p class="em-only_endmatter-idx3">in older adults, 184</p>
			<p class="em-only_endmatter-idx3">prevalence of, 184</p>
			<p class="em-only_endmatter-idx3">progression of, 36, 40</p>
			<p class="em-only_endmatter-idx3">studies of, 78</p>
			<p class="em-only_endmatter-idx2">hypertensive, 69, 70<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">radiation, 239</p>
			<p class="em-only_endmatter-idx1">Retinovascular occlusion, intravenous drug use as cause of, 199</p>
			<p class="em-only_endmatter-idx1">Retroviruses, 236, 266</p>
			<p class="em-only_endmatter-idx1">Revascularization, for angina pectoris, 91–92</p>
			<p class="em-only_endmatter-idx1">Reversible obstructive lung diseases, 123–124</p>
			<p class="em-only_endmatter-idx1">Rheumatic disorders</p>
			<p class="em-only_endmatter-idx2">ankylosing spondylitis, 154–155</p>
			<p class="em-only_endmatter-idx2">antiphospholipid syndrome, 148–149, 163–164</p>
			<p class="em-only_endmatter-idx2">dermatomyositis, 167<span class="endmatter-idx2_italic">f,</span> 167–168</p>
			<p class="em-only_endmatter-idx2">description of, 151</p>
			<p class="em-only_endmatter-idx2">enteropathic arthritis, 156</p>
			<p class="em-only_endmatter-idx2">juvenile idiopathic arthritis, 157–158, 158<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">ocular involvement in, 151</p>
			<p class="em-only_endmatter-idx2">polymyalgia rheumatica, 168</p>
			<p class="em-only_endmatter-idx2">polymyositis, 167–168</p>
			<p class="em-only_endmatter-idx2">psoriatic arthritis, 156–157</p>
			<p class="em-only_endmatter-idx2">reactive arthritis, 155–156<span class="endmatter-idx2_italic">f,</span> 157</p>
			<p class="em-only_endmatter-idx2">relapsing polychondritis, 168–169</p>
			<p class="em-only_endmatter-idx2">rheumatoid arthritis. <span class="endmatter-idx2_italic">See</span> Rheumatoid arthritis</p>
			<p class="em-only_endmatter-idx2">sarcoidosis, 162–163</p>
			<p class="em-only_endmatter-idx2">Sj<span class="endmatter-idx2_accent">ö</span>gren syndrome, 161, 166–167</p>
			<p class="em-only_endmatter-idx2">spondyloarthritis. <span class="endmatter-idx2_italic">See</span> Spondyloarthritis</p>
			<p class="em-only_endmatter-idx2">systemic lupus erythematosus. <span class="endmatter-idx2_italic">See</span> Systemic lupus erythematosus</p>
			<p class="em-only_endmatter-idx2">systemic sclerosis, 164–166, 165<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">treatment of</p>
			<p class="em-only_endmatter-idx3">corticosteroids, 174–176, 175<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">disease-&#173;modifying antirheumatic drugs. <span class="endmatter-idx3_italic">See</span> Disease-&#173;modifying antirheumatic drugs</p>
			<p class="em-only_endmatter-idx3">nonsteroidal anti-&#173;inflammatory drugs, 176</p>
			<p class="em-only_endmatter-idx2">vasculitis. <span class="endmatter-idx2_italic">See</span> Vasculitis/vasculitides</p>
			<p class="em-only_endmatter-idx1">Rheumatoid arthritis (RA)</p>
			<p class="em-only_endmatter-idx2">extra-&#173;articular manifestations of, 152–153</p>
			<p class="em-only_endmatter-idx2">hand deformities associated with, 152, 152<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">laboratory testing for, 153</p>
			<p class="em-only_endmatter-idx2">ocular manifestations of, 153</p>
			<p class="em-only_endmatter-idx2">prevalence of, 152</p>
			<p class="em-only_endmatter-idx2">treatment of, 153–154</p>
			<p class="em-only_endmatter-idx1">Rheumatoid &#173;factor (RF), 153</p>
			<p class="em-only_endmatter-idx1">Rifampin, 276</p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 308<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">tuberculosis treated with, 257</p>
			<p class="em-only_endmatter-idx1">Rilonacept, 180</p>
			<p class="em-only_endmatter-idx1">Rimantadine, 279</p>
			<p class="em-only_endmatter-idx1">“Ring sideroblast,” 137</p>
			<p class="em-only_endmatter-idx1">Risk</p>
			<p class="em-only_endmatter-idx2">absolute reduction of, 22</p>
			<p class="em-only_endmatter-idx2">definition of, 22</p>
			<p class="em-only_endmatter-idx2">relative, 22–23, 214</p>
			<p class="em-only_endmatter-idx1">Risk calculators, 23</p>
			<p class="em-only_endmatter-idx1">Risk difference, 22</p>
			<p class="em-only_endmatter-idx1">Risk &#173;factors, disease and, 13</p>
			<p class="em-only_endmatter-idx1">Risk reduction</p>
			<p class="em-only_endmatter-idx2">absolute, 22</p>
			<p class="em-only_endmatter-idx2">in diabetes mellitus, 35–36</p>
			<p class="em-only_endmatter-idx1">Ritipenem, 273</p>
			<p class="em-only_endmatter-idx1">Rituximab, 141, 180, 242</p>
			<p class="em-only_endmatter-idx1">Rivaroxaban, 149</p>
			<p class="em-only_endmatter-idx1">RNA viruses, 236, 237<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Rofecoxib, 176</p>
			<p class="em-only_endmatter-idx1">Ropinirole, 205</p>
			<p class="em-only_endmatter-idx1">Rosuvastatin, 75<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Rotavirus, 230</p>
			<p class="em-only_endmatter-idx1">Rotigotine, 205</p>
			<p class="em-only_endmatter-idx1">Run charts, 28, 30<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1 ParaOverride-3">Saccadic latency, 210</p>
			<p class="em-only_endmatter-idx1">Saccular aneurysms, subarachnoid hemorrhage caused by, 121</p>
			<p class="em-only_endmatter-idx1">Safinamide, 205</p>
			<p class="em-only_endmatter-idx1">SAH. <span class="endmatter-idx1_italic">See</span> Subarachnoid hemorrhage</p>
			<p class="em-only_endmatter-idx1">Salivary gland biopsy, for Sj<span class="endmatter-idx1_accent">ö</span>gren syndrome, 166</p>
			<p class="em-only_endmatter-idx1">Salmeterol, 128</p>
			<p class="em-only_endmatter-idx1">Sample size</p>
			<p class="em-only_endmatter-idx2">evaluation of, 5</p>
			<p class="em-only_endmatter-idx2">power and, 5</p>
			<p class="em-only_endmatter-idx2">power calculations to determine, 26</p>
			<p class="em-only_endmatter-idx1">Sarcoidosis, 162–163</p>
			<p class="em-only_endmatter-idx1">Scatter diagrams, 28, 29<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Schizoaffective disorder, 195</p>
			<p class="em-only_endmatter-idx1">Schizo&#173;phre&#173;nia</p>
			<p class="em-only_endmatter-idx2">antipsychotic drugs for, 200</p>
			<p class="em-only_endmatter-idx2">description of, 194–195</p>
			<p class="em-only_endmatter-idx1">Schizophreniform disorder, 195</p>
			<p class="em-only_endmatter-idx1">Scleritis, bisphosphonates and, 190</p>
			<p class="em-only_endmatter-idx1">Scleroderma. <span class="endmatter-idx1_italic">See</span> Systemic sclerosis</p>
			<p class="em-only_endmatter-idx1">Screening</p>
			<p class="em-only_endmatter-idx2">for atherosclerosis, 215</p>
			<p class="em-only_endmatter-idx2">for bladder cancer, 221</p>
			<p class="em-only_endmatter-idx2">for breast cancer, 215–217, 216<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">for cancer, 215–221</p>
			<p class="em-only_endmatter-idx2">for cervical cancer, 216<span class="endmatter-idx2_italic">t,</span> 217–218</p>
			<p class="em-only_endmatter-idx2">for colorectal cancer, 216<span class="endmatter-idx2_italic">t,</span> 218–219</p>
			<p class="em-only_endmatter-idx2">for coronary heart disease, 215</p>
			<p class="em-only_endmatter-idx2">costs of, 214</p>
			<p class="em-only_endmatter-idx2">for depression, 189</p>
			<p class="em-only_endmatter-idx2">for endometrial cancer, 216<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">for gastric cancer, 219</p>
			<p class="em-only_endmatter-idx2">for gastrointestinal cancer, 219–220</p>
			<p class="em-only_endmatter-idx2">for glaucoma, 184</p>
			<p class="em-only_endmatter-idx2">for hypertension, 214</p>
			<p class="em-only_endmatter-idx2">for infectious diseases, 222–223</p>
			<p class="em-only_endmatter-idx2">for lung cancer, 216<span class="endmatter-idx2_italic">t,</span> 220</p>
			<p class="em-only_endmatter-idx2">for melanoma, 220–221</p>
			<p class="em-only_endmatter-idx2">nonresearch uses of, 213</p>
			<p class="em-only_endmatter-idx2">for pancreatic cancer, 220</p>
			<p class="em-only_endmatter-idx2">for prostate cancer, 216<span class="endmatter-idx2_italic">t,</span> 221</p>
			<p class="em-only_endmatter-idx2">relative risk of, 213</p>
			<p class="em-only_endmatter-idx2">sensitivity of, 15–16, 17<span class="endmatter-idx2_italic">f,</span> 214</p>
			<p class="em-only_endmatter-idx2">specificity of, 15–16, 17<span class="endmatter-idx2_italic">f,</span> 213</p>
			<p class="em-only_endmatter-idx2">for syphilis, 222–223</p>
			<p class="em-only_endmatter-idx2">for tuberculosis, 222</p>
			<p class="em-only_endmatter-idx2">for urologic cancer, 221</p>
			<p class="em-only_endmatter-idx1">Scurvy, 140</p>
			<p class="em-only_endmatter-idx1">Secondary hypercoagulable states, 146, 148</p>
			<p class="em-only_endmatter-idx1">Secondary hypertension</p>
			<p class="em-only_endmatter-idx2">&#173;causes of, 53–54, 55<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in &#173;children, 68</p>
			<p class="em-only_endmatter-idx2">laboratory tests for, 55</p>
			<p class="em-only_endmatter-idx1">Secondary hypothyroidism, 45</p>
			<p class="em-only_endmatter-idx1">Second-&#173;generation antipsychotics, 199, 200<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Secukinumab, 180</p>
			<p class="em-only_endmatter-idx1">Seizures</p>
			<p class="em-only_endmatter-idx2">&#173;causes of, 303</p>
			<p class="em-only_endmatter-idx2">definition of, 303</p>
			<p class="em-only_endmatter-idx2">epileptic, 206–209</p>
			<p class="em-only_endmatter-idx2">local anesthetic agent as cause of, 291</p>
			<p class="em-only_endmatter-idx2">tonic-&#173;clonic, 306</p>
			<p class="em-only_endmatter-idx1">Se&#173;lection bias, 4, 11</p>
			<p class="em-only_endmatter-idx1">Selective COX-2 inhibitors, 176</p>
			<p class="em-only_endmatter-idx1">Selective serotonin reuptake inhibitors (SSRIs), 202, 203<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Selegiline, 205</p>
			<p class="em-only_endmatter-idx1">Sensitivity, of diagnostic and screening test, 15–16, 17<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Septic shock, 301</p>
			<p class="em-only_endmatter-idx1">Serotonin modulators, 203<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Serotonin-&#173;norepinephrine reuptake inhibitors, 203<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Serratia marcescens,</span> 251</p>
			<p class="em-only_endmatter-idx1">Serum, 131</p>
			<p class="em-only_endmatter-idx1">Shaken baby syndrome, 299</p>
			<p class="em-only_endmatter-idx1">Shiga toxin-&#173;producing <span class="endmatter-idx1_italic">Escherichia coli,</span> 142</p>
			<p class="em-only_endmatter-idx1">Shingrix, 227</p>
			<p class="em-only_endmatter-idx1">Shock</p>
			<p class="em-only_endmatter-idx2">assessment of, 300</p>
			<p class="em-only_endmatter-idx2">classification of, 300–301</p>
			<p class="em-only_endmatter-idx2">definition of, 300</p>
			<p class="em-only_endmatter-idx2">respiratory gas exchange failure in, 301</p>
			<p class="em-only_endmatter-idx2">treatment of, 300–301</p>
			<p class="em-only_endmatter-idx1">Sickle cell anemia/sickle cell disease (SCD), 135–136</p>
			<p class="em-only_endmatter-idx1">Sideroblastic anemia, 137</p>
			<p class="em-only_endmatter-idx1">Sigmoidoscopy, flexible, 218–219</p>
			<p class="em-only_endmatter-idx1">Sildenafil</p>
			<p class="em-only_endmatter-idx2">adverse ocular effects caused by, 130, 307, 309<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">pulmonary hypertension treated with, 130</p>
			<p class="em-only_endmatter-idx1">&#173;Simple partial seizures, 206–207</p>
			<p class="em-only_endmatter-idx1">Simvastatin, 75<span class="endmatter-idx1_italic">t,</span> 77</p>
			<p class="em-only_endmatter-idx1">Single-&#173;photon emission computed tomography (SPECT)</p>
			<p class="em-only_endmatter-idx2">in coronary heart disease diagnosis, 88</p>
			<p class="em-only_endmatter-idx2">epilepsy diagnosis using, 207</p>
			<p class="em-only_endmatter-idx1">Sinoatrial (SA) node, in cardiac rhythm, 101</p>
			<p class="em-only_endmatter-idx1">Sj<span class="endmatter-idx1_accent">ö</span>gren syndrome, 161, 166–167</p>
			<p class="em-only_endmatter-idx1">Skin</p>
			<p class="em-only_endmatter-idx2">cancer of, 220–221. <span class="endmatter-idx2_italic">See also</span> Melanoma</p>
			<p class="em-only_endmatter-idx2">systemic sclerosis manifestations of, 164–165, 165<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">SLE. <span class="endmatter-idx1_italic">See</span> Systemic lupus erythematosus</p>
			<p class="em-only_endmatter-idx1">Sleep, 53, 66–67</p>
			<p class="em-only_endmatter-idx1">Sleep apnea. <span class="endmatter-idx1_italic">See</span> Obstructive sleep apnea</p>
			<p class="em-only_endmatter-idx1">Small-&#173;vessel vasculitis, 169<span class="endmatter-idx1_italic">t,</span> 171–173</p>
			<p class="em-only_endmatter-idx1">Smoking</p>
			<p class="em-only_endmatter-idx2">cessation of</p>
			<p class="em-only_endmatter-idx3">for chronic obstructive pulmonary disease, 126</p>
			<p class="em-only_endmatter-idx3">for lung cancer prevention, 220</p>
			<p class="em-only_endmatter-idx2">as coronary heart disease risk &#173;factor, 73<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">lung cancer risks, 220</p>
			<p class="em-only_endmatter-idx2">pancreatic cancer risks, 220</p>
			<p class="em-only_endmatter-idx1">Sodium nitroprusside, 64</p>
			<p class="em-only_endmatter-idx1">Sodium restriction</p>
			<p class="em-only_endmatter-idx2">congestive heart failure managed with, 100</p>
			<p class="em-only_endmatter-idx2">hypertension managed with, 58<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Soluble guanylate cyclase activators, 64</p>
			<p class="em-only_endmatter-idx1">Somatic symptom and related disorders, 196–197</p>
			<p class="em-only_endmatter-idx1">Somatization, 196</p>
			<p class="em-only_endmatter-idx1">Somatoform disorders, 196–197</p>
			<p class="em-only_endmatter-idx1">Somatotroph adenomas, 47–48</p>
			<p class="em-only_endmatter-idx1">Specificity, of diagnostic and screening test, 15–16, 17<span class="endmatter-idx1_italic">f,</span> 214</p>
			<p class="em-only_endmatter-idx1">Splenectomy, 134, 141</p>
			<p class="em-only_endmatter-idx1">Splenic sequestration, 142</p>
			<p class="em-only_endmatter-idx1">Spondyloarthritis</p>
			<p class="em-only_endmatter-idx2">ankylosing spondylitis, 154–155</p>
			<p class="em-only_endmatter-idx2">definition of, 154</p>
			<p class="em-only_endmatter-idx2">enteropathic arthritis, 156</p>
			<p class="em-only_endmatter-idx2">inflammatory bowel disease and, 156</p>
			<p class="em-only_endmatter-idx2">reactive arthritis, 155–156<span class="endmatter-idx2_italic">f,</span> 157</p>
			<p class="em-only_endmatter-idx2">uveitis and, 157</p>
			<p class="em-only_endmatter-idx1">ST segment, 84<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">ST-&#173;segment elevation, 84–85<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">ST-&#173;segment elevation myo&#173;car&#173;dial infarction (STEMI)</p>
			<p class="em-only_endmatter-idx2">description of, 83</p>
			<p class="em-only_endmatter-idx2">reperfusion therapies for, 94</p>
			<p class="em-only_endmatter-idx2">thrombolysis for, 94–95</p>
			<p class="em-only_endmatter-idx2">treatment of, 94</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Staphylococcus</span> spp.</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">S aureus</span></p>
			<p class="em-only_endmatter-idx3">description of, 246</p>
			<p class="em-only_endmatter-idx3">methicillin-&#173;resistant, 246</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">S epidermidis,</span> 246–247</p>
			<p class="em-only_endmatter-idx1">Statins</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 77</p>
			<p class="em-only_endmatter-idx2">age-&#173;related macular degeneration and, 78–79</p>
			<p class="em-only_endmatter-idx2">angina pectoris treated with, 91</p>
			<p class="em-only_endmatter-idx2">cataracts and, 79</p>
			<p class="em-only_endmatter-idx2">dosing of, 75<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">hypercholesterolemia treated with, 75<span class="endmatter-idx2_italic">t,</span> 76–77</p>
			<p class="em-only_endmatter-idx2">ischemic stroke prevention using, 115</p>
			<p class="em-only_endmatter-idx2">stroke prevention using, 115</p>
			<p class="em-only_endmatter-idx1">Statistical tests</p>
			<p class="em-only_endmatter-idx2">clinical significance of, 7</p>
			<p class="em-only_endmatter-idx2">flow chart of, 7</p>
			<p class="em-only_endmatter-idx1">Status epilepticus, 303–304</p>
			<p class="em-only_endmatter-idx1">Stents, percutaneous coronary intervention with, 92</p>
			<p class="em-only_endmatter-idx1">Stereotactic radiosurgery, for arteriovenous malformations, 122</p>
			<p class="em-only_endmatter-idx1">Steroids. <span class="endmatter-idx1_italic">See</span> Corticosteroids</p>
			<p class="em-only_endmatter-idx1">Stevens-&#173;Johnson syndrome, 208</p>
			<p class="em-only_endmatter-idx1">Strawberry tongue, 171</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Streptococcus</span> spp.</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">S pneumoniae,</span> 247–248</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">S pyogenes,</span> 247</p>
			<p class="em-only_endmatter-idx1">Stress echocardiography, 87</p>
			<p class="em-only_endmatter-idx1">Stroke</p>
			<p class="em-only_endmatter-idx2">aspirin prophylaxis for, 89</p>
			<p class="em-only_endmatter-idx2">cardioembolic, 111</p>
			<p class="em-only_endmatter-idx2">carotid duplex ultrasonography for, 113</p>
			<p class="em-only_endmatter-idx2">ce&#173;re&#173;bral arteriography for, 113</p>
			<p class="em-only_endmatter-idx2">completed, 110</p>
			<p class="em-only_endmatter-idx2">computed tomography of, 112</p>
			<p class="em-only_endmatter-idx2">cryptogenic, 119</p>
			<p class="em-only_endmatter-idx2">deaths caused by, 109–110</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 111–112</p>
			<p class="em-only_endmatter-idx2">echocardiography evaluations, 112</p>
			<p class="em-only_endmatter-idx2">helical computed tomography angiography of, 113</p>
			<p class="em-only_endmatter-idx2">hypertension and, 66, 115</p>
			<p class="em-only_endmatter-idx2">imaging studies for, 112–113</p>
			<p class="em-only_endmatter-idx2">incidence of, 109</p>
			<p class="em-only_endmatter-idx2">ischemic. <span class="endmatter-idx2_italic">See also</span> Ce&#173;re&#173;bral ischemia</p>
			<p class="em-only_endmatter-idx3">blood pressure control for prevention of, 115</p>
			<p class="em-only_endmatter-idx3">cardioaortic &#173;causes of, 118–119</p>
			<p class="em-only_endmatter-idx3">carotid duplex ultrasonography for, 113</p>
			<p class="em-only_endmatter-idx3">carotid occlusive disease as cause of, 115–119</p>
			<p class="em-only_endmatter-idx3">&#173;causes of, 111</p>
			<p class="em-only_endmatter-idx3">ce&#173;re&#173;bral arteriography for, 113</p>
			<p class="em-only_endmatter-idx3">clinical manifestations of, 110–111</p>
			<p class="em-only_endmatter-idx3">diagnosis of, 111–112</p>
			<p class="em-only_endmatter-idx3">helical computed tomography angiography for, 113</p>
			<p class="em-only_endmatter-idx3">imaging studies for, 112–113</p>
			<p class="em-only_endmatter-idx3">magnetic resonance angiography evaluations, 112–113</p>
			<p class="em-only_endmatter-idx3">magnetic resonance imaging evaluations, 112–113</p>
			<p class="em-only_endmatter-idx3">management of, 111–112</p>
			<p class="em-only_endmatter-idx3">mechanical thrombectomy for, 113–114</p>
			<p class="em-only_endmatter-idx3">multimodal computed tomography for, 112</p>
			<p class="em-only_endmatter-idx3">nonarteriosclerotic &#173;causes of, 111</p>
			<p class="em-only_endmatter-idx3">penumbra, 110</p>
			<p class="em-only_endmatter-idx3">prevention of, 114–115</p>
			<p class="em-only_endmatter-idx3">recombinant tissue plasminogen activator for, 113</p>
			<p class="em-only_endmatter-idx3">reperfusion techniques, 114</p>
			<p class="em-only_endmatter-idx3">risk &#173;factors for, 111</p>
			<p class="em-only_endmatter-idx3">statins for prevention of, 115</p>
			<p class="em-only_endmatter-idx3">thrombolytic agents, 113</p>
			<p class="em-only_endmatter-idx3">transcranial Doppler ultrasonography for, 113</p>
			<p class="em-only_endmatter-idx3">treatment of, 113–114</p>
			<p class="em-only_endmatter-idx2">magnetic resonance angiography of, 112–113</p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 112–113</p>
			<p class="em-only_endmatter-idx2">management of, 111–112</p>
			<p class="em-only_endmatter-idx2">mortality rates for, 109–110</p>
			<p class="em-only_endmatter-idx2">nonarteriosclerotic &#173;causes of, 111</p>
			<p class="em-only_endmatter-idx2">prevention of, antithrombotic therapy, 114–115</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 111</p>
			<p class="em-only_endmatter-idx2">secondary, 114–115</p>
			<p class="em-only_endmatter-idx2">severity of, 111</p>
			<p class="em-only_endmatter-idx2">transcranial Doppler ultrasonography for, 113</p>
			<p class="em-only_endmatter-idx1">Subacute bacterial endocarditis, 248<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Subacute granulomatous thyroiditis, 45</p>
			<p class="em-only_endmatter-idx1">Subarachnoid hemorrhage (SAH), 121</p>
			<p class="em-only_endmatter-idx1">Subclinical depression, 189</p>
			<p class="em-only_endmatter-idx1">Subclinical hypothyroidism, 45</p>
			<p class="em-only_endmatter-idx1">Substance abuse disorders, 198–199</p>
			<p class="em-only_endmatter-idx1">Sudden cardiac death (SCD)</p>
			<p class="em-only_endmatter-idx2">definition of, 85</p>
			<p class="em-only_endmatter-idx2">implantable cardioverter-&#173;defibrillator for prevention of, 86, 105</p>
			<p class="em-only_endmatter-idx2">timing of, 85–86</p>
			<p class="em-only_endmatter-idx1">Sufentanil, 289</p>
			<p class="em-only_endmatter-idx1">Suicide</p>
			<p class="em-only_endmatter-idx2">depression and, 195</p>
			<p class="em-only_endmatter-idx2">in older adults, 188</p>
			<p class="em-only_endmatter-idx1">Sulfasalazine, 179</p>
			<p class="em-only_endmatter-idx1">Supraventricular tachycardias, 102–103</p>
			<p class="em-only_endmatter-idx1">Surgery. <span class="endmatter-idx1_italic">See</span> Cataract surgery; Ocular surgery</p>
			<p class="em-only_endmatter-idx1">Survival analy&#173;sis, 10</p>
			<p class="em-only_endmatter-idx1">Swan-&#173;neck deformity, 152, 152<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Syncope, 299</p>
			<p class="em-only_endmatter-idx1">Syphilis</p>
			<p class="em-only_endmatter-idx2">congenital, 222, 252</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 252–253</p>
			<p class="em-only_endmatter-idx2">in HIV patients, 253</p>
			<p class="em-only_endmatter-idx2">latent, 252</p>
			<p class="em-only_endmatter-idx2">lumbar puncture for, 253</p>
			<p class="em-only_endmatter-idx2">management of, 253</p>
			<p class="em-only_endmatter-idx2">ocular manifestations of, 252–253</p>
			<p class="em-only_endmatter-idx2">screening for, 222–223</p>
			<p class="em-only_endmatter-idx2">tertiary, 252</p>
			<p class="em-only_endmatter-idx2">transmission of, 222, 252</p>
			<p class="em-only_endmatter-idx1">Systematic reviews, 14</p>
			<p class="em-only_endmatter-idx1">Systemic lupus erythematosus (SLE)</p>
			<p class="em-only_endmatter-idx2">antinuclear antibody testing for, 160, 160<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">articular disease associated with, 158</p>
			<p class="em-only_endmatter-idx2">autoantibodies in, 161</p>
			<p class="em-only_endmatter-idx2">cardiac manifestations of, 159–160</p>
			<p class="em-only_endmatter-idx2">cutaneous manifestations of, 158, 159<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">definition of, 158</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 160<span class="endmatter-idx2_italic">t,</span> 160–161</p>
			<p class="em-only_endmatter-idx2">gastrointestinal manifestations of, 160</p>
			<p class="em-only_endmatter-idx2">gender predilection of, 158</p>
			<p class="em-only_endmatter-idx2">keratoconjunctivitis sicca in, 161</p>
			<p class="em-only_endmatter-idx2">malar rash associated with, 158, 159<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ocular manifestations of, 161</p>
			<p class="em-only_endmatter-idx2">racial predilection of, 158</p>
			<p class="em-only_endmatter-idx2">Raynaud phenomenon associated with, 159, 159<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">refractory, 161</p>
			<p class="em-only_endmatter-idx2">renal disease associated with, 158</p>
			<p class="em-only_endmatter-idx2">signs and symptoms of, 158–160, 159<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">thromboembolism in, 160</p>
			<p class="em-only_endmatter-idx2">treatment of, 161–162</p>
			<p class="em-only_endmatter-idx1">Systemic sclerosis (SSc), 164–166, 165<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Systolic blood pressure, 52, 56, 214</p>
			<p class="em-only_endmatter-idx1">Systolic dysfunction, 98–99</p>
			<p class="em-only_endmatter-idx1">T<span class="subscript _idGenCharOverride-1">3</span>. <span class="endmatter-idx1_italic">See</span> Triiodothyronine</p>
			<p class="em-only_endmatter-idx1">T<span class="subscript _idGenCharOverride-1">4</span>. <span class="endmatter-idx1_italic">See</span> Thyroxine</p>
			<p class="em-only_endmatter-idx1">T waves, in coronary heart disease, 86</p>
			<p class="em-only_endmatter-idx1">Tachyarrhythmias</p>
			<p class="em-only_endmatter-idx2">atrial fibrillation, 102–103, 103<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">atrial flutter, 102</p>
			<p class="em-only_endmatter-idx2">in congestive heart failure, 99</p>
			<p class="em-only_endmatter-idx2">definition of, 102</p>
			<p class="em-only_endmatter-idx2">implantable cardioverter-&#173;defibrillators for, <br />104–106</p>
			<p class="em-only_endmatter-idx2">supraventricular tachycardias, 102–103</p>
			<p class="em-only_endmatter-idx2">ventricular, 104</p>
			<p class="em-only_endmatter-idx2">ventricular fibrillation, 104</p>
			<p class="em-only_endmatter-idx1">Tachycardia</p>
			<p class="em-only_endmatter-idx2">narrow complex, 102</p>
			<p class="em-only_endmatter-idx2">supraventricular, 102–103</p>
			<p class="em-only_endmatter-idx2">ventricular, 104</p>
			<p class="em-only_endmatter-idx2">wide complex, 102</p>
			<p class="em-only_endmatter-idx1">Tacrolimus, 179</p>
			<p class="em-only_endmatter-idx1">Tadalafil, 309<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Takayasu arteritis, 170</p>
			<p class="em-only_endmatter-idx1">Tamoxifen, 309<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Tardive dyskinesia, 200</p>
			<p class="em-only_endmatter-idx1">Technetium-99m, 88</p>
			<p class="em-only_endmatter-idx1">Technosphere insulin, 37</p>
			<p class="em-only_endmatter-idx1">TED. <span class="endmatter-idx1_italic">See</span> Thyroid eye disease</p>
			<p class="em-only_endmatter-idx1">Teicoplanin, 274</p>
			<p class="em-only_endmatter-idx1">Tenofovir-&#173;emtricitabine, 268</p>
			<p class="em-only_endmatter-idx1">Teprotumumab, 44</p>
			<p class="em-only_endmatter-idx1">Terbinafine, 277</p>
			<p class="em-only_endmatter-idx1">Terson syndrome, 121</p>
			<p class="em-only_endmatter-idx1">Tertiary syphilis, 252</p>
			<p class="em-only_endmatter-idx1">Test-&#173;retest reliability, 24</p>
			<p class="em-only_endmatter-idx1">Tetanus and diphtheria immunization, 225<span class="endmatter-idx1_italic">t,</span> 229–230</p>
			<p class="em-only_endmatter-idx1">Tetracyclines</p>
			<p class="em-only_endmatter-idx2">description of, 275–276</p>
			<p class="em-only_endmatter-idx2">gonococcal infections treated with, 251</p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 308<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Thalamotomy, for Parkinson disease, 205</p>
			<p class="em-only_endmatter-idx1">Thalassemias, 134–135</p>
			<p class="em-only_endmatter-idx1">Thallium-201, 88</p>
			<p class="em-only_endmatter-idx1">Theophylline, 287</p>
			<p class="em-only_endmatter-idx1">Therapeutic ratio, 237</p>
			<p class="em-only_endmatter-idx1">Thiazide-&#173;type diuretics</p>
			<p class="em-only_endmatter-idx2">hypertension treated with, 59, 59<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">side effects of, 60</p>
			<p class="em-only_endmatter-idx1">Thiazolidinediones, 38</p>
			<p class="em-only_endmatter-idx1">Thiopental sodium, 290</p>
			<p class="em-only_endmatter-idx1">Thrombin, 138</p>
			<p class="em-only_endmatter-idx1">Thrombocytopenia</p>
			<p class="em-only_endmatter-idx2">idiopathic thrombocytopenic purpura, 141–142</p>
			<p class="em-only_endmatter-idx2">nonimmunologic, 142</p>
			<p class="em-only_endmatter-idx2">thrombotic thrombocytopenic purpura, 142</p>
			<p class="em-only_endmatter-idx1">Thrombocytosis, 142–143</p>
			<p class="em-only_endmatter-idx1">Thromboembolism. <span class="endmatter-idx1_italic">See also</span> Deep venous thrombosis</p>
			<p class="em-only_endmatter-idx2">in systemic lupus erythematosus, 160</p>
			<p class="em-only_endmatter-idx2">venous. <span class="endmatter-idx2_italic">See</span> Venous thromboembolism</p>
			<p class="em-only_endmatter-idx1">Thrombolytic therapy</p>
			<p class="em-only_endmatter-idx2">bleeding complications of, 94–95</p>
			<p class="em-only_endmatter-idx2">indications for, 150</p>
			<p class="em-only_endmatter-idx2">myo&#173;car&#173;dial infarction treated with, 94–95</p>
			<p class="em-only_endmatter-idx2">stroke treated with, 113</p>
			<p class="em-only_endmatter-idx1">Thrombophilia, 146–148</p>
			<p class="em-only_endmatter-idx1">Thrombopoietin receptor agonists, 141</p>
			<p class="em-only_endmatter-idx1">Thrombotic disorders</p>
			<p class="em-only_endmatter-idx2">activated protein C re&#173;sis&#173;tance, 146–147</p>
			<p class="em-only_endmatter-idx2">description of, 146</p>
			<p class="em-only_endmatter-idx2">hypercoagulable states, 146–148</p>
			<p class="em-only_endmatter-idx2">primary hypercoagulable states, 146–148</p>
			<p class="em-only_endmatter-idx1">Thrombotic thrombocytopenic purpura (TTP), 136, 142</p>
			<p class="em-only_endmatter-idx1">Thrombus, atrial, 102</p>
			<p class="em-only_endmatter-idx1">Thyroglobulin, antibodies to, 42</p>
			<p class="em-only_endmatter-idx1">Thyroid adenomas, 46</p>
			<p class="em-only_endmatter-idx1">Thyroid antibody tests, 42–43</p>
			<p class="em-only_endmatter-idx1">Thyroid cancer</p>
			<p class="em-only_endmatter-idx2">medullary, 46, 50</p>
			<p class="em-only_endmatter-idx2">papillary, 46</p>
			<p class="em-only_endmatter-idx2">types of, 46, 50</p>
			<p class="em-only_endmatter-idx1">Thyroid disease</p>
			<p class="em-only_endmatter-idx2">hyperthyroidism, 43–44</p>
			<p class="em-only_endmatter-idx2">hypothyroidism, 44–45</p>
			<p class="em-only_endmatter-idx2">physiology of, 41</p>
			<p class="em-only_endmatter-idx2">thyroiditis, 45–46</p>
			<p class="em-only_endmatter-idx2">toxic nodular goiter, 44</p>
			<p class="em-only_endmatter-idx2">tumors, 46</p>
			<p class="em-only_endmatter-idx1">Thyroid eye disease (TED)</p>
			<p class="em-only_endmatter-idx2">description of, 43–44</p>
			<p class="em-only_endmatter-idx2">teprotumumab for, 44</p>
			<p class="em-only_endmatter-idx1">Thyroid follicles, 41</p>
			<p class="em-only_endmatter-idx1">Thyroid function tests</p>
			<p class="em-only_endmatter-idx2">description of, 41</p>
			<p class="em-only_endmatter-idx2">in subacute thyroiditis, 45</p>
			<p class="em-only_endmatter-idx2">thyrotropin-&#173;releasing hormone, 42</p>
			<p class="em-only_endmatter-idx1">Thyroid gland</p>
			<p class="em-only_endmatter-idx2">biopsy of, 43</p>
			<p class="em-only_endmatter-idx2">lymphoma of, 46</p>
			<p class="em-only_endmatter-idx2">parafollicular cells of, 41</p>
			<p class="em-only_endmatter-idx2">physiology of, 41</p>
			<p class="em-only_endmatter-idx2">scanning of, 43</p>
			<p class="em-only_endmatter-idx2">tumors of, 46</p>
			<p class="em-only_endmatter-idx2">ultrasonography of, 43</p>
			<p class="em-only_endmatter-idx1">Thyroid hormones</p>
			<p class="em-only_endmatter-idx2">function of, 41</p>
			<p class="em-only_endmatter-idx2">secretory suppression of, 44</p>
			<p class="em-only_endmatter-idx2">T<span class="subscript _idGenCharOverride-1">3</span>. <span class="endmatter-idx2_italic">See</span> Triiodothyronine</p>
			<p class="em-only_endmatter-idx2">T<span class="subscript _idGenCharOverride-1">4</span>. <span class="endmatter-idx2_italic">See</span> Thyroxine</p>
			<p class="em-only_endmatter-idx1">Thyroid peroxidase antibody, 42</p>
			<p class="em-only_endmatter-idx1">Thyroid-&#173;stimulating immunoglobulins (TSI), 42</p>
			<p class="em-only_endmatter-idx1">Thyroid storm, 43</p>
			<p class="em-only_endmatter-idx1">Thyroiditis, 45–46</p>
			<p class="em-only_endmatter-idx1">Thyrotoxicosis, 43</p>
			<p class="em-only_endmatter-idx1">Thyrotropin-&#173;releasing hormone (TSH)</p>
			<p class="em-only_endmatter-idx2">secretion of, 41</p>
			<p class="em-only_endmatter-idx2">serum levels of, 42</p>
			<p class="em-only_endmatter-idx2">tests of, 42</p>
			<p class="em-only_endmatter-idx1">Thyroxine (T<span class="subscript _idGenCharOverride-1">4</span>)</p>
			<p class="em-only_endmatter-idx2">deiodination of, 41</p>
			<p class="em-only_endmatter-idx2">pregnancy levels of, 42</p>
			<p class="em-only_endmatter-idx2">secretion of, 41</p>
			<p class="em-only_endmatter-idx2">serum, mea&#173;sure&#173;ment of, 42</p>
			<p class="em-only_endmatter-idx2">structure of, 41</p>
			<p class="em-only_endmatter-idx2">total, 42</p>
			<p class="em-only_endmatter-idx1">Thyroxine-&#173;binding globulin (TBG), 41</p>
			<p class="em-only_endmatter-idx1">TIAs. <span class="endmatter-idx1_italic">See</span> Transient ischemic attacks</p>
			<p class="em-only_endmatter-idx1">Tick-&#173;borne encephalitis, 232</p>
			<p class="em-only_endmatter-idx1">Timentin, 273</p>
			<p class="em-only_endmatter-idx1">Tiotropium bromide, 128</p>
			<p class="em-only_endmatter-idx1">Tissue plasminogen activators (tPAs), 94</p>
			<p class="em-only_endmatter-idx1">TMVL. <span class="endmatter-idx1_italic">See</span> Transient monocular visual loss</p>
			<p class="em-only_endmatter-idx1">Tocilizumab, 180</p>
			<p class="em-only_endmatter-idx1">Todd paralysis, 207</p>
			<p class="em-only_endmatter-idx1">Tofacitinib, 180</p>
			<p class="em-only_endmatter-idx1">Tomopenem, 273</p>
			<p class="em-only_endmatter-idx1">Tonic-&#173;clonic seizures, 306</p>
			<p class="em-only_endmatter-idx1">Topiramate, 207–208, 308<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Topoisomerase inhibitors, 240<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Torsades de pointes, 104</p>
			<p class="em-only_endmatter-idx1">Toxic epidermal necrolysis (TEN), 208</p>
			<p class="em-only_endmatter-idx1">Toxic nodular goiter, 44</p>
			<p class="em-only_endmatter-idx1">Toxic optic neuropathy, 199</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Toxoplasma gondii,</span> 258–259</p>
			<p class="em-only_endmatter-idx1">Toxoplasmosis, 258–259</p>
			<p class="em-only_endmatter-idx1">Tracheotomy, 302</p>
			<p class="em-only_endmatter-idx1">Transcranial Doppler ultrasonography</p>
			<p class="em-only_endmatter-idx2">carotid stenosis diagnosis using, 116</p>
			<p class="em-only_endmatter-idx2">stroke evaluations using, 113</p>
			<p class="em-only_endmatter-idx1">Transesophageal echocardiography (TEE), 118</p>
			<p class="em-only_endmatter-idx1">Transfusion, for thalassemias, 134</p>
			<p class="em-only_endmatter-idx1">Transfusion-&#173;transmitted virus (TTV), 263</p>
			<p class="em-only_endmatter-idx1">Transient ce&#173;re&#173;bral ischemia</p>
			<p class="em-only_endmatter-idx2">description of, 110, 115</p>
			<p class="em-only_endmatter-idx2">stroke risks, 117–118</p>
			<p class="em-only_endmatter-idx1">Transient hypertension, 68</p>
			<p class="em-only_endmatter-idx1">Transient ischemic attacks (TIAs), 119</p>
			<p class="em-only_endmatter-idx1">Transient monocular visual loss (TMVL)</p>
			<p class="em-only_endmatter-idx2">carotid stenosis as cause of, 118</p>
			<p class="em-only_endmatter-idx2">&#173;giant cell arteritis presenting as, 119</p>
			<p class="em-only_endmatter-idx1">Transmissible spongiform encephalopathies, 211</p>
			<p class="em-only_endmatter-idx1">Transplantation</p>
			<p class="em-only_endmatter-idx2">cardiac, 100</p>
			<p class="em-only_endmatter-idx2">hematopoietic stem cell</p>
			<p class="em-only_endmatter-idx3">allogeneic, for thalassemias, 134</p>
			<p class="em-only_endmatter-idx3">complications of, 135</p>
			<p class="em-only_endmatter-idx3">sickle cell disease treated with, 135</p>
			<p class="em-only_endmatter-idx2">liver, 226</p>
			<p class="em-only_endmatter-idx2">pancreas, type 1 diabetes mellitus treated with, 37–38</p>
			<p class="em-only_endmatter-idx1">Transthoracic echocardiography (TTE), 118</p>
			<p class="em-only_endmatter-idx1">Transtracheal ventilation, 299</p>
			<p class="em-only_endmatter-idx1">Trastuzumab, 242</p>
			<p class="em-only_endmatter-idx1">Traumatic brain injuries (TBIs), 191</p>
			<p class="em-only_endmatter-idx1">Travel immunizations, 232</p>
			<p class="em-only_endmatter-idx1">Tremor, in Parkinson disease, 204</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Treponema pallidum,</span> 252–253. <span class="endmatter-idx1_italic">See also</span> Syphilis</p>
			<p class="em-only_endmatter-idx1">Treponemal antigen tests, 223, 253</p>
			<p class="em-only_endmatter-idx1">Triamcinolone, 175<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Triazoles, 277</p>
			<p class="em-only_endmatter-idx1">Tricyclic antidepressants, 203<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Triglycerides</p>
			<p class="em-only_endmatter-idx2">lipoprotein transport of, 72</p>
			<p class="em-only_endmatter-idx2">nonpharmacologic management of, 75</p>
			<p class="em-only_endmatter-idx1">Trihexyphenidyl, 205</p>
			<p class="em-only_endmatter-idx1">Triiodothyronine (T<span class="subscript _idGenCharOverride-1">3</span>)</p>
			<p class="em-only_endmatter-idx2">deiodination of, 41</p>
			<p class="em-only_endmatter-idx2">secretion of, 41</p>
			<p class="em-only_endmatter-idx2">serum, mea&#173;sure&#173;ment of, 42</p>
			<p class="em-only_endmatter-idx1">Trimethoprim-&#173;sulfamethoxazole (TMP-&#173;SMX), 276</p>
			<p class="em-only_endmatter-idx1">Troponins</p>
			<p class="em-only_endmatter-idx2">in acute coronary syndrome, 87</p>
			<p class="em-only_endmatter-idx2">I, 87</p>
			<p class="em-only_endmatter-idx2">T, 87</p>
			<p class="em-only_endmatter-idx1">T4/T8 ratio, 267</p>
			<p class="em-only_endmatter-idx1">Tuberculosis, screening for, 222</p>
			<p class="em-only_endmatter-idx1">Tumor necrosis factor-&#173;<span class="endmatter-idx1_greek">α</span> inhibitors, 180</p>
			<p class="em-only_endmatter-idx1">Tumor suppressor genes, 235</p>
			<p class="em-only_endmatter-idx1">Tumors, thyroid, 46</p>
			<p class="em-only_endmatter-idx1">Type 1 diabetes mellitus. <span class="endmatter-idx1_italic">See</span> Diabetes mellitus, type 1</p>
			<p class="em-only_endmatter-idx1">Type 2 diabetes mellitus. <span class="endmatter-idx1_italic">See</span> Diabetes mellitus, type 2</p>
			<p class="em-only_endmatter-idx1">Typhoid fever vaccination, 232</p>
			<p class="em-only_endmatter-idx1">Ulcerative colitis, 156</p>
			<p class="em-only_endmatter-idx1">Ultrasonography, thyroid gland, 43</p>
			<p class="em-only_endmatter-idx1">Ultraviolet (UV) light, melanomas caused by, 220</p>
			<p class="em-only_endmatter-idx1">Unasyn, 273</p>
			<p class="em-only_endmatter-idx1">Unfractionated heparin (UFH), 149</p>
			<p class="em-only_endmatter-idx1">Universal Protocol, 288–289</p>
			<p class="em-only_endmatter-idx1">Unstable angina pectoris, 83</p>
			<p class="em-only_endmatter-idx1">Urethritis, 255</p>
			<p class="em-only_endmatter-idx1">Urologic cancer screening, 221</p>
			<p class="em-only_endmatter-idx1">US Preventive Ser&#173;vices Task Force mammography recommendations, 217</p>
			<p class="em-only_endmatter-idx1">Ustekinumab, 180</p>
			<p class="em-only_endmatter-idx1">Uveitis</p>
			<p class="em-only_endmatter-idx2">Ebola virus as cause of, 264</p>
			<p class="em-only_endmatter-idx2">spondyloarthritis associated with, 157</p>
			<p class="em-only_endmatter-idx1">V-&#173;neck sign, 167</p>
			<p class="em-only_endmatter-idx1">Vaccines/vaccinations. <span class="endmatter-idx1_italic">See also</span> Immunizations</p>
			<p class="em-only_endmatter-idx2">cancer treatment uses of, 242</p>
			<p class="em-only_endmatter-idx2">cholera, 232</p>
			<p class="em-only_endmatter-idx2">&#173;future types of, 232–233</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Haemophilus influenzae,</span> 231–232, 250</p>
			<p class="em-only_endmatter-idx2">hepatitis B, 224, 226</p>
			<p class="em-only_endmatter-idx2">hepatitis C, 226</p>
			<p class="em-only_endmatter-idx2">&#173;human papillomavirus, 225<span class="endmatter-idx2_italic">t,</span> 231–232, 236</p>
			<p class="em-only_endmatter-idx2">influenza, 225<span class="endmatter-idx2_italic">t,</span> 226–227</p>
			<p class="em-only_endmatter-idx2">malaria, 232</p>
			<p class="em-only_endmatter-idx2">measles/mumps/rubella, 225<span class="endmatter-idx2_italic">t,</span> 228–229</p>
			<p class="em-only_endmatter-idx2">meningococcal, 231</p>
			<p class="em-only_endmatter-idx2">new types of, 232–233</p>
			<p class="em-only_endmatter-idx2">pneumococcal pneumonia, 230–231</p>
			<p class="em-only_endmatter-idx2">polio, 229</p>
			<p class="em-only_endmatter-idx2">rabies, 232</p>
			<p class="em-only_endmatter-idx2">rotavirus, 230</p>
			<p class="em-only_endmatter-idx2">tetanus and diphtheria, 225<span class="endmatter-idx2_italic">t,</span> 229–230</p>
			<p class="em-only_endmatter-idx2">tuberculosis, 222</p>
			<p class="em-only_endmatter-idx2">typhoid fever, 232</p>
			<p class="em-only_endmatter-idx2">varicella-&#173;zoster, 225<span class="endmatter-idx2_italic">t,</span> 227–228</p>
			<p class="em-only_endmatter-idx2">yellow fever, 232</p>
			<p class="em-only_endmatter-idx1">Vagus nerve stimulation (VNS), 208</p>
			<p class="em-only_endmatter-idx1">Valacyclovir</p>
			<p class="em-only_endmatter-idx2">herpes simplex virus treated with, 260, 278</p>
			<p class="em-only_endmatter-idx2">varicella-&#173;zoster treated with, 261</p>
			<p class="em-only_endmatter-idx1">Valganciclovir, 278–279</p>
			<p class="em-only_endmatter-idx1">Valproic acid, 203, 207</p>
			<p class="em-only_endmatter-idx1">Vancomycin</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Clostridium difficile</span> treated with, 249</p>
			<p class="em-only_endmatter-idx2">description of, 273–274</p>
			<p class="em-only_endmatter-idx2">enterococcal infections resistant to, 274</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Staphylococcus</span> spp. treated with, 247</p>
			<p class="em-only_endmatter-idx1">Variable-&#173;vessel vasculitis, 169<span class="endmatter-idx1_italic">t,</span> 173–174</p>
			<p class="em-only_endmatter-idx1">Variant angina pectoris, 83</p>
			<p class="em-only_endmatter-idx1">Varicella-&#173;zoster</p>
			<p class="em-only_endmatter-idx2">characteristics of, 260–261</p>
			<p class="em-only_endmatter-idx2">reactivation of, 260–261</p>
			<p class="em-only_endmatter-idx2">vaccination for, 225<span class="endmatter-idx2_italic">t,</span> 227–228</p>
			<p class="em-only_endmatter-idx1">Vascular dementia, 210</p>
			<p class="em-only_endmatter-idx1">Vascular disorders, 140–141</p>
			<p class="em-only_endmatter-idx1">Vascular endothelial growth factor (VEGF), antibodies against, 241</p>
			<p class="em-only_endmatter-idx1">Vasculitis/vasculitides</p>
			<p class="em-only_endmatter-idx2">antineutrophil cytoplasmic autoantibody-&#173;associated, 169<span class="endmatter-idx2_italic">t,</span> 171–173</p>
			<p class="em-only_endmatter-idx2">Beh<span class="endmatter-idx2_accent">ç</span>et disease, 173–174</p>
			<p class="em-only_endmatter-idx2">choroidal, 171</p>
			<p class="em-only_endmatter-idx2">classification of, 169<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">Cogan syndrome, 174</p>
			<p class="em-only_endmatter-idx2">eosinophilic granulomatosis with polyangiitis, 172</p>
			<p class="em-only_endmatter-idx2">&#173;giant cell arteritis. <span class="endmatter-idx2_italic">See</span> &#173;Giant cell arteritis</p>
			<p class="em-only_endmatter-idx2">granulomatosis with polyangiitis, 171–172</p>
			<p class="em-only_endmatter-idx2">Kawasaki disease, 171</p>
			<p class="em-only_endmatter-idx2">large-&#173;vessel, 169<span class="endmatter-idx2_italic">t,</span> 170</p>
			<p class="em-only_endmatter-idx2">medium-&#173;sized–&#173;vessel, 169<span class="endmatter-idx2_italic">t,</span> 170–171</p>
			<p class="em-only_endmatter-idx2">microscopic polyangiitis, 172–173</p>
			<p class="em-only_endmatter-idx2">overview of, 169–170</p>
			<p class="em-only_endmatter-idx2">polyarteritis nodosa, 170–171</p>
			<p class="em-only_endmatter-idx2">small-&#173;vessel, 169<span class="endmatter-idx2_italic">t,</span> 171–173</p>
			<p class="em-only_endmatter-idx2">Takayasu arteritis, 170</p>
			<p class="em-only_endmatter-idx2">variable-&#173;vessel, 169<span class="endmatter-idx2_italic">t,</span> 173–174</p>
			<p class="em-only_endmatter-idx1">Vasopressin, 47, 301</p>
			<p class="em-only_endmatter-idx1">Vasopressor drugs, 301</p>
			<p class="em-only_endmatter-idx1">Vasovagal episodes. <span class="endmatter-idx1_italic">See</span> Syncope</p>
			<p class="em-only_endmatter-idx1">Vaughan Williams classification, of antiarrhythmic drugs, 102, 102<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Venous thromboembolism</p>
			<p class="em-only_endmatter-idx2">protein C deficiency in, 147</p>
			<p class="em-only_endmatter-idx2">protein S deficiency in, 147</p>
			<p class="em-only_endmatter-idx2">prothrombin G20210A and, 147</p>
			<p class="em-only_endmatter-idx1">Ventricular contractility, 81</p>
			<p class="em-only_endmatter-idx1">Ventricular dysfunction, 65</p>
			<p class="em-only_endmatter-idx1">Ventricular fibrillation (VF), 104</p>
			<p class="em-only_endmatter-idx1">Ventricular tachyarrhythmias, 104</p>
			<p class="em-only_endmatter-idx1">Ventricular tachycardia, 104–105</p>
			<p class="em-only_endmatter-idx1">Ventriculography, 89</p>
			<p class="em-only_endmatter-idx1">Vertical gaze deviation, seizures and, 208</p>
			<p class="em-only_endmatter-idx1">Very-&#173;low-&#173;density lipoproteins (VLDLs), 72</p>
			<p class="em-only_endmatter-idx1">Vigabatrin, 209</p>
			<p class="em-only_endmatter-idx1">Viruses</p>
			<p class="em-only_endmatter-idx2">cancer associated with, 236, 237<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">DNA, 236, 237<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">RNA, 236, 237<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Vision loss, 184</p>
			<p class="em-only_endmatter-idx1">Visual disorders, 191</p>
			<p class="em-only_endmatter-idx1">Vitamin B<span class="subscript _idGenCharOverride-1">12</span> deficiency</p>
			<p class="em-only_endmatter-idx2">anemia caused by, 133</p>
			<p class="em-only_endmatter-idx2">folate deficiency versus, 134</p>
			<p class="em-only_endmatter-idx1">Vitamin&#160;K</p>
			<p class="em-only_endmatter-idx2">deficiency of, 145</p>
			<p class="em-only_endmatter-idx2">functions of, 145</p>
			<p class="em-only_endmatter-idx1">Vitamin K antagonists</p>
			<p class="em-only_endmatter-idx2">coronary heart disease treated with, 90<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">direct oral anticoagulants versus, 149</p>
			<p class="em-only_endmatter-idx1">Vitamin K-&#173;dependent &#173;factors, 139</p>
			<p class="em-only_endmatter-idx1">von Willebrand disease (vWD), 144–145</p>
			<p class="em-only_endmatter-idx1">von Willebrand &#173;factor (vWF), 144–145</p>
			<p class="em-only_endmatter-idx1">Voriconazole, 277</p>
			<p class="em-only_endmatter-idx1">Vulnerable populations, 4</p>
			<p class="em-only_endmatter-idx1">Warfarin</p>
			<p class="em-only_endmatter-idx2">cessation of, before ocular surgery, 286</p>
			<p class="em-only_endmatter-idx2">ge&#173;ne&#173;tic testing used in dosing of, 140</p>
			<p class="em-only_endmatter-idx2">indications for, 150</p>
			<p class="em-only_endmatter-idx2">ocular adverse effects of, 309<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">therapeutic uses of, 149–150</p>
			<p class="em-only_endmatter-idx1">Wegener granulomatosis. <span class="endmatter-idx1_italic">See</span> Granulomatosis with polyangiitis</p>
			<p class="em-only_endmatter-idx1">Weight loss, hypertension managed with, 58<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Weight management, coronary heart disease risk modification using, 73<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Wernicke disease, 199</p>
			<p class="em-only_endmatter-idx1">Wheezing, 124</p>
			<p class="em-only_endmatter-idx1">Wide complex tachycardias, 102</p>
			<p class="em-only_endmatter-idx1">Wilcoxon signed rank test, 7</p>
			<p class="em-only_endmatter-idx1">Wilson disease, 136</p>
			<p class="em-only_endmatter-idx1">Withdrawal syndromes, hypertension caused <br />by, 68–69</p>
			<p class="em-only_endmatter-idx1">&#173;Women</p>
			<p class="em-only_endmatter-idx2">congestive heart failure in, 95</p>
			<p class="em-only_endmatter-idx2">coronary heart disease in, 82</p>
			<p class="em-only_endmatter-idx2">hypertension in, 67–68</p>
			<p class="em-only_endmatter-idx1">Work of breathing, dyspnea and, 124</p>
			<p class="em-only_endmatter-idx1">World Health Organ&#173;ization (WHO)</p>
			<p class="em-only_endmatter-idx2">antibiotic-&#173;resistant pathogen prioritization by, 276–277</p>
			<p class="em-only_endmatter-idx2">behavioral and neurologic disorder focus of, 193</p>
			<p class="em-only_endmatter-idx2">immunization guidelines of, 224</p>
			<p class="em-only_endmatter-idx2">&#173;Mental Health Gap Action Program, 194</p>
			<p class="em-only_endmatter-idx1">Wounds, tetanus immunizations in, 230</p>
			<p class="em-only_endmatter-idx1">Wrong-&#173;site surgery, 288</p>
			<p class="em-only_endmatter-idx1">Yeasts, <span class="endmatter-idx1_italic">Candida</span>, 258, 278<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Yellow fever vaccination, 232</p>
			<p class="em-only_endmatter-idx1">Zanamivir, 279</p>
			<p class="em-only_endmatter-idx1">Zika virus, 265–266</p>
			<p class="em-only_endmatter-idx1">Zollinger-&#173;Ellison syndrome, 50</p>
			<p class="em-only_endmatter-idx1">Zostavax, 227</p>
			<p class="em-only_endmatter-idx1">Zoster. <span class="endmatter-idx1_italic">See</span> Varicella-zoster</p>
			<p class="em-only_endmatter-idx1">Zosyn, 273</p>
		</div>
	</body>
</html>
